<?xml version="1.0" encoding="UTF-8"?>
<drug type="small molecule" created="2005-06-13" updated="2020-01-02">
  <drugbank-id primary="true">DB01064</drugbank-id>
  <drugbank-id>APRD00182</drugbank-id>
  <name>Isoprenaline</name>
  <description>Isopropyl analog of epinephrine; beta-sympathomimetic that acts on the heart, bronchi, skeletal muscle, alimentary tract, etc. It is used mainly as bronchodilator and heart stimulant.</description>
  <cas-number>7683-59-2</cas-number>
  <unii>L628TT009W</unii>
  <average-mass>211.2576</average-mass>
  <monoisotopic-mass>211.120843415</monoisotopic-mass>
  <state>solid</state>
  <groups>
    <group>approved</group>
    <group>investigational</group>
  </groups>
  <general-references>
    <articles/>
    <textbooks/>
    <links/>
    <attachments/>
  </general-references>
  <synthesis-reference>U.S. Patent 2,308,232.&#13;
U.S. Patent 2,715,141.</synthesis-reference>
  <indication>For the treatment of mild or transient episodes of heart block that do not require electric shock or pacemaker therapy also used in management of asthma and chronic bronchitis</indication>
  <pharmacodynamics>Isoproterenol is a relatively selective beta2-adrenergic bronchodilator. Isoproterenol is indicated for the relief of bronchospasm associated with chronic obstructive pulmonary disease. The pharmacologic effects of beta adrenergic agonist drugs, including Isoproterenol, are at least in part attributable to stimulation through beta adrenergic receptors of intracellular adenyl cyclase, the enzyme which catalyzes the conversion of adenosine triphosphate (ATP) to cyclic- 3',5'- adenosine monophosphate (c-AMP). Increased c-AMP levels are associated with relaxation of bronchial smooth muscle and inhibition of release of mediators of immediate hypersensitivity from cells, especially from mast cells.</pharmacodynamics>
  <mechanism-of-action>The pharmacologic effects of isoproterenol are at least in part attributable to stimulation through beta-adrenergic receptors of intracellular adenyl cyclase, the enzyme that catalyzes the conversion of adenosine triphosphate (ATP) to cyclic AMP. Increased cyclic AMP levels are associated with relaxation of bronchial smooth muscle and inhibition of release of mediators of immediate hypersensitivity from cells, especially from mast cells.</mechanism-of-action>
  <toxicity/>
  <metabolism/>
  <absorption/>
  <half-life/>
  <protein-binding/>
  <route-of-elimination>Excretion following inhalation administration is primarily renal and the major metabolite is the sulfate conjugate of isoproterenol.</route-of-elimination>
  <volume-of-distribution/>
  <clearance/>
  <classification>
    <description>This compound belongs to the class of organic compounds known as catechols. These are compounds containing a 1,2-benzenediol moiety.</description>
    <direct-parent>Catechols</direct-parent>
    <kingdom>Organic compounds</kingdom>
    <superclass>Benzenoids</superclass>
    <class>Phenols</class>
    <subclass>Benzenediols</subclass>
    <alternative-parent>1,2-aminoalcohols</alternative-parent>
    <alternative-parent>1-hydroxy-2-unsubstituted benzenoids</alternative-parent>
    <alternative-parent>1-hydroxy-4-unsubstituted benzenoids</alternative-parent>
    <alternative-parent>Aralkylamines</alternative-parent>
    <alternative-parent>Aromatic alcohols</alternative-parent>
    <alternative-parent>Benzene and substituted derivatives</alternative-parent>
    <alternative-parent>Dialkylamines</alternative-parent>
    <alternative-parent>Hydrocarbon derivatives</alternative-parent>
    <alternative-parent>Organopnictogen compounds</alternative-parent>
    <alternative-parent>Secondary alcohols</alternative-parent>
    <substituent>1,2-aminoalcohol</substituent>
    <substituent>1-hydroxy-2-unsubstituted benzenoid</substituent>
    <substituent>1-hydroxy-4-unsubstituted benzenoid</substituent>
    <substituent>Alcohol</substituent>
    <substituent>Amine</substituent>
    <substituent>Aralkylamine</substituent>
    <substituent>Aromatic alcohol</substituent>
    <substituent>Aromatic homomonocyclic compound</substituent>
    <substituent>Catechol</substituent>
    <substituent>Hydrocarbon derivative</substituent>
    <substituent>Monocyclic benzene moiety</substituent>
    <substituent>Organic nitrogen compound</substituent>
    <substituent>Organic oxygen compound</substituent>
    <substituent>Organonitrogen compound</substituent>
    <substituent>Organooxygen compound</substituent>
    <substituent>Organopnictogen compound</substituent>
    <substituent>Secondary alcohol</substituent>
    <substituent>Secondary aliphatic amine</substituent>
    <substituent>Secondary amine</substituent>
  </classification>
  <salts>
    <salt>
      <drugbank-id primary="true">DBSALT000429</drugbank-id>
      <name>Isoprenaline hydrochloride</name>
      <unii>DIA2A74855</unii>
      <cas-number>51-30-9</cas-number>
      <inchikey>IROWCYIEJAOFOW-UHFFFAOYSA-N</inchikey>
      <average-mass>247.719</average-mass>
      <monoisotopic-mass>247.097521154</monoisotopic-mass>
    </salt>
    <salt>
      <drugbank-id primary="true">DBSALT001403</drugbank-id>
      <name>Isoproterenol sulfate</name>
      <unii>925FX3X776</unii>
      <cas-number>6078-56-4</cas-number>
      <inchikey>CUQPTVCVZLUXJB-UHFFFAOYSA-N</inchikey>
      <average-mass>556.62</average-mass>
      <monoisotopic-mass>556.23019591</monoisotopic-mass>
    </salt>
  </salts>
  <synonyms>
    <synonym language="english" coder="">(±)-isoprenaline</synonym>
    <synonym language="english" coder="">(±)-isoproterenol</synonym>
    <synonym language="english" coder="">1-(3,4-dihydroxyphenyl)-2-(isopropylamino)ethanol</synonym>
    <synonym language="english" coder="">1-(3,4-dihydroxyphenyl)-2-isopropylaminoethanol</synonym>
    <synonym language="english" coder="">3,4-dihydroxy-α-[(isopropylamino)methyl]benzyl alcohol</synonym>
    <synonym language="spanish" coder="inn">Isoprenalina</synonym>
    <synonym language="french" coder="inn">Isoprénaline</synonym>
    <synonym language="english" coder="inn">Isoprenaline</synonym>
    <synonym language="latin" coder="inn">Isoprenalinum</synonym>
    <synonym language="english" coder="">Isopropyl noradrenaline</synonym>
    <synonym language="english" coder="usan">Isoproterenol</synonym>
    <synonym language="english" coder="">N-isopropyl-β-dihydroxyphenyl-β-hydroxyethylamine</synonym>
    <synonym language="english" coder="">N-Isopropylnoradrenaline</synonym>
    <synonym language="english" coder="">N-Isopropylnorepinephrine</synonym>
    <synonym language="english" coder="">α-(isopropylaminomethyl)protocatechuyl alcohol</synonym>
  </synonyms>
  <products>
    <product>
      <name>Duo-Medihaler</name>
      <labeller>3M Company</labeller>
      <ndc-id/>
      <ndc-product-code>0089-0735</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1962-08-25</started-marketing-on>
      <ended-marketing-on>2006-12-29</ended-marketing-on>
      <dosage-form>Aerosol, metered</dosage-form>
      <strength/>
      <route>Respiratory (inhalation)</route>
      <fda-application-number>NDA013296</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Isoproterenol</name>
      <labeller>Cipla USA Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>69097-521</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2018-06-26</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Injection, solution</dosage-form>
      <strength>0.2 mg/1mL</strength>
      <route>Intracardiac; Intramuscular; Intravenous; Subcutaneous</route>
      <fda-application-number>ANDA210322</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Isoproterenol</name>
      <labeller>Cipla USA Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>69097-522</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2018-06-26</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Injection, solution</dosage-form>
      <strength>1 mg/5mL</strength>
      <route>Intracardiac; Intramuscular; Intravenous; Subcutaneous</route>
      <fda-application-number>ANDA210322</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Isoproterenol HCl Inj 1:5000</name>
      <labeller>International Medication Systems, Limited</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>00243612</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1977-12-31</started-marketing-on>
      <ended-marketing-on>1997-08-15</ended-marketing-on>
      <dosage-form>Liquid</dosage-form>
      <strength/>
      <route>Intravenous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Isoproterenol Hydrochloride</name>
      <labeller>Amphastar Pharmaceuticals, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>0548-9501</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2018-07-16</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Injection, solution</dosage-form>
      <strength>0.2 mg/1mL</strength>
      <route>Intracardiac; Intramuscular; Intravenous; Subcutaneous</route>
      <fda-application-number>ANDA210106</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Isoproterenol Hydrochloride</name>
      <labeller>Amphastar Pharmaceuticals, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>0548-9502</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2018-07-16</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Injection, solution</dosage-form>
      <strength>0.2 mg/1mL</strength>
      <route>Intracardiac; Intramuscular; Intravenous; Subcutaneous</route>
      <fda-application-number>ANDA210106</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Isoproterenol Hydrochloride</name>
      <labeller>Nexus Pharmaceuticals Inc</labeller>
      <ndc-id/>
      <ndc-product-code>14789-011</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2017-08-03</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Injection, solution</dosage-form>
      <strength>0.2 mg/1mL</strength>
      <route>Intramuscular; Intravenous</route>
      <fda-application-number>ANDA206961</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Isoproterenol Hydrochloride</name>
      <labeller>Nexus Pharmaceuticals Inc</labeller>
      <ndc-id/>
      <ndc-product-code>14789-015</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2017-08-03</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Injection, solution</dosage-form>
      <strength>0.2 mg/1mL</strength>
      <route>Intramuscular; Intravenous</route>
      <fda-application-number>ANDA206961</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Isoproterenol Hydrochloride</name>
      <labeller>Amneal Pharmaceuticals LLC</labeller>
      <ndc-id/>
      <ndc-product-code>70121-1604</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2018-10-22</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Injection, solution</dosage-form>
      <strength>0.2 mg/1mL</strength>
      <route>Intracardiac; Intramuscular; Intravenous; Subcutaneous</route>
      <fda-application-number>ANDA210576</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Isoproterenol Hydrochloride</name>
      <labeller>Amneal Pharmaceuticals LLC</labeller>
      <ndc-id/>
      <ndc-product-code>70121-1605</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2018-10-22</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Injection, solution</dosage-form>
      <strength>1 mg/5mL</strength>
      <route>Intracardiac; Intramuscular; Intravenous; Subcutaneous</route>
      <fda-application-number>ANDA210576</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Isoproterenol Hydrochloride Injection USP</name>
      <labeller>Sandoz Canada Incorporated</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>00897639</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1991-12-31</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Solution</dosage-form>
      <strength/>
      <route>Intramuscular; Intravenous; Subcutaneous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Isoproterenol Hydrochloride Injection USP</name>
      <labeller>Omega Laboratories Ltd</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02290049</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on/>
      <ended-marketing-on/>
      <dosage-form>Solution</dosage-form>
      <strength/>
      <route>Intramuscular; Intravenous; Subcutaneous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Isuprel</name>
      <labeller>Marathon Pharmaceuticals</labeller>
      <ndc-id/>
      <ndc-product-code>42998-402</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2013-12-01</started-marketing-on>
      <ended-marketing-on>2016-06-01</ended-marketing-on>
      <dosage-form>Injection, solution</dosage-form>
      <strength>0.2 mg/1mL</strength>
      <route>Intracardiac; Intramuscular; Intravenous; Subcutaneous</route>
      <fda-application-number>NDA010515</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Isuprel</name>
      <labeller>Hospira, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>0409-1410</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2005-08-01</started-marketing-on>
      <ended-marketing-on>2015-02-01</ended-marketing-on>
      <dosage-form>Injection, solution</dosage-form>
      <strength>0.2 mg/1mL</strength>
      <route>Intracardiac; Intramuscular; Intravenous; Subcutaneous</route>
      <fda-application-number>NDA010515</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Isuprel</name>
      <labeller>General Injectables &amp; Vaccines</labeller>
      <ndc-id/>
      <ndc-product-code>52584-021</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2010-03-01</started-marketing-on>
      <ended-marketing-on>2017-01-17</ended-marketing-on>
      <dosage-form>Injection, solution</dosage-form>
      <strength>0.2 mg/1mL</strength>
      <route>Intracardiac; Intramuscular; Intravenous; Subcutaneous</route>
      <fda-application-number>NDA010515</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Isuprel</name>
      <labeller>Cardinal Health</labeller>
      <ndc-id/>
      <ndc-product-code>55154-4729</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2012-06-18</started-marketing-on>
      <ended-marketing-on>2015-01-31</ended-marketing-on>
      <dosage-form>Injection, solution</dosage-form>
      <strength>0.2 mg/1mL</strength>
      <route>Intracardiac; Intramuscular; Intravenous; Subcutaneous</route>
      <fda-application-number>NDA010515</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Isuprel</name>
      <labeller>Cardinal Health</labeller>
      <ndc-id/>
      <ndc-product-code>55154-6988</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2012-06-18</started-marketing-on>
      <ended-marketing-on>2013-07-31</ended-marketing-on>
      <dosage-form>Injection, solution</dosage-form>
      <strength>0.2 mg/1mL</strength>
      <route>Intracardiac; Intramuscular; Intravenous; Subcutaneous</route>
      <fda-application-number>NDA010515</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Isuprel</name>
      <labeller>Hospira, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>0409-1442</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2013-11-30</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Injection, solution</dosage-form>
      <strength>0.2 mg/1mL</strength>
      <route>Intracardiac; Intramuscular; Intravenous; Subcutaneous</route>
      <fda-application-number>NDA010515</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>false</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Isuprel</name>
      <labeller>Bausch Health US LLC</labeller>
      <ndc-id/>
      <ndc-product-code>0187-4330</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2013-12-01</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Injection, solution</dosage-form>
      <strength>0.2 mg/1mL</strength>
      <route>Intracardiac; Intramuscular; Intravenous; Subcutaneous</route>
      <fda-application-number>NDA010515</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Isuprel Inj 0.2mg/ml</name>
      <labeller>Sterling Winthrop Inc.</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>01912976</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1992-12-31</started-marketing-on>
      <ended-marketing-on>1996-09-10</ended-marketing-on>
      <dosage-form>Liquid</dosage-form>
      <strength/>
      <route>Intramuscular; Intravenous; Subcutaneous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Isuprel Liq 0.2mg/ml</name>
      <labeller>Sanofi</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02026937</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1956-12-31</started-marketing-on>
      <ended-marketing-on>2001-08-10</ended-marketing-on>
      <dosage-form>Liquid</dosage-form>
      <strength/>
      <route>Intracardiac; Intramuscular; Intravenous; Subcutaneous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Isuprel Liq 0.5%</name>
      <labeller>Sanofi</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02017652</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1954-12-31</started-marketing-on>
      <ended-marketing-on>1999-07-15</ended-marketing-on>
      <dosage-form>Liquid</dosage-form>
      <strength/>
      <route>Respiratory (inhalation)</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Isuprel Liq Inh 0.5%</name>
      <labeller>Sterling Winthrop Inc.</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>01923870</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1992-12-31</started-marketing-on>
      <ended-marketing-on>1996-09-10</ended-marketing-on>
      <dosage-form>Liquid</dosage-form>
      <strength/>
      <route>Respiratory (inhalation)</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Isuprel Mistometer 125mcg/aem</name>
      <labeller>Sterling Winthrop Inc.</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>01928449</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1992-12-31</started-marketing-on>
      <ended-marketing-on>1996-09-10</ended-marketing-on>
      <dosage-form>Aerosol, metered</dosage-form>
      <strength/>
      <route>Respiratory (inhalation)</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Isuprel Mistometer Aem 0.25%</name>
      <labeller>Sanofi</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02017660</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1958-12-31</started-marketing-on>
      <ended-marketing-on>1998-10-24</ended-marketing-on>
      <dosage-form>Aerosol, metered</dosage-form>
      <strength/>
      <route>Respiratory (inhalation)</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Medihaler-Iso</name>
      <labeller>3M Company</labeller>
      <ndc-id/>
      <ndc-product-code>0089-0785</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1956-03-19</started-marketing-on>
      <ended-marketing-on>2006-12-29</ended-marketing-on>
      <dosage-form>Aerosol</dosage-form>
      <strength>0.08 ug/1</strength>
      <route>Respiratory (inhalation)</route>
      <fda-application-number>NDA010375</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
  </products>
  <international-brands>
    <international-brand>
      <name>Proternol L</name>
      <company>Kowa Souyaku</company>
    </international-brand>
    <international-brand>
      <name>Saventrine</name>
      <company>Pharmax</company>
    </international-brand>
  </international-brands>
  <mixtures>
    <mixture>
      <name>Isuprel</name>
      <ingredients>Isoprenaline</ingredients>
    </mixture>
    <mixture>
      <name>Isuprel</name>
      <ingredients>Isoprenaline</ingredients>
    </mixture>
    <mixture>
      <name>Medihaler-Iso</name>
      <ingredients>Isoprenaline</ingredients>
    </mixture>
    <mixture>
      <name>Duo-Medihaler</name>
      <ingredients>Isoprenaline + Phenylephrine</ingredients>
    </mixture>
    <mixture>
      <name>Isuprel</name>
      <ingredients>Isoprenaline</ingredients>
    </mixture>
    <mixture>
      <name>Isuprel</name>
      <ingredients>Isoprenaline</ingredients>
    </mixture>
    <mixture>
      <name>Isuprel</name>
      <ingredients>Isoprenaline</ingredients>
    </mixture>
    <mixture>
      <name>Isoproterenol Hydrochloride</name>
      <ingredients>Isoprenaline</ingredients>
    </mixture>
    <mixture>
      <name>Isoproterenol Hydrochloride</name>
      <ingredients>Isoprenaline</ingredients>
    </mixture>
    <mixture>
      <name>Isuprel</name>
      <ingredients>Isoprenaline</ingredients>
    </mixture>
    <mixture>
      <name>Isoproterenol Hydrochloride</name>
      <ingredients>Isoprenaline</ingredients>
    </mixture>
    <mixture>
      <name>Isoproterenol Hydrochloride</name>
      <ingredients>Isoprenaline</ingredients>
    </mixture>
    <mixture>
      <name>Isoproterenol</name>
      <ingredients>Isoprenaline</ingredients>
    </mixture>
    <mixture>
      <name>Isoproterenol</name>
      <ingredients>Isoprenaline</ingredients>
    </mixture>
    <mixture>
      <name>Isuprel</name>
      <ingredients>Isoprenaline</ingredients>
    </mixture>
    <mixture>
      <name>Isoproterenol Hydrochloride</name>
      <ingredients>Isoprenaline</ingredients>
    </mixture>
    <mixture>
      <name>Isoproterenol Hydrochloride</name>
      <ingredients>Isoprenaline</ingredients>
    </mixture>
    <mixture>
      <name>Isoproterenol Hydrochloride Injection USP</name>
      <ingredients>Isoprenaline</ingredients>
    </mixture>
    <mixture>
      <name>Isuprel Inj 0.2mg/ml</name>
      <ingredients>Isoprenaline</ingredients>
    </mixture>
    <mixture>
      <name>Isuprel Liq Inh 0.5%</name>
      <ingredients>Isoprenaline</ingredients>
    </mixture>
    <mixture>
      <name>Isuprel Mistometer 125mcg/aem</name>
      <ingredients>Isoprenaline</ingredients>
    </mixture>
    <mixture>
      <name>Isuprel Liq 0.5%</name>
      <ingredients>Isoprenaline</ingredients>
    </mixture>
    <mixture>
      <name>Isuprel Mistometer Aem 0.25%</name>
      <ingredients>Isoprenaline</ingredients>
    </mixture>
    <mixture>
      <name>Isuprel Liq 0.2mg/ml</name>
      <ingredients>Isoprenaline</ingredients>
    </mixture>
    <mixture>
      <name>Isoproterenol HCl Inj 1:5000</name>
      <ingredients>Isoprenaline</ingredients>
    </mixture>
    <mixture>
      <name>Isoproterenol Hydrochloride Injection USP</name>
      <ingredients>Isoprenaline</ingredients>
    </mixture>
  </mixtures>
  <packagers>
    <packager>
      <name>Amend</name>
      <url/>
    </packager>
    <packager>
      <name>Baxter International Inc.</name>
      <url>http://www.baxter.com</url>
    </packager>
    <packager>
      <name>ESI Lederle</name>
      <url/>
    </packager>
    <packager>
      <name>Hospira Inc.</name>
      <url>http://www.hospira.com</url>
    </packager>
  </packagers>
  <manufacturers/>
  <prices>
    <price>
      <description>Isoproterenol sulfate cryst</description>
      <cost currency="USD">2.86</cost>
      <unit>g</unit>
    </price>
    <price>
      <description>Isuprel 0.2 mg/ml ampul</description>
      <cost currency="USD">17.63</cost>
      <unit>ml</unit>
    </price>
    <price>
      <description>Isoproterenol 0.2 mg/ml amp</description>
      <cost currency="USD">0.73</cost>
      <unit>ml</unit>
    </price>
  </prices>
  <categories>
    <category>
      <category>Adrenergic Agents</category>
      <mesh-id>D018663</mesh-id>
    </category>
    <category>
      <category>Adrenergic Agonists</category>
      <mesh-id>D000322</mesh-id>
    </category>
    <category>
      <category>Adrenergic and Dopaminergic Agents</category>
      <mesh-id/>
    </category>
    <category>
      <category>Adrenergic beta-2 Receptor Agonists</category>
      <mesh-id>D058666</mesh-id>
    </category>
    <category>
      <category>Adrenergic beta-Agonists</category>
      <mesh-id>D000318</mesh-id>
    </category>
    <category>
      <category>Adrenergics for Systemic Use</category>
      <mesh-id/>
    </category>
    <category>
      <category>Adrenergics, Inhalants</category>
      <mesh-id/>
    </category>
    <category>
      <category>Agents producing tachycardia</category>
      <mesh-id/>
    </category>
    <category>
      <category>Agents that produce hypertension</category>
      <mesh-id/>
    </category>
    <category>
      <category>Alcohols</category>
      <mesh-id>D000438</mesh-id>
    </category>
    <category>
      <category>Amines</category>
      <mesh-id>D000588</mesh-id>
    </category>
    <category>
      <category>Amino Alcohols</category>
      <mesh-id>D000605</mesh-id>
    </category>
    <category>
      <category>Anti-Asthmatic Agents</category>
      <mesh-id>D018927</mesh-id>
    </category>
    <category>
      <category>Autonomic Agents</category>
      <mesh-id>D001337</mesh-id>
    </category>
    <category>
      <category>Benzene Derivatives</category>
      <mesh-id>D001555</mesh-id>
    </category>
    <category>
      <category>Bronchodilator Agents</category>
      <mesh-id>D001993</mesh-id>
    </category>
    <category>
      <category>Cardiac Stimulants Excl. Cardiac Glycosides</category>
      <mesh-id/>
    </category>
    <category>
      <category>Cardiac Therapy</category>
      <mesh-id/>
    </category>
    <category>
      <category>Cardiotonic Agents</category>
      <mesh-id>D002316</mesh-id>
    </category>
    <category>
      <category>Cardiovascular Agents</category>
      <mesh-id>D002317</mesh-id>
    </category>
    <category>
      <category>Catecholamines</category>
      <mesh-id>D002395</mesh-id>
    </category>
    <category>
      <category>Catechols</category>
      <mesh-id>D002396</mesh-id>
    </category>
    <category>
      <category>Compounds used in a research, industrial, or household setting</category>
      <mesh-id>D020313</mesh-id>
    </category>
    <category>
      <category>Drugs for Obstructive Airway Diseases</category>
      <mesh-id/>
    </category>
    <category>
      <category>Ethanolamines</category>
      <mesh-id>D004983</mesh-id>
    </category>
    <category>
      <category>Neurotransmitter Agents</category>
      <mesh-id>D018377</mesh-id>
    </category>
    <category>
      <category>Non-selective Beta-adrenergic Agonists</category>
      <mesh-id/>
    </category>
    <category>
      <category>Peripheral Nervous System Agents</category>
      <mesh-id>D018373</mesh-id>
    </category>
    <category>
      <category>Phenols</category>
      <mesh-id>D010636</mesh-id>
    </category>
    <category>
      <category>Protective Agents</category>
      <mesh-id>D020011</mesh-id>
    </category>
    <category>
      <category>Respiratory System Agents</category>
      <mesh-id>D019141</mesh-id>
    </category>
    <category>
      <category>Sympathomimetics</category>
      <mesh-id>D013566</mesh-id>
    </category>
  </categories>
  <affected-organisms>
    <affected-organism>Humans and other mammals</affected-organism>
  </affected-organisms>
  <dosages>
    <dosage>
      <form>Aerosol, metered</form>
      <route>Respiratory (inhalation)</route>
      <strength/>
    </dosage>
    <dosage>
      <form>Injection, solution</form>
      <route>Intracardiac; Intramuscular; Intravenous; Subcutaneous</route>
      <strength>1 mg/5mL</strength>
    </dosage>
    <dosage>
      <form>Liquid</form>
      <route>Intravenous</route>
      <strength/>
    </dosage>
    <dosage>
      <form>Injection, solution</form>
      <route>Intramuscular; Intravenous</route>
      <strength>0.2 mg/1mL</strength>
    </dosage>
    <dosage>
      <form>Solution</form>
      <route>Intramuscular; Intravenous; Subcutaneous</route>
      <strength/>
    </dosage>
    <dosage>
      <form>Injection, solution</form>
      <route>Intracardiac; Intramuscular; Intravenous; Subcutaneous</route>
      <strength>0.2 mg/1mL</strength>
    </dosage>
    <dosage>
      <form>Liquid</form>
      <route>Intramuscular; Intravenous; Subcutaneous</route>
      <strength/>
    </dosage>
    <dosage>
      <form>Liquid</form>
      <route>Intracardiac; Intramuscular; Intravenous; Subcutaneous</route>
      <strength/>
    </dosage>
    <dosage>
      <form>Liquid</form>
      <route>Respiratory (inhalation)</route>
      <strength/>
    </dosage>
    <dosage>
      <form>Aerosol, metered</form>
      <route>Respiratory (inhalation)</route>
      <strength/>
    </dosage>
    <dosage>
      <form>Aerosol</form>
      <route>Respiratory (inhalation)</route>
      <strength>0.08 ug/1</strength>
    </dosage>
  </dosages>
  <atc-codes>
    <atc-code code="C01CA02">
      <level code="C01CA">Adrenergic and dopaminergic agents</level>
      <level code="C01C">CARDIAC STIMULANTS EXCL. CARDIAC GLYCOSIDES</level>
      <level code="C01">CARDIAC THERAPY</level>
      <level code="C">CARDIOVASCULAR SYSTEM</level>
    </atc-code>
    <atc-code code="R03AK02">
      <level code="R03AK">Adrenergics in combination with corticosteroids or other drugs, excl. anticholinergics</level>
      <level code="R03A">ADRENERGICS, INHALANTS</level>
      <level code="R03">DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES</level>
      <level code="R">RESPIRATORY SYSTEM</level>
    </atc-code>
    <atc-code code="R03AB02">
      <level code="R03AB">Non-selective beta-adrenoreceptor agonists</level>
      <level code="R03A">ADRENERGICS, INHALANTS</level>
      <level code="R03">DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES</level>
      <level code="R">RESPIRATORY SYSTEM</level>
    </atc-code>
    <atc-code code="R03CB01">
      <level code="R03CB">Non-selective beta-adrenoreceptor agonists</level>
      <level code="R03C">ADRENERGICS FOR SYSTEMIC USE</level>
      <level code="R03">DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES</level>
      <level code="R">RESPIRATORY SYSTEM</level>
    </atc-code>
    <atc-code code="R03CB51">
      <level code="R03CB">Non-selective beta-adrenoreceptor agonists</level>
      <level code="R03C">ADRENERGICS FOR SYSTEMIC USE</level>
      <level code="R03">DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES</level>
      <level code="R">RESPIRATORY SYSTEM</level>
    </atc-code>
  </atc-codes>
  <ahfs-codes>
    <ahfs-code>12:12.08.04</ahfs-code>
  </ahfs-codes>
  <pdb-entries/>
  <fda-label>//s3-us-west-2.amazonaws.com/drugbank/fda_labels/DB01064.pdf?1265922810</fda-label>
  <msds>//s3-us-west-2.amazonaws.com/drugbank/msds/DB01064.pdf?1265922747</msds>
  <patents/>
  <food-interactions/>
  <drug-interactions>
    <drug-interaction>
      <drugbank-id>DB00177</drugbank-id>
      <name>Valsartan</name>
      <description>Isoprenaline may decrease the antihypertensive activities of Valsartan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00178</drugbank-id>
      <name>Ramipril</name>
      <description>Isoprenaline may decrease the antihypertensive activities of Ramipril.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00206</drugbank-id>
      <name>Reserpine</name>
      <description>Isoprenaline may decrease the antihypertensive activities of Reserpine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00212</drugbank-id>
      <name>Remikiren</name>
      <description>Isoprenaline may decrease the antihypertensive activities of Remikiren.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00270</drugbank-id>
      <name>Isradipine</name>
      <description>Isoprenaline may decrease the antihypertensive activities of Isradipine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00275</drugbank-id>
      <name>Olmesartan</name>
      <description>Isoprenaline may decrease the antihypertensive activities of Olmesartan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00325</drugbank-id>
      <name>Nitroprusside</name>
      <description>Isoprenaline may decrease the antihypertensive activities of Nitroprusside.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00343</drugbank-id>
      <name>Diltiazem</name>
      <description>Isoprenaline may decrease the antihypertensive activities of Diltiazem.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00350</drugbank-id>
      <name>Minoxidil</name>
      <description>Isoprenaline may decrease the antihypertensive activities of Minoxidil.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00374</drugbank-id>
      <name>Treprostinil</name>
      <description>Isoprenaline may decrease the antihypertensive activities of Treprostinil.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00381</drugbank-id>
      <name>Amlodipine</name>
      <description>Isoprenaline may decrease the antihypertensive activities of Amlodipine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00393</drugbank-id>
      <name>Nimodipine</name>
      <description>Isoprenaline may decrease the antihypertensive activities of Nimodipine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00401</drugbank-id>
      <name>Nisoldipine</name>
      <description>Isoprenaline may decrease the antihypertensive activities of Nisoldipine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00492</drugbank-id>
      <name>Fosinopril</name>
      <description>Isoprenaline may decrease the antihypertensive activities of Fosinopril.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00519</drugbank-id>
      <name>Trandolapril</name>
      <description>Isoprenaline may decrease the antihypertensive activities of Trandolapril.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00528</drugbank-id>
      <name>Lercanidipine</name>
      <description>Isoprenaline may decrease the antihypertensive activities of Lercanidipine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00542</drugbank-id>
      <name>Benazepril</name>
      <description>Isoprenaline may decrease the antihypertensive activities of Benazepril.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00559</drugbank-id>
      <name>Bosentan</name>
      <description>Isoprenaline may decrease the antihypertensive activities of Bosentan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00584</drugbank-id>
      <name>Enalapril</name>
      <description>Isoprenaline may decrease the antihypertensive activities of Enalapril.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00606</drugbank-id>
      <name>Cyclothiazide</name>
      <description>Isoprenaline may decrease the antihypertensive activities of Cyclothiazide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00616</drugbank-id>
      <name>Candoxatril</name>
      <description>Isoprenaline may decrease the antihypertensive activities of Candoxatril.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00657</drugbank-id>
      <name>Mecamylamine</name>
      <description>Isoprenaline may decrease the antihypertensive activities of Mecamylamine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00678</drugbank-id>
      <name>Losartan</name>
      <description>Isoprenaline may decrease the antihypertensive activities of Losartan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00691</drugbank-id>
      <name>Moexipril</name>
      <description>Isoprenaline may decrease the antihypertensive activities of Moexipril.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00700</drugbank-id>
      <name>Eplerenone</name>
      <description>Isoprenaline may decrease the antihypertensive activities of Eplerenone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00722</drugbank-id>
      <name>Lisinopril</name>
      <description>Isoprenaline may decrease the antihypertensive activities of Lisinopril.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00727</drugbank-id>
      <name>Nitroglycerin</name>
      <description>Isoprenaline may decrease the antihypertensive activities of Nitroglycerin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00765</drugbank-id>
      <name>Metyrosine</name>
      <description>Isoprenaline may decrease the antihypertensive activities of Metyrosine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00785</drugbank-id>
      <name>Cryptenamine</name>
      <description>Isoprenaline may decrease the antihypertensive activities of Cryptenamine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00790</drugbank-id>
      <name>Perindopril</name>
      <description>Isoprenaline may decrease the antihypertensive activities of Perindopril.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00796</drugbank-id>
      <name>Candesartan cilexetil</name>
      <description>Isoprenaline may decrease the antihypertensive activities of Candesartan cilexetil.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00800</drugbank-id>
      <name>Fenoldopam</name>
      <description>Isoprenaline may decrease the antihypertensive activities of Fenoldopam.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00820</drugbank-id>
      <name>Tadalafil</name>
      <description>Isoprenaline may decrease the antihypertensive activities of Tadalafil.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00876</drugbank-id>
      <name>Eprosartan</name>
      <description>Isoprenaline may decrease the antihypertensive activities of Eprosartan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00881</drugbank-id>
      <name>Quinapril</name>
      <description>Isoprenaline may decrease the antihypertensive activities of Quinapril.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00966</drugbank-id>
      <name>Telmisartan</name>
      <description>Isoprenaline may decrease the antihypertensive activities of Telmisartan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00968</drugbank-id>
      <name>Methyldopa</name>
      <description>Isoprenaline may decrease the antihypertensive activities of Methyldopa.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01029</drugbank-id>
      <name>Irbesartan</name>
      <description>Isoprenaline may decrease the antihypertensive activities of Irbesartan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01054</drugbank-id>
      <name>Nitrendipine</name>
      <description>Isoprenaline may decrease the antihypertensive activities of Nitrendipine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01089</drugbank-id>
      <name>Deserpidine</name>
      <description>Isoprenaline may decrease the antihypertensive activities of Deserpidine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01090</drugbank-id>
      <name>Pentolinium</name>
      <description>Isoprenaline may decrease the antihypertensive activities of Pentolinium.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01116</drugbank-id>
      <name>Trimethaphan</name>
      <description>Isoprenaline may decrease the antihypertensive activities of Trimethaphan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01119</drugbank-id>
      <name>Diazoxide</name>
      <description>Isoprenaline may decrease the antihypertensive activities of Diazoxide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01197</drugbank-id>
      <name>Captopril</name>
      <description>Isoprenaline may decrease the antihypertensive activities of Captopril.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01240</drugbank-id>
      <name>Epoprostenol</name>
      <description>Isoprenaline may decrease the antihypertensive activities of Epoprostenol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01244</drugbank-id>
      <name>Bepridil</name>
      <description>Isoprenaline may decrease the antihypertensive activities of Bepridil.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01275</drugbank-id>
      <name>Hydralazine</name>
      <description>Isoprenaline may decrease the antihypertensive activities of Hydralazine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01340</drugbank-id>
      <name>Cilazapril</name>
      <description>Isoprenaline may decrease the antihypertensive activities of Cilazapril.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01347</drugbank-id>
      <name>Saprisartan</name>
      <description>Isoprenaline may decrease the antihypertensive activities of Saprisartan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01348</drugbank-id>
      <name>Spirapril</name>
      <description>Isoprenaline may decrease the antihypertensive activities of Spirapril.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01388</drugbank-id>
      <name>Mibefradil</name>
      <description>Isoprenaline may decrease the antihypertensive activities of Mibefradil.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04831</drugbank-id>
      <name>Tienilic acid</name>
      <description>Isoprenaline may decrease the antihypertensive activities of Tienilic acid.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04840</drugbank-id>
      <name>Debrisoquine</name>
      <description>Isoprenaline may decrease the antihypertensive activities of Debrisoquine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06268</drugbank-id>
      <name>Sitaxentan</name>
      <description>Isoprenaline may decrease the antihypertensive activities of Sitaxentan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06403</drugbank-id>
      <name>Ambrisentan</name>
      <description>Isoprenaline may decrease the antihypertensive activities of Ambrisentan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06445</drugbank-id>
      <name>Diethylnorspermine</name>
      <description>Isoprenaline may decrease the antihypertensive activities of Diethylnorspermine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06712</drugbank-id>
      <name>Nilvadipine</name>
      <description>Isoprenaline may decrease the antihypertensive activities of Nilvadipine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06762</drugbank-id>
      <name>Pinacidil</name>
      <description>Isoprenaline may decrease the antihypertensive activities of Pinacidil.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB07767</drugbank-id>
      <name>Ferulic acid</name>
      <description>Isoprenaline may decrease the antihypertensive activities of Ferulic acid.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08836</drugbank-id>
      <name>Temocapril</name>
      <description>Isoprenaline may decrease the antihypertensive activities of Temocapril.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08931</drugbank-id>
      <name>Riociguat</name>
      <description>Isoprenaline may decrease the antihypertensive activities of Riociguat.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08932</drugbank-id>
      <name>Macitentan</name>
      <description>Isoprenaline may decrease the antihypertensive activities of Macitentan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08960</drugbank-id>
      <name>Hexamethonium</name>
      <description>Isoprenaline may decrease the antihypertensive activities of Hexamethonium.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09026</drugbank-id>
      <name>Aliskiren</name>
      <description>Isoprenaline may decrease the antihypertensive activities of Aliskiren.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09220</drugbank-id>
      <name>Nicorandil</name>
      <description>Isoprenaline may decrease the antihypertensive activities of Nicorandil.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09235</drugbank-id>
      <name>Efonidipine</name>
      <description>Isoprenaline may decrease the antihypertensive activities of Efonidipine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09236</drugbank-id>
      <name>Lacidipine</name>
      <description>Isoprenaline may decrease the antihypertensive activities of Lacidipine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09238</drugbank-id>
      <name>Manidipine</name>
      <description>Isoprenaline may decrease the antihypertensive activities of Manidipine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09363</drugbank-id>
      <name>Rauwolfia serpentina root</name>
      <description>Isoprenaline may decrease the antihypertensive activities of Rauwolfia serpentina root.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09477</drugbank-id>
      <name>Enalaprilat</name>
      <description>Isoprenaline may decrease the antihypertensive activities of Enalaprilat.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11362</drugbank-id>
      <name>Selexipag</name>
      <description>Isoprenaline may decrease the antihypertensive activities of Selexipag.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11720</drugbank-id>
      <name>Angiotensin 1-7</name>
      <description>Isoprenaline may decrease the antihypertensive activities of Angiotensin 1-7.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11783</drugbank-id>
      <name>Imidapril</name>
      <description>Isoprenaline may decrease the antihypertensive activities of Imidapril.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12054</drugbank-id>
      <name>BQ-123</name>
      <description>Isoprenaline may decrease the antihypertensive activities of BQ-123.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12093</drugbank-id>
      <name>Tetrahydropalmatine</name>
      <description>Isoprenaline may decrease the antihypertensive activities of Tetrahydropalmatine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12465</drugbank-id>
      <name>Ketanserin</name>
      <description>Isoprenaline may decrease the antihypertensive activities of Ketanserin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12766</drugbank-id>
      <name>Cicletanine</name>
      <description>Isoprenaline may decrease the antihypertensive activities of Cicletanine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12945</drugbank-id>
      <name>Dihydralazine</name>
      <description>Isoprenaline may decrease the antihypertensive activities of Dihydralazine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13166</drugbank-id>
      <name>Zofenopril</name>
      <description>Isoprenaline may decrease the antihypertensive activities of Zofenopril.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13211</drugbank-id>
      <name>Guanoxan</name>
      <description>Isoprenaline may decrease the antihypertensive activities of Guanoxan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13312</drugbank-id>
      <name>Delapril</name>
      <description>Isoprenaline may decrease the antihypertensive activities of Delapril.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13374</drugbank-id>
      <name>Vincamine</name>
      <description>Isoprenaline may decrease the antihypertensive activities of Vincamine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13400</drugbank-id>
      <name>Linsidomine</name>
      <description>Isoprenaline may decrease the antihypertensive activities of Linsidomine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13410</drugbank-id>
      <name>Guanoxabenz</name>
      <description>Isoprenaline may decrease the antihypertensive activities of Guanoxabenz.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13429</drugbank-id>
      <name>Tolonidine</name>
      <description>Isoprenaline may decrease the antihypertensive activities of Tolonidine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13435</drugbank-id>
      <name>Endralazine</name>
      <description>Isoprenaline may decrease the antihypertensive activities of Endralazine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13452</drugbank-id>
      <name>Cadralazine</name>
      <description>Isoprenaline may decrease the antihypertensive activities of Cadralazine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13575</drugbank-id>
      <name>Bietaserpine</name>
      <description>Isoprenaline may decrease the antihypertensive activities of Bietaserpine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13604</drugbank-id>
      <name>Guanazodine</name>
      <description>Isoprenaline may decrease the antihypertensive activities of Guanazodine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13631</drugbank-id>
      <name>Methoserpidine</name>
      <description>Isoprenaline may decrease the antihypertensive activities of Methoserpidine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13779</drugbank-id>
      <name>Guanoclor</name>
      <description>Isoprenaline may decrease the antihypertensive activities of Guanoclor.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13801</drugbank-id>
      <name>Muzolimine</name>
      <description>Isoprenaline may decrease the antihypertensive activities of Muzolimine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13803</drugbank-id>
      <name>Xipamide</name>
      <description>Isoprenaline may decrease the antihypertensive activities of Xipamide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13919</drugbank-id>
      <name>Candesartan</name>
      <description>Isoprenaline may decrease the antihypertensive activities of Candesartan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14068</drugbank-id>
      <name>Dexniguldipine</name>
      <description>Isoprenaline may decrease the antihypertensive activities of Dexniguldipine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14094</drugbank-id>
      <name>Tocopherylquinone</name>
      <description>Isoprenaline may decrease the antihypertensive activities of Tocopherylquinone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14125</drugbank-id>
      <name>Benazeprilat</name>
      <description>Isoprenaline may decrease the antihypertensive activities of Benazeprilat.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14207</drugbank-id>
      <name>Fosinoprilat</name>
      <description>Isoprenaline may decrease the antihypertensive activities of Fosinoprilat.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14208</drugbank-id>
      <name>Ramiprilat</name>
      <description>Isoprenaline may decrease the antihypertensive activities of Ramiprilat.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14213</drugbank-id>
      <name>Perindoprilat</name>
      <description>Isoprenaline may decrease the antihypertensive activities of Perindoprilat.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14217</drugbank-id>
      <name>Quinaprilat</name>
      <description>Isoprenaline may decrease the antihypertensive activities of Quinaprilat.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01023</drugbank-id>
      <name>Felodipine</name>
      <description>Felodipine may decrease the antihypertensive activities of Isoprenaline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00601</drugbank-id>
      <name>Linezolid</name>
      <description>The risk or severity of hypertension can be increased when Linezolid is combined with Isoprenaline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00035</drugbank-id>
      <name>Desmopressin</name>
      <description>The risk or severity of hypertension can be increased when Desmopressin is combined with Isoprenaline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00091</drugbank-id>
      <name>Cyclosporine</name>
      <description>The risk or severity of hypertension can be increased when Cyclosporine is combined with Isoprenaline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00159</drugbank-id>
      <name>Icosapent</name>
      <description>The risk or severity of hypertension can be increased when Icosapent is combined with Isoprenaline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00216</drugbank-id>
      <name>Eletriptan</name>
      <description>The risk or severity of hypertension can be increased when Eletriptan is combined with Isoprenaline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00217</drugbank-id>
      <name>Bethanidine</name>
      <description>The risk or severity of hypertension can be increased when Bethanidine is combined with Isoprenaline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00244</drugbank-id>
      <name>Mesalazine</name>
      <description>The risk or severity of hypertension can be increased when Mesalazine is combined with Isoprenaline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00292</drugbank-id>
      <name>Etomidate</name>
      <description>The risk or severity of hypertension can be increased when Etomidate is combined with Isoprenaline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00315</drugbank-id>
      <name>Zolmitriptan</name>
      <description>The risk or severity of hypertension can be increased when Zolmitriptan is combined with Isoprenaline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00328</drugbank-id>
      <name>Indomethacin</name>
      <description>The risk or severity of hypertension can be increased when Indomethacin is combined with Isoprenaline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00370</drugbank-id>
      <name>Mirtazapine</name>
      <description>The risk or severity of hypertension can be increased when Mirtazapine is combined with Isoprenaline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00422</drugbank-id>
      <name>Methylphenidate</name>
      <description>The risk or severity of hypertension can be increased when Methylphenidate is combined with Isoprenaline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00461</drugbank-id>
      <name>Nabumetone</name>
      <description>The risk or severity of hypertension can be increased when Nabumetone is combined with Isoprenaline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00465</drugbank-id>
      <name>Ketorolac</name>
      <description>The risk or severity of hypertension can be increased when Ketorolac is combined with Isoprenaline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00469</drugbank-id>
      <name>Tenoxicam</name>
      <description>The risk or severity of hypertension can be increased when Tenoxicam is combined with Isoprenaline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00482</drugbank-id>
      <name>Celecoxib</name>
      <description>The risk or severity of hypertension can be increased when Celecoxib is combined with Isoprenaline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00490</drugbank-id>
      <name>Buspirone</name>
      <description>The risk or severity of hypertension can be increased when Buspirone is combined with Isoprenaline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00500</drugbank-id>
      <name>Tolmetin</name>
      <description>The risk or severity of hypertension can be increased when Tolmetin is combined with Isoprenaline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00533</drugbank-id>
      <name>Rofecoxib</name>
      <description>The risk or severity of hypertension can be increased when Rofecoxib is combined with Isoprenaline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00554</drugbank-id>
      <name>Piroxicam</name>
      <description>The risk or severity of hypertension can be increased when Piroxicam is combined with Isoprenaline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00561</drugbank-id>
      <name>Doxapram</name>
      <description>The risk or severity of hypertension can be increased when Doxapram is combined with Isoprenaline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00572</drugbank-id>
      <name>Atropine</name>
      <description>The risk or severity of hypertension can be increased when Atropine is combined with Isoprenaline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00573</drugbank-id>
      <name>Fenoprofen</name>
      <description>The risk or severity of hypertension can be increased when Fenoprofen is combined with Isoprenaline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00575</drugbank-id>
      <name>Clonidine</name>
      <description>The risk or severity of hypertension can be increased when Clonidine is combined with Isoprenaline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00580</drugbank-id>
      <name>Valdecoxib</name>
      <description>The risk or severity of hypertension can be increased when Valdecoxib is combined with Isoprenaline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00586</drugbank-id>
      <name>Diclofenac</name>
      <description>The risk or severity of hypertension can be increased when Diclofenac is combined with Isoprenaline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00605</drugbank-id>
      <name>Sulindac</name>
      <description>The risk or severity of hypertension can be increased when Sulindac is combined with Isoprenaline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00629</drugbank-id>
      <name>Guanabenz</name>
      <description>The risk or severity of hypertension can be increased when Guanabenz is combined with Isoprenaline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00633</drugbank-id>
      <name>Dexmedetomidine</name>
      <description>The risk or severity of hypertension can be increased when Dexmedetomidine is combined with Isoprenaline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00669</drugbank-id>
      <name>Sumatriptan</name>
      <description>The risk or severity of hypertension can be increased when Sumatriptan is combined with Isoprenaline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00708</drugbank-id>
      <name>Sufentanil</name>
      <description>The risk or severity of hypertension can be increased when Sufentanil is combined with Isoprenaline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00712</drugbank-id>
      <name>Flurbiprofen</name>
      <description>The risk or severity of hypertension can be increased when Flurbiprofen is combined with Isoprenaline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00749</drugbank-id>
      <name>Etodolac</name>
      <description>The risk or severity of hypertension can be increased when Etodolac is combined with Isoprenaline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00784</drugbank-id>
      <name>Mefenamic acid</name>
      <description>The risk or severity of hypertension can be increased when Mefenamic acid is combined with Isoprenaline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00788</drugbank-id>
      <name>Naproxen</name>
      <description>The risk or severity of hypertension can be increased when Naproxen is combined with Isoprenaline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00795</drugbank-id>
      <name>Sulfasalazine</name>
      <description>The risk or severity of hypertension can be increased when Sulfasalazine is combined with Isoprenaline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00802</drugbank-id>
      <name>Alfentanil</name>
      <description>The risk or severity of hypertension can be increased when Alfentanil is combined with Isoprenaline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00812</drugbank-id>
      <name>Phenylbutazone</name>
      <description>The risk or severity of hypertension can be increased when Phenylbutazone is combined with Isoprenaline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00813</drugbank-id>
      <name>Fentanyl</name>
      <description>The risk or severity of hypertension can be increased when Fentanyl is combined with Isoprenaline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00814</drugbank-id>
      <name>Meloxicam</name>
      <description>The risk or severity of hypertension can be increased when Meloxicam is combined with Isoprenaline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00818</drugbank-id>
      <name>Propofol</name>
      <description>The risk or severity of hypertension can be increased when Propofol is combined with Isoprenaline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00821</drugbank-id>
      <name>Carprofen</name>
      <description>The risk or severity of hypertension can be increased when Carprofen is combined with Isoprenaline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00861</drugbank-id>
      <name>Diflunisal</name>
      <description>The risk or severity of hypertension can be increased when Diflunisal is combined with Isoprenaline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00886</drugbank-id>
      <name>Omapatrilat</name>
      <description>The risk or severity of hypertension can be increased when Omapatrilat is combined with Isoprenaline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00899</drugbank-id>
      <name>Remifentanil</name>
      <description>The risk or severity of hypertension can be increased when Remifentanil is combined with Isoprenaline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00918</drugbank-id>
      <name>Almotriptan</name>
      <description>The risk or severity of hypertension can be increased when Almotriptan is combined with Isoprenaline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00936</drugbank-id>
      <name>Salicylic acid</name>
      <description>The risk or severity of hypertension can be increased when Salicylic acid is combined with Isoprenaline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00939</drugbank-id>
      <name>Meclofenamic acid</name>
      <description>The risk or severity of hypertension can be increased when Meclofenamic acid is combined with Isoprenaline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00945</drugbank-id>
      <name>Acetylsalicylic acid</name>
      <description>The risk or severity of hypertension can be increased when Acetylsalicylic acid is combined with Isoprenaline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00952</drugbank-id>
      <name>Naratriptan</name>
      <description>The risk or severity of hypertension can be increased when Naratriptan is combined with Isoprenaline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00953</drugbank-id>
      <name>Rizatriptan</name>
      <description>The risk or severity of hypertension can be increased when Rizatriptan is combined with Isoprenaline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00991</drugbank-id>
      <name>Oxaprozin</name>
      <description>The risk or severity of hypertension can be increased when Oxaprozin is combined with Isoprenaline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00998</drugbank-id>
      <name>Frovatriptan</name>
      <description>The risk or severity of hypertension can be increased when Frovatriptan is combined with Isoprenaline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01009</drugbank-id>
      <name>Ketoprofen</name>
      <description>The risk or severity of hypertension can be increased when Ketoprofen is combined with Isoprenaline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01014</drugbank-id>
      <name>Balsalazide</name>
      <description>The risk or severity of hypertension can be increased when Balsalazide is combined with Isoprenaline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01018</drugbank-id>
      <name>Guanfacine</name>
      <description>The risk or severity of hypertension can be increased when Guanfacine is combined with Isoprenaline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01050</drugbank-id>
      <name>Ibuprofen</name>
      <description>The risk or severity of hypertension can be increased when Ibuprofen is combined with Isoprenaline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01126</drugbank-id>
      <name>Dutasteride</name>
      <description>The risk or severity of hypertension can be increased when Isoprenaline is combined with Dutasteride.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01180</drugbank-id>
      <name>Rescinnamine</name>
      <description>The risk or severity of hypertension can be increased when Isoprenaline is combined with Rescinnamine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01216</drugbank-id>
      <name>Finasteride</name>
      <description>The risk or severity of hypertension can be increased when Isoprenaline is combined with Finasteride.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01250</drugbank-id>
      <name>Olsalazine</name>
      <description>The risk or severity of hypertension can be increased when Isoprenaline is combined with Olsalazine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01283</drugbank-id>
      <name>Lumiracoxib</name>
      <description>The risk or severity of hypertension can be increased when Isoprenaline is combined with Lumiracoxib.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01392</drugbank-id>
      <name>Yohimbine</name>
      <description>The risk or severity of hypertension can be increased when Isoprenaline is combined with Yohimbine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01397</drugbank-id>
      <name>Magnesium salicylate</name>
      <description>The risk or severity of hypertension can be increased when Isoprenaline is combined with Magnesium salicylate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01399</drugbank-id>
      <name>Salsalate</name>
      <description>The risk or severity of hypertension can be increased when Isoprenaline is combined with Salsalate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01401</drugbank-id>
      <name>Choline magnesium trisalicylate</name>
      <description>The risk or severity of hypertension can be increased when Isoprenaline is combined with Choline magnesium trisalicylate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01419</drugbank-id>
      <name>Antrafenine</name>
      <description>The risk or severity of hypertension can be increased when Isoprenaline is combined with Antrafenine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01424</drugbank-id>
      <name>Aminophenazone</name>
      <description>The risk or severity of hypertension can be increased when Isoprenaline is combined with Aminophenazone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01435</drugbank-id>
      <name>Antipyrine</name>
      <description>The risk or severity of hypertension can be increased when Isoprenaline is combined with Antipyrine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01472</drugbank-id>
      <name>4-Methoxyamphetamine</name>
      <description>The risk or severity of hypertension can be increased when Isoprenaline is combined with 4-Methoxyamphetamine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01579</drugbank-id>
      <name>Phendimetrazine</name>
      <description>The risk or severity of hypertension can be increased when Isoprenaline is combined with Phendimetrazine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01591</drugbank-id>
      <name>Solifenacin</name>
      <description>The risk or severity of hypertension can be increased when Isoprenaline is combined with Solifenacin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01600</drugbank-id>
      <name>Tiaprofenic acid</name>
      <description>The risk or severity of hypertension can be increased when Isoprenaline is combined with Tiaprofenic acid.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01628</drugbank-id>
      <name>Etoricoxib</name>
      <description>The risk or severity of hypertension can be increased when Isoprenaline is combined with Etoricoxib.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB02032</drugbank-id>
      <name>1-(3-Mercapto-2-Methyl-Propionyl)-Pyrrolidine-2-Carboxylic Acid</name>
      <description>The risk or severity of hypertension can be increased when Isoprenaline is combined with 1-(3-Mercapto-2-Methyl-Propionyl)-Pyrrolidine-2-Carboxylic Acid.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB02224</drugbank-id>
      <name>Taxifolin</name>
      <description>The risk or severity of hypertension can be increased when Isoprenaline is combined with Taxifolin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB03585</drugbank-id>
      <name>Oxyphenbutazone</name>
      <description>The risk or severity of hypertension can be increased when Isoprenaline is combined with Oxyphenbutazone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04552</drugbank-id>
      <name>Niflumic acid</name>
      <description>The risk or severity of hypertension can be increased when Isoprenaline is combined with Niflumic acid.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04581</drugbank-id>
      <name>1-benzylimidazole</name>
      <description>The risk or severity of hypertension can be increased when Isoprenaline is combined with 1-benzylimidazole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04743</drugbank-id>
      <name>Nimesulide</name>
      <description>The risk or severity of hypertension can be increased when Isoprenaline is combined with Nimesulide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04812</drugbank-id>
      <name>Benoxaprofen</name>
      <description>The risk or severity of hypertension can be increased when Isoprenaline is combined with Benoxaprofen.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04817</drugbank-id>
      <name>Metamizole</name>
      <description>The risk or severity of hypertension can be increased when Isoprenaline is combined with Metamizole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04828</drugbank-id>
      <name>Zomepirac</name>
      <description>The risk or severity of hypertension can be increased when Isoprenaline is combined with Zomepirac.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04908</drugbank-id>
      <name>Flibanserin</name>
      <description>The risk or severity of hypertension can be increased when Isoprenaline is combined with Flibanserin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04948</drugbank-id>
      <name>Lofexidine</name>
      <description>The risk or severity of hypertension can be increased when Isoprenaline is combined with Lofexidine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB05095</drugbank-id>
      <name>Cimicoxib</name>
      <description>The risk or severity of hypertension can be increased when Isoprenaline is combined with Cimicoxib.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB05271</drugbank-id>
      <name>Rotigotine</name>
      <description>The risk or severity of hypertension can be increased when Isoprenaline is combined with Rotigotine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB05395</drugbank-id>
      <name>Amibegron</name>
      <description>The risk or severity of hypertension can be increased when Isoprenaline is combined with Amibegron.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB05562</drugbank-id>
      <name>Naluzotan</name>
      <description>The risk or severity of hypertension can be increased when Isoprenaline is combined with Naluzotan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06016</drugbank-id>
      <name>Cariprazine</name>
      <description>The risk or severity of hypertension can be increased when Isoprenaline is combined with Cariprazine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06148</drugbank-id>
      <name>Mianserin</name>
      <description>The risk or severity of hypertension can be increased when Isoprenaline is combined with Mianserin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06190</drugbank-id>
      <name>Solabegron</name>
      <description>The risk or severity of hypertension can be increased when Isoprenaline is combined with Solabegron.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06678</drugbank-id>
      <name>Esmirtazapine</name>
      <description>The risk or severity of hypertension can be increased when Isoprenaline is combined with Esmirtazapine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06684</drugbank-id>
      <name>Vilazodone</name>
      <description>The risk or severity of hypertension can be increased when Isoprenaline is combined with Vilazodone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06694</drugbank-id>
      <name>Xylometazoline</name>
      <description>The risk or severity of hypertension can be increased when Isoprenaline is combined with Xylometazoline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06701</drugbank-id>
      <name>Dexmethylphenidate</name>
      <description>The risk or severity of hypertension can be increased when Isoprenaline is combined with Dexmethylphenidate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06706</drugbank-id>
      <name>Isometheptene</name>
      <description>The risk or severity of hypertension can be increased when Isoprenaline is combined with Isometheptene.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06711</drugbank-id>
      <name>Naphazoline</name>
      <description>The risk or severity of hypertension can be increased when Isoprenaline is combined with Naphazoline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06725</drugbank-id>
      <name>Lornoxicam</name>
      <description>The risk or severity of hypertension can be increased when Isoprenaline is combined with Lornoxicam.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06736</drugbank-id>
      <name>Aceclofenac</name>
      <description>The risk or severity of hypertension can be increased when Isoprenaline is combined with Aceclofenac.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06737</drugbank-id>
      <name>Zaltoprofen</name>
      <description>The risk or severity of hypertension can be increased when Isoprenaline is combined with Zaltoprofen.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06763</drugbank-id>
      <name>Saralasin</name>
      <description>The risk or severity of hypertension can be increased when Isoprenaline is combined with Saralasin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB07402</drugbank-id>
      <name>Azapropazone</name>
      <description>The risk or severity of hypertension can be increased when Isoprenaline is combined with Azapropazone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB07477</drugbank-id>
      <name>Felbinac</name>
      <description>The risk or severity of hypertension can be increased when Isoprenaline is combined with Felbinac.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08439</drugbank-id>
      <name>Parecoxib</name>
      <description>The risk or severity of hypertension can be increased when Isoprenaline is combined with Parecoxib.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08797</drugbank-id>
      <name>Salicylamide</name>
      <description>The risk or severity of hypertension can be increased when Isoprenaline is combined with Salicylamide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08810</drugbank-id>
      <name>Cinitapride</name>
      <description>The risk or severity of hypertension can be increased when Isoprenaline is combined with Cinitapride.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08815</drugbank-id>
      <name>Lurasidone</name>
      <description>The risk or severity of hypertension can be increased when Isoprenaline is combined with Lurasidone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08893</drugbank-id>
      <name>Mirabegron</name>
      <description>The risk or severity of hypertension can be increased when Isoprenaline is combined with Mirabegron.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08925</drugbank-id>
      <name>Adrafinil</name>
      <description>The risk or severity of hypertension can be increased when Isoprenaline is combined with Adrafinil.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08940</drugbank-id>
      <name>Kebuzone</name>
      <description>The risk or severity of hypertension can be increased when Isoprenaline is combined with Kebuzone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08942</drugbank-id>
      <name>Isoxicam</name>
      <description>The risk or severity of hypertension can be increased when Isoprenaline is combined with Isoxicam.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08951</drugbank-id>
      <name>Indoprofen</name>
      <description>The risk or severity of hypertension can be increased when Isoprenaline is combined with Indoprofen.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08954</drugbank-id>
      <name>Ifenprodil</name>
      <description>The risk or severity of hypertension can be increased when Isoprenaline is combined with Ifenprodil.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08955</drugbank-id>
      <name>Ibuproxam</name>
      <description>The risk or severity of hypertension can be increased when Isoprenaline is combined with Ibuproxam.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08976</drugbank-id>
      <name>Floctafenine</name>
      <description>The risk or severity of hypertension can be increased when Isoprenaline is combined with Floctafenine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08981</drugbank-id>
      <name>Fenbufen</name>
      <description>The risk or severity of hypertension can be increased when Isoprenaline is combined with Fenbufen.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08984</drugbank-id>
      <name>Etofenamate</name>
      <description>The risk or severity of hypertension can be increased when Isoprenaline is combined with Etofenamate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08991</drugbank-id>
      <name>Epirizole</name>
      <description>The risk or severity of hypertension can be increased when Isoprenaline is combined with Epirizole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09068</drugbank-id>
      <name>Vortioxetine</name>
      <description>The risk or severity of hypertension can be increased when Isoprenaline is combined with Vortioxetine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09084</drugbank-id>
      <name>Benzydamine</name>
      <description>The risk or severity of hypertension can be increased when Isoprenaline is combined with Benzydamine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09202</drugbank-id>
      <name>Cirazoline</name>
      <description>The risk or severity of hypertension can be increased when Isoprenaline is combined with Cirazoline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09205</drugbank-id>
      <name>Moxisylyte</name>
      <description>The risk or severity of hypertension can be increased when Isoprenaline is combined with Moxisylyte.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09212</drugbank-id>
      <name>Loxoprofen</name>
      <description>The risk or severity of hypertension can be increased when Isoprenaline is combined with Loxoprofen.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09213</drugbank-id>
      <name>Dexibuprofen</name>
      <description>The risk or severity of hypertension can be increased when Isoprenaline is combined with Dexibuprofen.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09214</drugbank-id>
      <name>Dexketoprofen</name>
      <description>The risk or severity of hypertension can be increased when Isoprenaline is combined with Dexketoprofen.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09215</drugbank-id>
      <name>Droxicam</name>
      <description>The risk or severity of hypertension can be increased when Isoprenaline is combined with Droxicam.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09216</drugbank-id>
      <name>Tolfenamic acid</name>
      <description>The risk or severity of hypertension can be increased when Isoprenaline is combined with Tolfenamic acid.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09217</drugbank-id>
      <name>Firocoxib</name>
      <description>The risk or severity of hypertension can be increased when Isoprenaline is combined with Firocoxib.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09218</drugbank-id>
      <name>Clonixin</name>
      <description>The risk or severity of hypertension can be increased when Isoprenaline is combined with Clonixin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09242</drugbank-id>
      <name>Moxonidine</name>
      <description>The risk or severity of hypertension can be increased when Isoprenaline is combined with Moxonidine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09285</drugbank-id>
      <name>Morniflumate</name>
      <description>The risk or severity of hypertension can be increased when Isoprenaline is combined with Morniflumate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09288</drugbank-id>
      <name>Propacetamol</name>
      <description>The risk or severity of hypertension can be increased when Isoprenaline is combined with Propacetamol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09295</drugbank-id>
      <name>Talniflumate</name>
      <description>The risk or severity of hypertension can be increased when Isoprenaline is combined with Talniflumate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11278</drugbank-id>
      <name>DL-Methylephedrine</name>
      <description>The risk or severity of hypertension can be increased when Isoprenaline is combined with DL-Methylephedrine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11373</drugbank-id>
      <name>Amitraz</name>
      <description>The risk or severity of hypertension can be increased when Isoprenaline is combined with Amitraz.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11428</drugbank-id>
      <name>Medetomidine</name>
      <description>The risk or severity of hypertension can be increased when Isoprenaline is combined with Medetomidine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11455</drugbank-id>
      <name>Robenacoxib</name>
      <description>The risk or severity of hypertension can be increased when Isoprenaline is combined with Robenacoxib.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11466</drugbank-id>
      <name>Tepoxalin</name>
      <description>The risk or severity of hypertension can be increased when Isoprenaline is combined with Tepoxalin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11477</drugbank-id>
      <name>Xylazine</name>
      <description>The risk or severity of hypertension can be increased when Isoprenaline is combined with Xylazine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11481</drugbank-id>
      <name>Atipamezole</name>
      <description>The risk or severity of hypertension can be increased when Isoprenaline is combined with Atipamezole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11518</drugbank-id>
      <name>Flunixin</name>
      <description>The risk or severity of hypertension can be increased when Isoprenaline is combined with Flunixin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11541</drugbank-id>
      <name>Ractopamine</name>
      <description>The risk or severity of hypertension can be increased when Isoprenaline is combined with Ractopamine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11543</drugbank-id>
      <name>Romifidine</name>
      <description>The risk or severity of hypertension can be increased when Isoprenaline is combined with Romifidine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11556</drugbank-id>
      <name>Detomidine</name>
      <description>The risk or severity of hypertension can be increased when Isoprenaline is combined with Detomidine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11738</drugbank-id>
      <name>Rilmenidine</name>
      <description>The risk or severity of hypertension can be increased when Isoprenaline is combined with Rilmenidine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11755</drugbank-id>
      <name>Tetrahydrocannabivarin</name>
      <description>The risk or severity of hypertension can be increased when Isoprenaline is combined with Tetrahydrocannabivarin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12092</drugbank-id>
      <name>Naftopidil</name>
      <description>The risk or severity of hypertension can be increased when Isoprenaline is combined with Naftopidil.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12248</drugbank-id>
      <name>Tulobuterol</name>
      <description>The risk or severity of hypertension can be increased when Isoprenaline is combined with Tulobuterol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12313</drugbank-id>
      <name>Dopexamine</name>
      <description>The risk or severity of hypertension can be increased when Isoprenaline is combined with Dopexamine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12361</drugbank-id>
      <name>Piclozotan</name>
      <description>The risk or severity of hypertension can be increased when Isoprenaline is combined with Piclozotan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12371</drugbank-id>
      <name>Siponimod</name>
      <description>The risk or severity of hypertension can be increased when Isoprenaline is combined with Siponimod.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12445</drugbank-id>
      <name>Nitroaspirin</name>
      <description>The risk or severity of hypertension can be increased when Isoprenaline is combined with Nitroaspirin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12480</drugbank-id>
      <name>Betulinic Acid</name>
      <description>The risk or severity of hypertension can be increased when Isoprenaline is combined with Betulinic Acid.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12545</drugbank-id>
      <name>Indobufen</name>
      <description>The risk or severity of hypertension can be increased when Isoprenaline is combined with Indobufen.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12551</drugbank-id>
      <name>Idazoxan</name>
      <description>The risk or severity of hypertension can be increased when Isoprenaline is combined with Idazoxan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12610</drugbank-id>
      <name>Ebselen</name>
      <description>The risk or severity of hypertension can be increased when Isoprenaline is combined with Ebselen.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12779</drugbank-id>
      <name>Higenamine</name>
      <description>The risk or severity of hypertension can be increased when Isoprenaline is combined with Higenamine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12846</drugbank-id>
      <name>Reproterol</name>
      <description>The risk or severity of hypertension can be increased when Isoprenaline is combined with Reproterol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13001</drugbank-id>
      <name>Tinoridine</name>
      <description>The risk or severity of hypertension can be increased when Isoprenaline is combined with Tinoridine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13167</drugbank-id>
      <name>Alclofenac</name>
      <description>The risk or severity of hypertension can be increased when Isoprenaline is combined with Alclofenac.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13217</drugbank-id>
      <name>Fentiazac</name>
      <description>The risk or severity of hypertension can be increased when Isoprenaline is combined with Fentiazac.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13232</drugbank-id>
      <name>Suxibuzone</name>
      <description>The risk or severity of hypertension can be increased when Isoprenaline is combined with Suxibuzone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13251</drugbank-id>
      <name>Octopamine</name>
      <description>The risk or severity of hypertension can be increased when Isoprenaline is combined with Octopamine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13286</drugbank-id>
      <name>Bumadizone</name>
      <description>The risk or severity of hypertension can be increased when Isoprenaline is combined with Bumadizone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13314</drugbank-id>
      <name>Alminoprofen</name>
      <description>The risk or severity of hypertension can be increased when Isoprenaline is combined with Alminoprofen.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13317</drugbank-id>
      <name>Flunoxaprofen</name>
      <description>The risk or severity of hypertension can be increased when Isoprenaline is combined with Flunoxaprofen.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13364</drugbank-id>
      <name>Feprazone</name>
      <description>The risk or severity of hypertension can be increased when Isoprenaline is combined with Feprazone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13371</drugbank-id>
      <name>Difenpiramide</name>
      <description>The risk or severity of hypertension can be increased when Isoprenaline is combined with Difenpiramide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13378</drugbank-id>
      <name>Norfenefrine</name>
      <description>The risk or severity of hypertension can be increased when Isoprenaline is combined with Norfenefrine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13398</drugbank-id>
      <name>Oxyfedrine</name>
      <description>The risk or severity of hypertension can be increased when Isoprenaline is combined with Oxyfedrine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13407</drugbank-id>
      <name>Nifenazone</name>
      <description>The risk or severity of hypertension can be increased when Isoprenaline is combined with Nifenazone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13432</drugbank-id>
      <name>Lonazolac</name>
      <description>The risk or severity of hypertension can be increased when Isoprenaline is combined with Lonazolac.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13481</drugbank-id>
      <name>Tenidap</name>
      <description>The risk or severity of hypertension can be increased when Isoprenaline is combined with Tenidap.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13501</drugbank-id>
      <name>Bendazac</name>
      <description>The risk or severity of hypertension can be increased when Isoprenaline is combined with Bendazac.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13510</drugbank-id>
      <name>Buflomedil</name>
      <description>The risk or severity of hypertension can be increased when Isoprenaline is combined with Buflomedil.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13514</drugbank-id>
      <name>Pranoprofen</name>
      <description>The risk or severity of hypertension can be increased when Isoprenaline is combined with Pranoprofen.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13524</drugbank-id>
      <name>Propyphenazone</name>
      <description>The risk or severity of hypertension can be increased when Isoprenaline is combined with Propyphenazone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13527</drugbank-id>
      <name>Proglumetacin</name>
      <description>The risk or severity of hypertension can be increased when Isoprenaline is combined with Proglumetacin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13538</drugbank-id>
      <name>Guacetisal</name>
      <description>The risk or severity of hypertension can be increased when Isoprenaline is combined with Guacetisal.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13544</drugbank-id>
      <name>Ethenzamide</name>
      <description>The risk or severity of hypertension can be increased when Isoprenaline is combined with Ethenzamide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13559</drugbank-id>
      <name>Rimiterol</name>
      <description>The risk or severity of hypertension can be increased when Isoprenaline is combined with Rimiterol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13612</drugbank-id>
      <name>Carbaspirin calcium</name>
      <description>The risk or severity of hypertension can be increased when Isoprenaline is combined with Carbaspirin calcium.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13629</drugbank-id>
      <name>Mofebutazone</name>
      <description>The risk or severity of hypertension can be increased when Isoprenaline is combined with Mofebutazone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13649</drugbank-id>
      <name>Proquazone</name>
      <description>The risk or severity of hypertension can be increased when Isoprenaline is combined with Proquazone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13657</drugbank-id>
      <name>Benorilate</name>
      <description>The risk or severity of hypertension can be increased when Isoprenaline is combined with Benorilate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13722</drugbank-id>
      <name>Pirprofen</name>
      <description>The risk or severity of hypertension can be increased when Isoprenaline is combined with Pirprofen.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13781</drugbank-id>
      <name>Xamoterol</name>
      <description>The risk or severity of hypertension can be increased when Isoprenaline is combined with Xamoterol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13783</drugbank-id>
      <name>Acemetacin</name>
      <description>The risk or severity of hypertension can be increased when Isoprenaline is combined with Acemetacin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13860</drugbank-id>
      <name>Imidazole salicylate</name>
      <description>The risk or severity of hypertension can be increased when Isoprenaline is combined with Imidazole salicylate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14010</drugbank-id>
      <name>5-methoxy-N,N-dimethyltryptamine</name>
      <description>The risk or severity of hypertension can be increased when Isoprenaline is combined with 5-methoxy-N,N-dimethyltryptamine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14059</drugbank-id>
      <name>SC-236</name>
      <description>The risk or severity of hypertension can be increased when Isoprenaline is combined with SC-236.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14060</drugbank-id>
      <name>NS-398</name>
      <description>The risk or severity of hypertension can be increased when Isoprenaline is combined with NS-398.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14231</drugbank-id>
      <name>Quinoline Yellow WS</name>
      <description>The risk or severity of hypertension can be increased when Isoprenaline is combined with Quinoline Yellow WS.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00895</drugbank-id>
      <name>Benzylpenicilloyl polylysine</name>
      <description>Isoprenaline may decrease effectiveness of Benzylpenicilloyl polylysine as a diagnostic agent.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00421</drugbank-id>
      <name>Spironolactone</name>
      <description>The therapeutic efficacy of Isoprenaline can be decreased when used in combination with Spironolactone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00180</drugbank-id>
      <name>Flunisolide</name>
      <description>The risk or severity of hypokalemia can be increased when Flunisolide is combined with Isoprenaline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00394</drugbank-id>
      <name>Beclomethasone dipropionate</name>
      <description>The risk or severity of hypokalemia can be increased when Beclomethasone dipropionate is combined with Isoprenaline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00443</drugbank-id>
      <name>Betamethasone</name>
      <description>The risk or severity of hypokalemia can be increased when Betamethasone is combined with Isoprenaline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00588</drugbank-id>
      <name>Fluticasone propionate</name>
      <description>The risk or severity of hypokalemia can be increased when Fluticasone propionate is combined with Isoprenaline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00591</drugbank-id>
      <name>Fluocinolone acetonide</name>
      <description>The risk or severity of hypokalemia can be increased when Fluocinolone acetonide is combined with Isoprenaline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00620</drugbank-id>
      <name>Triamcinolone</name>
      <description>The risk or severity of hypokalemia can be increased when Triamcinolone is combined with Isoprenaline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00635</drugbank-id>
      <name>Prednisone</name>
      <description>The risk or severity of hypokalemia can be increased when Prednisone is combined with Isoprenaline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00687</drugbank-id>
      <name>Fludrocortisone</name>
      <description>The risk or severity of hypokalemia can be increased when Fludrocortisone is combined with Isoprenaline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00741</drugbank-id>
      <name>Hydrocortisone</name>
      <description>The risk or severity of hypokalemia can be increased when Hydrocortisone is combined with Isoprenaline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00764</drugbank-id>
      <name>Mometasone</name>
      <description>The risk or severity of hypokalemia can be increased when Mometasone is combined with Isoprenaline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00860</drugbank-id>
      <name>Prednisolone</name>
      <description>The risk or severity of hypokalemia can be increased when Prednisolone is combined with Isoprenaline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00959</drugbank-id>
      <name>Methylprednisolone</name>
      <description>The risk or severity of hypokalemia can be increased when Methylprednisolone is combined with Isoprenaline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01108</drugbank-id>
      <name>Trilostane</name>
      <description>The risk or severity of hypokalemia can be increased when Trilostane is combined with Isoprenaline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01222</drugbank-id>
      <name>Budesonide</name>
      <description>The risk or severity of hypokalemia can be increased when Budesonide is combined with Isoprenaline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01234</drugbank-id>
      <name>Dexamethasone</name>
      <description>The risk or severity of hypokalemia can be increased when Dexamethasone is combined with Isoprenaline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01285</drugbank-id>
      <name>Corticotropin</name>
      <description>The risk or severity of hypokalemia can be increased when Corticotropin is combined with Isoprenaline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01380</drugbank-id>
      <name>Cortisone acetate</name>
      <description>The risk or severity of hypokalemia can be increased when Cortisone acetate is combined with Isoprenaline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01384</drugbank-id>
      <name>Paramethasone</name>
      <description>The risk or severity of hypokalemia can be increased when Paramethasone is combined with Isoprenaline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01410</drugbank-id>
      <name>Ciclesonide</name>
      <description>The risk or severity of hypokalemia can be increased when Ciclesonide is combined with Isoprenaline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04630</drugbank-id>
      <name>Aldosterone</name>
      <description>The risk or severity of hypokalemia can be increased when Aldosterone is combined with Isoprenaline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08906</drugbank-id>
      <name>Fluticasone furoate</name>
      <description>The risk or severity of hypokalemia can be increased when Fluticasone furoate is combined with Isoprenaline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08970</drugbank-id>
      <name>Fluprednidene</name>
      <description>The risk or severity of hypokalemia can be increased when Fluprednidene is combined with Isoprenaline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08971</drugbank-id>
      <name>Fluocortolone</name>
      <description>The risk or severity of hypokalemia can be increased when Fluocortolone is combined with Isoprenaline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09091</drugbank-id>
      <name>Tixocortol</name>
      <description>The risk or severity of hypokalemia can be increased when Tixocortol is combined with Isoprenaline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09378</drugbank-id>
      <name>Fluprednisolone</name>
      <description>The risk or severity of hypokalemia can be increased when Fluprednisolone is combined with Isoprenaline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09383</drugbank-id>
      <name>Meprednisone</name>
      <description>The risk or severity of hypokalemia can be increased when Meprednisone is combined with Isoprenaline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11487</drugbank-id>
      <name>Dexamethasone isonicotinate</name>
      <description>The risk or severity of hypokalemia can be increased when Dexamethasone isonicotinate is combined with Isoprenaline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11529</drugbank-id>
      <name>Melengestrol</name>
      <description>The risk or severity of hypokalemia can be increased when Melengestrol is combined with Isoprenaline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11750</drugbank-id>
      <name>Clobetasol</name>
      <description>The risk or severity of hypokalemia can be increased when Clobetasol is combined with Isoprenaline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11921</drugbank-id>
      <name>Deflazacort</name>
      <description>The risk or severity of hypokalemia can be increased when Deflazacort is combined with Isoprenaline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13003</drugbank-id>
      <name>Cortivazol</name>
      <description>The risk or severity of hypokalemia can be increased when Cortivazol is combined with Isoprenaline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13208</drugbank-id>
      <name>Prednylidene</name>
      <description>The risk or severity of hypokalemia can be increased when Prednylidene is combined with Isoprenaline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13223</drugbank-id>
      <name>Fluocortin</name>
      <description>The risk or severity of hypokalemia can be increased when Fluocortin is combined with Isoprenaline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13491</drugbank-id>
      <name>Fluperolone</name>
      <description>The risk or severity of hypokalemia can be increased when Fluperolone is combined with Isoprenaline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13664</drugbank-id>
      <name>Formocortal</name>
      <description>The risk or severity of hypokalemia can be increased when Formocortal is combined with Isoprenaline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13728</drugbank-id>
      <name>Halometasone</name>
      <description>The risk or severity of hypokalemia can be increased when Halometasone is combined with Isoprenaline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13843</drugbank-id>
      <name>Cloprednol</name>
      <description>The risk or severity of hypokalemia can be increased when Cloprednol is combined with Isoprenaline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13856</drugbank-id>
      <name>Fluclorolone</name>
      <description>The risk or severity of hypokalemia can be increased when Fluclorolone is combined with Isoprenaline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13867</drugbank-id>
      <name>Fluticasone</name>
      <description>The risk or severity of hypokalemia can be increased when Fluticasone is combined with Isoprenaline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14512</drugbank-id>
      <name>Mometasone furoate</name>
      <description>The risk or severity of hypokalemia can be increased when Mometasone furoate is combined with Isoprenaline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14538</drugbank-id>
      <name>Hydrocortisone aceponate</name>
      <description>The risk or severity of hypokalemia can be increased when Hydrocortisone aceponate is combined with Isoprenaline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14539</drugbank-id>
      <name>Hydrocortisone acetate</name>
      <description>The risk or severity of hypokalemia can be increased when Hydrocortisone acetate is combined with Isoprenaline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14541</drugbank-id>
      <name>Hydrocortisone cypionate</name>
      <description>The risk or severity of hypokalemia can be increased when Hydrocortisone cypionate is combined with Isoprenaline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14545</drugbank-id>
      <name>Hydrocortisone succinate</name>
      <description>The risk or severity of hypokalemia can be increased when Hydrocortisone succinate is combined with Isoprenaline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00873</drugbank-id>
      <name>Loteprednol</name>
      <description>The risk or severity of hypokalemia can be increased when Loteprednol is combined with Isoprenaline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14631</drugbank-id>
      <name>Prednisolone phosphate</name>
      <description>The risk or severity of hypokalemia can be increased when Prednisolone phosphate is combined with Isoprenaline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14633</drugbank-id>
      <name>Prednisolone hemisuccinate</name>
      <description>The risk or severity of hypokalemia can be increased when Prednisolone hemisuccinate is combined with Isoprenaline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14634</drugbank-id>
      <name>Fluprednidene acetate</name>
      <description>The risk or severity of hypokalemia can be increased when Fluprednidene acetate is combined with Isoprenaline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14643</drugbank-id>
      <name>Methylprednisolone aceponate</name>
      <description>The risk or severity of hypokalemia can be increased when Methylprednisolone aceponate is combined with Isoprenaline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14644</drugbank-id>
      <name>Methylprednisolone hemisuccinate</name>
      <description>The risk or severity of hypokalemia can be increased when Methylprednisolone hemisuccinate is combined with Isoprenaline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14646</drugbank-id>
      <name>Prednisone acetate</name>
      <description>The risk or severity of hypokalemia can be increased when Prednisone acetate is combined with Isoprenaline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14652</drugbank-id>
      <name>Clocortolone acetate</name>
      <description>The risk or severity of hypokalemia can be increased when Clocortolone acetate is combined with Isoprenaline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14659</drugbank-id>
      <name>Melengestrol acetate</name>
      <description>The risk or severity of hypokalemia can be increased when Melengestrol acetate is combined with Isoprenaline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14669</drugbank-id>
      <name>Betamethasone phosphate</name>
      <description>The risk or severity of hypokalemia can be increased when Betamethasone phosphate is combined with Isoprenaline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14681</drugbank-id>
      <name>Cortisone</name>
      <description>The risk or severity of hypokalemia can be increased when Cortisone is combined with Isoprenaline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00289</drugbank-id>
      <name>Atomoxetine</name>
      <description>Atomoxetine may increase the tachycardic activities of Isoprenaline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09059</drugbank-id>
      <name>Atosiban</name>
      <description>The risk or severity of adverse effects can be increased when Isoprenaline is combined with Atosiban.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06698</drugbank-id>
      <name>Betahistine</name>
      <description>The therapeutic efficacy of Isoprenaline can be decreased when used in combination with Betahistine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09042</drugbank-id>
      <name>Tedizolid phosphate</name>
      <description>Tedizolid phosphate may increase the hypertensive activities of Isoprenaline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00201</drugbank-id>
      <name>Caffeine</name>
      <description>The serum concentration of Caffeine can be decreased when it is combined with Isoprenaline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00277</drugbank-id>
      <name>Theophylline</name>
      <description>The serum concentration of Theophylline can be decreased when it is combined with Isoprenaline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00651</drugbank-id>
      <name>Dyphylline</name>
      <description>The serum concentration of Dyphylline can be decreased when it is combined with Isoprenaline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00806</drugbank-id>
      <name>Pentoxifylline</name>
      <description>The serum concentration of Pentoxifylline can be decreased when it is combined with Isoprenaline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01033</drugbank-id>
      <name>Mercaptopurine</name>
      <description>The serum concentration of Mercaptopurine can be decreased when it is combined with Isoprenaline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01223</drugbank-id>
      <name>Aminophylline</name>
      <description>The serum concentration of Aminophylline can be decreased when it is combined with Isoprenaline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01303</drugbank-id>
      <name>Oxtriphylline</name>
      <description>The serum concentration of Oxtriphylline can be decreased when it is combined with Isoprenaline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01412</drugbank-id>
      <name>Theobromine</name>
      <description>The serum concentration of Theobromine can be decreased when it is combined with Isoprenaline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01482</drugbank-id>
      <name>Fenethylline</name>
      <description>The serum concentration of Fenethylline can be decreased when it is combined with Isoprenaline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01667</drugbank-id>
      <name>8-azaguanine</name>
      <description>The serum concentration of 8-azaguanine can be decreased when it is combined with Isoprenaline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01978</drugbank-id>
      <name>7,9-Dimethylguanine</name>
      <description>The serum concentration of 7,9-Dimethylguanine can be decreased when it is combined with Isoprenaline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB02134</drugbank-id>
      <name>Xanthine</name>
      <description>The serum concentration of Xanthine can be decreased when it is combined with Isoprenaline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB02245</drugbank-id>
      <name>7-Deazaguanine</name>
      <description>The serum concentration of 7-Deazaguanine can be decreased when it is combined with Isoprenaline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB02377</drugbank-id>
      <name>Guanine</name>
      <description>The serum concentration of Guanine can be decreased when it is combined with Isoprenaline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB02489</drugbank-id>
      <name>9-Methylguanine</name>
      <description>The serum concentration of 9-Methylguanine can be decreased when it is combined with Isoprenaline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB02568</drugbank-id>
      <name>Peldesine</name>
      <description>The serum concentration of Peldesine can be decreased when it is combined with Isoprenaline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04076</drugbank-id>
      <name>Hypoxanthine</name>
      <description>The serum concentration of Hypoxanthine can be decreased when it is combined with Isoprenaline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04356</drugbank-id>
      <name>9-Deazaguanine</name>
      <description>The serum concentration of 9-Deazaguanine can be decreased when it is combined with Isoprenaline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06479</drugbank-id>
      <name>Propentofylline</name>
      <description>The serum concentration of Propentofylline can be decreased when it is combined with Isoprenaline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06575</drugbank-id>
      <name>Valomaciclovir</name>
      <description>The serum concentration of Valomaciclovir can be decreased when it is combined with Isoprenaline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB07954</drugbank-id>
      <name>3-isobutyl-1-methyl-7H-xanthine</name>
      <description>The serum concentration of 3-isobutyl-1-methyl-7H-xanthine can be decreased when it is combined with Isoprenaline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08844</drugbank-id>
      <name>Uric acid</name>
      <description>The serum concentration of Uric acid can be decreased when it is combined with Isoprenaline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09273</drugbank-id>
      <name>Doxofylline</name>
      <description>The serum concentration of Doxofylline can be decreased when it is combined with Isoprenaline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11919</drugbank-id>
      <name>6-O-benzylguanine</name>
      <description>The serum concentration of 6-O-benzylguanine can be decreased when it is combined with Isoprenaline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12406</drugbank-id>
      <name>Lisofylline</name>
      <description>The serum concentration of Lisofylline can be decreased when it is combined with Isoprenaline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12531</drugbank-id>
      <name>Lobucavir</name>
      <description>The serum concentration of Lobucavir can be decreased when it is combined with Isoprenaline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12926</drugbank-id>
      <name>Cafedrine</name>
      <description>The serum concentration of Cafedrine can be decreased when it is combined with Isoprenaline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12927</drugbank-id>
      <name>Theodrenaline</name>
      <description>The serum concentration of Theodrenaline can be decreased when it is combined with Isoprenaline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13203</drugbank-id>
      <name>Bamifylline</name>
      <description>The serum concentration of Bamifylline can be decreased when it is combined with Isoprenaline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13449</drugbank-id>
      <name>Proxyphylline</name>
      <description>The serum concentration of Proxyphylline can be decreased when it is combined with Isoprenaline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13573</drugbank-id>
      <name>Acefylline</name>
      <description>The serum concentration of Acefylline can be decreased when it is combined with Isoprenaline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13592</drugbank-id>
      <name>Etamiphylline</name>
      <description>The serum concentration of Etamiphylline can be decreased when it is combined with Isoprenaline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13634</drugbank-id>
      <name>Pentifylline</name>
      <description>The serum concentration of Pentifylline can be decreased when it is combined with Isoprenaline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13812</drugbank-id>
      <name>Bufylline</name>
      <description>The serum concentration of Bufylline can be decreased when it is combined with Isoprenaline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14018</drugbank-id>
      <name>Bromotheophylline</name>
      <description>The serum concentration of Bromotheophylline can be decreased when it is combined with Isoprenaline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14029</drugbank-id>
      <name>Furafylline</name>
      <description>The serum concentration of Furafylline can be decreased when it is combined with Isoprenaline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14132</drugbank-id>
      <name>8-chlorotheophylline</name>
      <description>The serum concentration of 8-chlorotheophylline can be decreased when it is combined with Isoprenaline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB15122</drugbank-id>
      <name>PCS-499</name>
      <description>The serum concentration of PCS-499 can be decreased when it is combined with Isoprenaline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00228</drugbank-id>
      <name>Enflurane</name>
      <description>Enflurane may increase the arrhythmogenic activities of Isoprenaline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00753</drugbank-id>
      <name>Isoflurane</name>
      <description>Isoflurane may increase the arrhythmogenic activities of Isoprenaline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01028</drugbank-id>
      <name>Methoxyflurane</name>
      <description>Methoxyflurane may increase the arrhythmogenic activities of Isoprenaline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01159</drugbank-id>
      <name>Halothane</name>
      <description>Halothane may increase the arrhythmogenic activities of Isoprenaline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01189</drugbank-id>
      <name>Desflurane</name>
      <description>Desflurane may increase the arrhythmogenic activities of Isoprenaline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01236</drugbank-id>
      <name>Sevoflurane</name>
      <description>Sevoflurane may increase the arrhythmogenic activities of Isoprenaline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06690</drugbank-id>
      <name>Nitrous oxide</name>
      <description>Nitrous oxide may increase the arrhythmogenic activities of Isoprenaline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13323</drugbank-id>
      <name>Trichloroethylene</name>
      <description>Trichloroethylene may increase the arrhythmogenic activities of Isoprenaline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13453</drugbank-id>
      <name>Xenon</name>
      <description>Xenon may increase the arrhythmogenic activities of Isoprenaline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13598</drugbank-id>
      <name>Diethyl ether</name>
      <description>Diethyl ether may increase the arrhythmogenic activities of Isoprenaline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06704</drugbank-id>
      <name>Iobenguane</name>
      <description>Isoprenaline can cause a decrease in the absorption of Iobenguane resulting in a reduced serum concentration and potentially a decrease in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00247</drugbank-id>
      <name>Methysergide</name>
      <description>Methysergide may increase the hypertensive and vasoconstricting activities of Isoprenaline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00248</drugbank-id>
      <name>Cabergoline</name>
      <description>Cabergoline may increase the hypertensive and vasoconstricting activities of Isoprenaline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00320</drugbank-id>
      <name>Dihydroergotamine</name>
      <description>Dihydroergotamine may increase the hypertensive and vasoconstricting activities of Isoprenaline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00353</drugbank-id>
      <name>Methylergometrine</name>
      <description>Methylergometrine may increase the hypertensive and vasoconstricting activities of Isoprenaline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00589</drugbank-id>
      <name>Lisuride</name>
      <description>Lisuride may increase the hypertensive and vasoconstricting activities of Isoprenaline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00696</drugbank-id>
      <name>Ergotamine</name>
      <description>Ergotamine may increase the hypertensive and vasoconstricting activities of Isoprenaline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00699</drugbank-id>
      <name>Nicergoline</name>
      <description>Nicergoline may increase the hypertensive and vasoconstricting activities of Isoprenaline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01049</drugbank-id>
      <name>Ergoloid mesylate</name>
      <description>Ergoloid mesylate may increase the hypertensive and vasoconstricting activities of Isoprenaline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01186</drugbank-id>
      <name>Pergolide</name>
      <description>Pergolide may increase the hypertensive and vasoconstricting activities of Isoprenaline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01200</drugbank-id>
      <name>Bromocriptine</name>
      <description>Bromocriptine may increase the hypertensive and vasoconstricting activities of Isoprenaline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01253</drugbank-id>
      <name>Ergometrine</name>
      <description>Ergometrine may increase the hypertensive and vasoconstricting activities of Isoprenaline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04829</drugbank-id>
      <name>Lysergic acid diethylamide</name>
      <description>Lysergic acid diethylamide may increase the hypertensive and vasoconstricting activities of Isoprenaline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11273</drugbank-id>
      <name>Dihydroergocornine</name>
      <description>Dihydroergocornine may increase the hypertensive and vasoconstricting activities of Isoprenaline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13345</drugbank-id>
      <name>Dihydroergocristine</name>
      <description>Dihydroergocristine may increase the hypertensive and vasoconstricting activities of Isoprenaline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13385</drugbank-id>
      <name>Dihydroergocryptine</name>
      <description>Dihydroergocryptine may increase the hypertensive and vasoconstricting activities of Isoprenaline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13399</drugbank-id>
      <name>Terguride</name>
      <description>Terguride may increase the hypertensive and vasoconstricting activities of Isoprenaline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13520</drugbank-id>
      <name>Metergoline</name>
      <description>Metergoline may increase the hypertensive and vasoconstricting activities of Isoprenaline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00285</drugbank-id>
      <name>Venlafaxine</name>
      <description>Venlafaxine may increase the tachycardic activities of Isoprenaline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00476</drugbank-id>
      <name>Duloxetine</name>
      <description>Duloxetine may increase the tachycardic activities of Isoprenaline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01105</drugbank-id>
      <name>Sibutramine</name>
      <description>Sibutramine may increase the tachycardic activities of Isoprenaline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04896</drugbank-id>
      <name>Milnacipran</name>
      <description>Milnacipran may increase the tachycardic activities of Isoprenaline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06700</drugbank-id>
      <name>Desvenlafaxine</name>
      <description>Desvenlafaxine may increase the tachycardic activities of Isoprenaline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08918</drugbank-id>
      <name>Levomilnacipran</name>
      <description>Levomilnacipran may increase the tachycardic activities of Isoprenaline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00246</drugbank-id>
      <name>Ziprasidone</name>
      <description>The therapeutic efficacy of Isoprenaline can be decreased when used in combination with Ziprasidone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00334</drugbank-id>
      <name>Olanzapine</name>
      <description>The therapeutic efficacy of Isoprenaline can be decreased when used in combination with Olanzapine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00346</drugbank-id>
      <name>Alfuzosin</name>
      <description>The therapeutic efficacy of Isoprenaline can be decreased when used in combination with Alfuzosin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00363</drugbank-id>
      <name>Clozapine</name>
      <description>The therapeutic efficacy of Isoprenaline can be decreased when used in combination with Clozapine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00420</drugbank-id>
      <name>Promazine</name>
      <description>The therapeutic efficacy of Isoprenaline can be decreased when used in combination with Promazine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00450</drugbank-id>
      <name>Droperidol</name>
      <description>The therapeutic efficacy of Isoprenaline can be decreased when used in combination with Droperidol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00457</drugbank-id>
      <name>Prazosin</name>
      <description>The therapeutic efficacy of Isoprenaline can be decreased when used in combination with Prazosin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00477</drugbank-id>
      <name>Chlorpromazine</name>
      <description>The therapeutic efficacy of Isoprenaline can be decreased when used in combination with Chlorpromazine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00590</drugbank-id>
      <name>Doxazosin</name>
      <description>The therapeutic efficacy of Isoprenaline can be decreased when used in combination with Doxazosin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00622</drugbank-id>
      <name>Nicardipine</name>
      <description>The therapeutic efficacy of Isoprenaline can be decreased when used in combination with Nicardipine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00656</drugbank-id>
      <name>Trazodone</name>
      <description>The therapeutic efficacy of Isoprenaline can be decreased when used in combination with Trazodone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00661</drugbank-id>
      <name>Verapamil</name>
      <description>The therapeutic efficacy of Isoprenaline can be decreased when used in combination with Verapamil.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00679</drugbank-id>
      <name>Thioridazine</name>
      <description>The therapeutic efficacy of Isoprenaline can be decreased when used in combination with Thioridazine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00692</drugbank-id>
      <name>Phentolamine</name>
      <description>The therapeutic efficacy of Isoprenaline can be decreased when used in combination with Phentolamine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00706</drugbank-id>
      <name>Tamsulosin</name>
      <description>The therapeutic efficacy of Isoprenaline can be decreased when used in combination with Tamsulosin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00734</drugbank-id>
      <name>Risperidone</name>
      <description>The therapeutic efficacy of Isoprenaline can be decreased when used in combination with Risperidone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00777</drugbank-id>
      <name>Propiomazine</name>
      <description>The therapeutic efficacy of Isoprenaline can be decreased when used in combination with Propiomazine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00797</drugbank-id>
      <name>Tolazoline</name>
      <description>The therapeutic efficacy of Isoprenaline can be decreased when used in combination with Tolazoline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00831</drugbank-id>
      <name>Trifluoperazine</name>
      <description>The therapeutic efficacy of Isoprenaline can be decreased when used in combination with Trifluoperazine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00875</drugbank-id>
      <name>Flupentixol</name>
      <description>The therapeutic efficacy of Isoprenaline can be decreased when used in combination with Flupentixol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00908</drugbank-id>
      <name>Quinidine</name>
      <description>The therapeutic efficacy of Isoprenaline can be decreased when used in combination with Quinidine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00925</drugbank-id>
      <name>Phenoxybenzamine</name>
      <description>The therapeutic efficacy of Isoprenaline can be decreased when used in combination with Phenoxybenzamine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01149</drugbank-id>
      <name>Nefazodone</name>
      <description>The therapeutic efficacy of Isoprenaline can be decreased when used in combination with Nefazodone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01162</drugbank-id>
      <name>Terazosin</name>
      <description>The therapeutic efficacy of Isoprenaline can be decreased when used in combination with Terazosin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01224</drugbank-id>
      <name>Quetiapine</name>
      <description>The therapeutic efficacy of Isoprenaline can be decreased when used in combination with Quetiapine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01238</drugbank-id>
      <name>Aripiprazole</name>
      <description>The therapeutic efficacy of Isoprenaline can be decreased when used in combination with Aripiprazole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01267</drugbank-id>
      <name>Paliperidone</name>
      <description>The therapeutic efficacy of Isoprenaline can be decreased when used in combination with Paliperidone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01403</drugbank-id>
      <name>Methotrimeprazine</name>
      <description>The therapeutic efficacy of Isoprenaline can be decreased when used in combination with Methotrimeprazine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01608</drugbank-id>
      <name>Periciazine</name>
      <description>The therapeutic efficacy of Isoprenaline can be decreased when used in combination with Periciazine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01614</drugbank-id>
      <name>Acepromazine</name>
      <description>The therapeutic efficacy of Isoprenaline can be decreased when used in combination with Acepromazine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01622</drugbank-id>
      <name>Thioproperazine</name>
      <description>The therapeutic efficacy of Isoprenaline can be decreased when used in combination with Thioproperazine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01624</drugbank-id>
      <name>Zuclopenthixol</name>
      <description>The therapeutic efficacy of Isoprenaline can be decreased when used in combination with Zuclopenthixol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04855</drugbank-id>
      <name>Dronedarone</name>
      <description>The therapeutic efficacy of Isoprenaline can be decreased when used in combination with Dronedarone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04946</drugbank-id>
      <name>Iloperidone</name>
      <description>The therapeutic efficacy of Isoprenaline can be decreased when used in combination with Iloperidone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06153</drugbank-id>
      <name>Pizotifen</name>
      <description>The therapeutic efficacy of Isoprenaline can be decreased when used in combination with Pizotifen.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06207</drugbank-id>
      <name>Silodosin</name>
      <description>The therapeutic efficacy of Isoprenaline can be decreased when used in combination with Silodosin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06216</drugbank-id>
      <name>Asenapine</name>
      <description>The therapeutic efficacy of Isoprenaline can be decreased when used in combination with Asenapine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08950</drugbank-id>
      <name>Indoramin</name>
      <description>The therapeutic efficacy of Isoprenaline can be decreased when used in combination with Indoramin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09128</drugbank-id>
      <name>Brexpiprazole</name>
      <description>The therapeutic efficacy of Isoprenaline can be decreased when used in combination with Brexpiprazole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09206</drugbank-id>
      <name>Trimazosin</name>
      <description>The therapeutic efficacy of Isoprenaline can be decreased when used in combination with Trimazosin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09239</drugbank-id>
      <name>Niguldipine</name>
      <description>The therapeutic efficacy of Isoprenaline can be decreased when used in combination with Niguldipine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12230</drugbank-id>
      <name>Bunazosin</name>
      <description>The therapeutic efficacy of Isoprenaline can be decreased when used in combination with Bunazosin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12278</drugbank-id>
      <name>Propiverine</name>
      <description>The therapeutic efficacy of Isoprenaline can be decreased when used in combination with Propiverine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12661</drugbank-id>
      <name>Urapidil</name>
      <description>The therapeutic efficacy of Isoprenaline can be decreased when used in combination with Urapidil.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14185</drugbank-id>
      <name>Aripiprazole lauroxil</name>
      <description>The therapeutic efficacy of Isoprenaline can be decreased when used in combination with Aripiprazole lauroxil.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00321</drugbank-id>
      <name>Amitriptyline</name>
      <description>The risk or severity of hypertension can be increased when Amitriptyline is combined with Isoprenaline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00344</drugbank-id>
      <name>Protriptyline</name>
      <description>The risk or severity of hypertension can be increased when Protriptyline is combined with Isoprenaline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00458</drugbank-id>
      <name>Imipramine</name>
      <description>The risk or severity of hypertension can be increased when Imipramine is combined with Isoprenaline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00540</drugbank-id>
      <name>Nortriptyline</name>
      <description>The risk or severity of hypertension can be increased when Nortriptyline is combined with Isoprenaline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00543</drugbank-id>
      <name>Amoxapine</name>
      <description>The risk or severity of hypertension can be increased when Amoxapine is combined with Isoprenaline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00726</drugbank-id>
      <name>Trimipramine</name>
      <description>The risk or severity of hypertension can be increased when Trimipramine is combined with Isoprenaline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01142</drugbank-id>
      <name>Doxepin</name>
      <description>The risk or severity of hypertension can be increased when Doxepin is combined with Isoprenaline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01151</drugbank-id>
      <name>Desipramine</name>
      <description>The risk or severity of hypertension can be increased when Desipramine is combined with Isoprenaline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01242</drugbank-id>
      <name>Clomipramine</name>
      <description>The risk or severity of hypertension can be increased when Clomipramine is combined with Isoprenaline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04836</drugbank-id>
      <name>Amineptine</name>
      <description>The risk or severity of hypertension can be increased when Amineptine is combined with Isoprenaline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08996</drugbank-id>
      <name>Dimetacrine</name>
      <description>The risk or severity of hypertension can be increased when Dimetacrine is combined with Isoprenaline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09016</drugbank-id>
      <name>Butriptyline</name>
      <description>The risk or severity of hypertension can be increased when Butriptyline is combined with Isoprenaline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09167</drugbank-id>
      <name>Dosulepin</name>
      <description>The risk or severity of hypertension can be increased when Dosulepin is combined with Isoprenaline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09289</drugbank-id>
      <name>Tianeptine</name>
      <description>The risk or severity of hypertension can be increased when Tianeptine is combined with Isoprenaline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09307</drugbank-id>
      <name>Oxaprotiline</name>
      <description>The risk or severity of hypertension can be increased when Oxaprotiline is combined with Isoprenaline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12930</drugbank-id>
      <name>Opipramol</name>
      <description>The risk or severity of hypertension can be increased when Opipramol is combined with Isoprenaline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13114</drugbank-id>
      <name>Amitriptylinoxide</name>
      <description>The risk or severity of hypertension can be increased when Amitriptylinoxide is combined with Isoprenaline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13225</drugbank-id>
      <name>Dibenzepin</name>
      <description>The risk or severity of hypertension can be increased when Dibenzepin is combined with Isoprenaline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13246</drugbank-id>
      <name>Quinupramine</name>
      <description>The risk or severity of hypertension can be increased when Quinupramine is combined with Isoprenaline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13384</drugbank-id>
      <name>Melitracen</name>
      <description>The risk or severity of hypertension can be increased when Melitracen is combined with Isoprenaline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13411</drugbank-id>
      <name>Lofepramine</name>
      <description>The risk or severity of hypertension can be increased when Lofepramine is combined with Isoprenaline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13496</drugbank-id>
      <name>Iprindole</name>
      <description>The risk or severity of hypertension can be increased when Iprindole is combined with Isoprenaline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13782</drugbank-id>
      <name>Imipramine oxide</name>
      <description>The risk or severity of hypertension can be increased when Imipramine oxide is combined with Isoprenaline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00373</drugbank-id>
      <name>Timolol</name>
      <description>Timolol may decrease the bronchodilatory activities of Isoprenaline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00489</drugbank-id>
      <name>Sotalol</name>
      <description>Sotalol may decrease the bronchodilatory activities of Isoprenaline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00571</drugbank-id>
      <name>Propranolol</name>
      <description>Propranolol may decrease the bronchodilatory activities of Isoprenaline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00866</drugbank-id>
      <name>Alprenolol</name>
      <description>Alprenolol may decrease the bronchodilatory activities of Isoprenaline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00960</drugbank-id>
      <name>Pindolol</name>
      <description>Pindolol may decrease the bronchodilatory activities of Isoprenaline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01203</drugbank-id>
      <name>Nadolol</name>
      <description>Nadolol may decrease the bronchodilatory activities of Isoprenaline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01359</drugbank-id>
      <name>Penbutolol</name>
      <description>Penbutolol may decrease the bronchodilatory activities of Isoprenaline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01580</drugbank-id>
      <name>Oxprenolol</name>
      <description>Oxprenolol may decrease the bronchodilatory activities of Isoprenaline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08807</drugbank-id>
      <name>Bopindolol</name>
      <description>Bopindolol may decrease the bronchodilatory activities of Isoprenaline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08808</drugbank-id>
      <name>Bupranolol</name>
      <description>Bupranolol may decrease the bronchodilatory activities of Isoprenaline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13508</drugbank-id>
      <name>Cloranolol</name>
      <description>Cloranolol may decrease the bronchodilatory activities of Isoprenaline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13530</drugbank-id>
      <name>Mepindolol</name>
      <description>Mepindolol may decrease the bronchodilatory activities of Isoprenaline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13775</drugbank-id>
      <name>Tertatolol</name>
      <description>Tertatolol may decrease the bronchodilatory activities of Isoprenaline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00232</drugbank-id>
      <name>Methyclothiazide</name>
      <description>Isoprenaline may increase the hypokalemic activities of Methyclothiazide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00310</drugbank-id>
      <name>Chlorthalidone</name>
      <description>Isoprenaline may increase the hypokalemic activities of Chlorthalidone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00436</drugbank-id>
      <name>Bendroflumethiazide</name>
      <description>Isoprenaline may increase the hypokalemic activities of Bendroflumethiazide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00524</drugbank-id>
      <name>Metolazone</name>
      <description>Isoprenaline may increase the hypokalemic activities of Metolazone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00562</drugbank-id>
      <name>Benzthiazide</name>
      <description>Isoprenaline may increase the hypokalemic activities of Benzthiazide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00774</drugbank-id>
      <name>Hydroflumethiazide</name>
      <description>Isoprenaline may increase the hypokalemic activities of Hydroflumethiazide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00808</drugbank-id>
      <name>Indapamide</name>
      <description>Isoprenaline may increase the hypokalemic activities of Indapamide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00880</drugbank-id>
      <name>Chlorothiazide</name>
      <description>Isoprenaline may increase the hypokalemic activities of Chlorothiazide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00999</drugbank-id>
      <name>Hydrochlorothiazide</name>
      <description>Isoprenaline may increase the hypokalemic activities of Hydrochlorothiazide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01021</drugbank-id>
      <name>Trichlormethiazide</name>
      <description>Isoprenaline may increase the hypokalemic activities of Trichlormethiazide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01324</drugbank-id>
      <name>Polythiazide</name>
      <description>Isoprenaline may increase the hypokalemic activities of Polythiazide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01325</drugbank-id>
      <name>Quinethazone</name>
      <description>Isoprenaline may increase the hypokalemic activities of Quinethazone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13532</drugbank-id>
      <name>Cyclopenthiazide</name>
      <description>Isoprenaline may increase the hypokalemic activities of Cyclopenthiazide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13989</drugbank-id>
      <name>Epitizide</name>
      <description>Isoprenaline may increase the hypokalemic activities of Epitizide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00182</drugbank-id>
      <name>Amphetamine</name>
      <description>The risk or severity of adverse effects can be increased when Amphetamine is combined with Isoprenaline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00191</drugbank-id>
      <name>Phentermine</name>
      <description>The risk or severity of adverse effects can be increased when Phentermine is combined with Isoprenaline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00211</drugbank-id>
      <name>Midodrine</name>
      <description>The risk or severity of adverse effects can be increased when Midodrine is combined with Isoprenaline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00610</drugbank-id>
      <name>Metaraminol</name>
      <description>The risk or severity of adverse effects can be increased when Metaraminol is combined with Isoprenaline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00723</drugbank-id>
      <name>Methoxamine</name>
      <description>The risk or severity of adverse effects can be increased when Methoxamine is combined with Isoprenaline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00830</drugbank-id>
      <name>Phenmetrazine</name>
      <description>The risk or severity of adverse effects can be increased when Phenmetrazine is combined with Isoprenaline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00852</drugbank-id>
      <name>Pseudoephedrine</name>
      <description>The risk or severity of adverse effects can be increased when Pseudoephedrine is combined with Isoprenaline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00865</drugbank-id>
      <name>Benzphetamine</name>
      <description>The risk or severity of adverse effects can be increased when Benzphetamine is combined with Isoprenaline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00935</drugbank-id>
      <name>Oxymetazoline</name>
      <description>The risk or severity of adverse effects can be increased when Oxymetazoline is combined with Isoprenaline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00937</drugbank-id>
      <name>Diethylpropion</name>
      <description>The risk or severity of adverse effects can be increased when Diethylpropion is combined with Isoprenaline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00988</drugbank-id>
      <name>Dopamine</name>
      <description>The risk or severity of adverse effects can be increased when Dopamine is combined with Isoprenaline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01255</drugbank-id>
      <name>Lisdexamfetamine</name>
      <description>The risk or severity of adverse effects can be increased when Isoprenaline is combined with Lisdexamfetamine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01364</drugbank-id>
      <name>Ephedrine</name>
      <description>The risk or severity of adverse effects can be increased when Isoprenaline is combined with Ephedrine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01365</drugbank-id>
      <name>Mephentermine</name>
      <description>The risk or severity of adverse effects can be increased when Isoprenaline is combined with Mephentermine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01442</drugbank-id>
      <name>MMDA</name>
      <description>The risk or severity of adverse effects can be increased when Isoprenaline is combined with MMDA.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01454</drugbank-id>
      <name>Midomafetamine</name>
      <description>The risk or severity of adverse effects can be increased when Isoprenaline is combined with Midomafetamine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01467</drugbank-id>
      <name>2,5-Dimethoxy-4-ethylamphetamine</name>
      <description>The risk or severity of adverse effects can be increased when Isoprenaline is combined with 2,5-Dimethoxy-4-ethylamphetamine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01484</drugbank-id>
      <name>4-Bromo-2,5-dimethoxyamphetamine</name>
      <description>The risk or severity of adverse effects can be increased when Isoprenaline is combined with 4-Bromo-2,5-dimethoxyamphetamine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01509</drugbank-id>
      <name>Tenamfetamine</name>
      <description>The risk or severity of adverse effects can be increased when Isoprenaline is combined with Tenamfetamine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01556</drugbank-id>
      <name>Chlorphentermine</name>
      <description>The risk or severity of adverse effects can be increased when Isoprenaline is combined with Chlorphentermine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01566</drugbank-id>
      <name>Methylenedioxyethamphetamine</name>
      <description>The risk or severity of adverse effects can be increased when Isoprenaline is combined with Methylenedioxyethamphetamine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01576</drugbank-id>
      <name>Dextroamphetamine</name>
      <description>The risk or severity of adverse effects can be increased when Isoprenaline is combined with Dextroamphetamine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01577</drugbank-id>
      <name>Metamfetamine</name>
      <description>The risk or severity of adverse effects can be increased when Isoprenaline is combined with Metamfetamine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06152</drugbank-id>
      <name>Nylidrin</name>
      <description>The risk or severity of adverse effects can be increased when Isoprenaline is combined with Nylidrin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06764</drugbank-id>
      <name>Tetryzoline</name>
      <description>The risk or severity of adverse effects can be increased when Isoprenaline is combined with Tetryzoline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08841</drugbank-id>
      <name>Tyramine</name>
      <description>The risk or severity of adverse effects can be increased when Isoprenaline is combined with Tyramine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08941</drugbank-id>
      <name>Isoxsuprine</name>
      <description>The risk or severity of adverse effects can be increased when Isoprenaline is combined with Isoxsuprine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08985</drugbank-id>
      <name>Etilefrine</name>
      <description>The risk or severity of adverse effects can be increased when Isoprenaline is combined with Etilefrine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09203</drugbank-id>
      <name>Synephrine</name>
      <description>The risk or severity of adverse effects can be increased when Isoprenaline is combined with Synephrine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09480</drugbank-id>
      <name>Iofetamine I-123</name>
      <description>The risk or severity of adverse effects can be increased when Isoprenaline is combined with Iofetamine I-123.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12080</drugbank-id>
      <name>Ritobegron</name>
      <description>The risk or severity of adverse effects can be increased when Isoprenaline is combined with Ritobegron.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13064</drugbank-id>
      <name>Tramazoline</name>
      <description>The risk or severity of adverse effects can be increased when Isoprenaline is combined with Tramazoline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13108</drugbank-id>
      <name>Mephedrone</name>
      <description>The risk or severity of adverse effects can be increased when Isoprenaline is combined with Mephedrone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13341</drugbank-id>
      <name>Fenozolone</name>
      <description>The risk or severity of adverse effects can be increased when Isoprenaline is combined with Fenozolone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13624</drugbank-id>
      <name>Methoxyphenamine</name>
      <description>The risk or severity of adverse effects can be increased when Isoprenaline is combined with Methoxyphenamine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13692</drugbank-id>
      <name>Tretoquinol</name>
      <description>The risk or severity of adverse effects can be increased when Isoprenaline is combined with Tretoquinol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13703</drugbank-id>
      <name>Gepefrine</name>
      <description>The risk or severity of adverse effects can be increased when Isoprenaline is combined with Gepefrine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13777</drugbank-id>
      <name>Prenalterol</name>
      <description>The risk or severity of adverse effects can be increased when Isoprenaline is combined with Prenalterol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13852</drugbank-id>
      <name>Mefenorex</name>
      <description>The risk or severity of adverse effects can be increased when Isoprenaline is combined with Mefenorex.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13940</drugbank-id>
      <name>2,5-Dimethoxy-4-ethylthioamphetamine</name>
      <description>The risk or severity of adverse effects can be increased when Isoprenaline is combined with 2,5-Dimethoxy-4-ethylthioamphetamine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00470</drugbank-id>
      <name>Dronabinol</name>
      <description>The risk or severity of Tachycardia can be increased when Dronabinol is combined with Isoprenaline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00486</drugbank-id>
      <name>Nabilone</name>
      <description>The risk or severity of Tachycardia can be increased when Nabilone is combined with Isoprenaline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB05077</drugbank-id>
      <name>SLV319</name>
      <description>The risk or severity of Tachycardia can be increased when SLV319 is combined with Isoprenaline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB05372</drugbank-id>
      <name>CP-945598</name>
      <description>The risk or severity of Tachycardia can be increased when CP-945598 is combined with Isoprenaline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06155</drugbank-id>
      <name>Rimonabant</name>
      <description>The risk or severity of Tachycardia can be increased when Rimonabant is combined with Isoprenaline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06624</drugbank-id>
      <name>Taranabant</name>
      <description>The risk or severity of Tachycardia can be increased when Taranabant is combined with Isoprenaline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09061</drugbank-id>
      <name>Cannabidiol</name>
      <description>The risk or severity of Tachycardia can be increased when Cannabidiol is combined with Isoprenaline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11903</drugbank-id>
      <name>GW842166</name>
      <description>The risk or severity of Tachycardia can be increased when GW842166 is combined with Isoprenaline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12193</drugbank-id>
      <name>Ajulemic acid</name>
      <description>The risk or severity of Tachycardia can be increased when Ajulemic acid is combined with Isoprenaline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12649</drugbank-id>
      <name>Ibipinabant</name>
      <description>The risk or severity of Tachycardia can be increased when Ibipinabant is combined with Isoprenaline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13070</drugbank-id>
      <name>Surinabant</name>
      <description>The risk or severity of Tachycardia can be increased when Surinabant is combined with Isoprenaline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13950</drugbank-id>
      <name>WIN 55212-2</name>
      <description>The risk or severity of Tachycardia can be increased when WIN 55212-2 is combined with Isoprenaline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14011</drugbank-id>
      <name>Nabiximols</name>
      <description>The risk or severity of Tachycardia can be increased when Nabiximols is combined with Isoprenaline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14043</drugbank-id>
      <name>Palmidrol</name>
      <description>The risk or severity of Tachycardia can be increased when Palmidrol is combined with Isoprenaline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14737</drugbank-id>
      <name>Cannabinol</name>
      <description>The risk or severity of Tachycardia can be increased when Cannabinol is combined with Isoprenaline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00214</drugbank-id>
      <name>Torasemide</name>
      <description>The risk or severity of hypokalemia can be increased when Isoprenaline is combined with Torasemide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00695</drugbank-id>
      <name>Furosemide</name>
      <description>The risk or severity of hypokalemia can be increased when Isoprenaline is combined with Furosemide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00887</drugbank-id>
      <name>Bumetanide</name>
      <description>The risk or severity of hypokalemia can be increased when Isoprenaline is combined with Bumetanide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00903</drugbank-id>
      <name>Etacrynic acid</name>
      <description>The risk or severity of hypokalemia can be increased when Isoprenaline is combined with Etacrynic acid.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB02925</drugbank-id>
      <name>Piretanide</name>
      <description>The risk or severity of hypokalemia can be increased when Isoprenaline is combined with Piretanide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08961</drugbank-id>
      <name>Azosemide</name>
      <description>The risk or severity of hypokalemia can be increased when Isoprenaline is combined with Azosemide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00614</drugbank-id>
      <name>Furazolidone</name>
      <description>The risk or severity of adverse effects can be increased when Furazolidone is combined with Isoprenaline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00721</drugbank-id>
      <name>Procaine</name>
      <description>The risk or severity of adverse effects can be increased when Procaine is combined with Isoprenaline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00752</drugbank-id>
      <name>Tranylcypromine</name>
      <description>The risk or severity of adverse effects can be increased when Tranylcypromine is combined with Isoprenaline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00780</drugbank-id>
      <name>Phenelzine</name>
      <description>The risk or severity of adverse effects can be increased when Phenelzine is combined with Isoprenaline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00805</drugbank-id>
      <name>Minaprine</name>
      <description>The risk or severity of adverse effects can be increased when Minaprine is combined with Isoprenaline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01037</drugbank-id>
      <name>Selegiline</name>
      <description>The risk or severity of adverse effects can be increased when Selegiline is combined with Isoprenaline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01168</drugbank-id>
      <name>Procarbazine</name>
      <description>The risk or severity of adverse effects can be increased when Procarbazine is combined with Isoprenaline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01171</drugbank-id>
      <name>Moclobemide</name>
      <description>The risk or severity of adverse effects can be increased when Moclobemide is combined with Isoprenaline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01247</drugbank-id>
      <name>Isocarboxazid</name>
      <description>The risk or severity of adverse effects can be increased when Isocarboxazid is combined with Isoprenaline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01367</drugbank-id>
      <name>Rasagiline</name>
      <description>The risk or severity of adverse effects can be increased when Rasagiline is combined with Isoprenaline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01626</drugbank-id>
      <name>Pargyline</name>
      <description>The risk or severity of adverse effects can be increased when Pargyline is combined with Isoprenaline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04017</drugbank-id>
      <name>Clorgiline</name>
      <description>The risk or severity of adverse effects can be increased when Clorgiline is combined with Isoprenaline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04818</drugbank-id>
      <name>Iproniazid</name>
      <description>The risk or severity of adverse effects can be increased when Iproniazid is combined with Isoprenaline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04820</drugbank-id>
      <name>Nialamide</name>
      <description>The risk or severity of adverse effects can be increased when Nialamide is combined with Isoprenaline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06654</drugbank-id>
      <name>Safinamide</name>
      <description>The risk or severity of adverse effects can be increased when Safinamide is combined with Isoprenaline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08550</drugbank-id>
      <name>7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline</name>
      <description>The risk or severity of adverse effects can be increased when 7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline is combined with Isoprenaline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09241</drugbank-id>
      <name>Methylene blue</name>
      <description>The risk or severity of adverse effects can be increased when Methylene blue is combined with Isoprenaline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09243</drugbank-id>
      <name>Hydracarbazine</name>
      <description>The risk or severity of adverse effects can be increased when Hydracarbazine is combined with Isoprenaline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09244</drugbank-id>
      <name>Pirlindole</name>
      <description>The risk or severity of adverse effects can be increased when Pirlindole is combined with Isoprenaline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09245</drugbank-id>
      <name>Toloxatone</name>
      <description>The risk or severity of adverse effects can be increased when Toloxatone is combined with Isoprenaline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09246</drugbank-id>
      <name>Benmoxin</name>
      <description>The risk or severity of adverse effects can be increased when Benmoxin is combined with Isoprenaline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09248</drugbank-id>
      <name>Mebanazine</name>
      <description>The risk or severity of adverse effects can be increased when Mebanazine is combined with Isoprenaline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09249</drugbank-id>
      <name>Octamoxin</name>
      <description>The risk or severity of adverse effects can be increased when Octamoxin is combined with Isoprenaline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09250</drugbank-id>
      <name>Pheniprazine</name>
      <description>The risk or severity of adverse effects can be increased when Pheniprazine is combined with Isoprenaline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09251</drugbank-id>
      <name>Phenoxypropazine</name>
      <description>The risk or severity of adverse effects can be increased when Phenoxypropazine is combined with Isoprenaline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09252</drugbank-id>
      <name>Pivhydrazine</name>
      <description>The risk or severity of adverse effects can be increased when Pivhydrazine is combined with Isoprenaline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09253</drugbank-id>
      <name>Safrazine</name>
      <description>The risk or severity of adverse effects can be increased when Safrazine is combined with Isoprenaline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09254</drugbank-id>
      <name>Caroxazone</name>
      <description>The risk or severity of adverse effects can be increased when Caroxazone is combined with Isoprenaline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13875</drugbank-id>
      <name>Harmaline</name>
      <description>The risk or severity of adverse effects can be increased when Harmaline is combined with Isoprenaline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13876</drugbank-id>
      <name>Brofaromine</name>
      <description>The risk or severity of adverse effects can be increased when Brofaromine is combined with Isoprenaline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00221</drugbank-id>
      <name>Isoetharine</name>
      <description>The risk or severity of adverse effects can be increased when Isoetharine is combined with Isoprenaline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00397</drugbank-id>
      <name>Phenylpropanolamine</name>
      <description>The risk or severity of adverse effects can be increased when Phenylpropanolamine is combined with Isoprenaline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00816</drugbank-id>
      <name>Orciprenaline</name>
      <description>The risk or severity of adverse effects can be increased when Orciprenaline is combined with Isoprenaline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00841</drugbank-id>
      <name>Dobutamine</name>
      <description>The risk or severity of adverse effects can be increased when Dobutamine is combined with Isoprenaline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00867</drugbank-id>
      <name>Ritodrine</name>
      <description>The risk or severity of adverse effects can be increased when Ritodrine is combined with Isoprenaline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00871</drugbank-id>
      <name>Terbutaline</name>
      <description>The risk or severity of adverse effects can be increased when Terbutaline is combined with Isoprenaline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00901</drugbank-id>
      <name>Bitolterol</name>
      <description>The risk or severity of adverse effects can be increased when Bitolterol is combined with Isoprenaline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00938</drugbank-id>
      <name>Salmeterol</name>
      <description>The risk or severity of adverse effects can be increased when Salmeterol is combined with Isoprenaline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00983</drugbank-id>
      <name>Formoterol</name>
      <description>The risk or severity of adverse effects can be increased when Formoterol is combined with Isoprenaline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01001</drugbank-id>
      <name>Salbutamol</name>
      <description>The risk or severity of adverse effects can be increased when Salbutamol is combined with Isoprenaline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01102</drugbank-id>
      <name>Arbutamine</name>
      <description>The risk or severity of adverse effects can be increased when Isoprenaline is combined with Arbutamine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01274</drugbank-id>
      <name>Arformoterol</name>
      <description>The risk or severity of adverse effects can be increased when Isoprenaline is combined with Arformoterol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01288</drugbank-id>
      <name>Fenoterol</name>
      <description>The risk or severity of adverse effects can be increased when Isoprenaline is combined with Fenoterol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01291</drugbank-id>
      <name>Pirbuterol</name>
      <description>The risk or severity of adverse effects can be increased when Isoprenaline is combined with Pirbuterol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01363</drugbank-id>
      <name>Ephedra sinica root</name>
      <description>The risk or severity of adverse effects can be increased when Isoprenaline is combined with Ephedra sinica root.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01366</drugbank-id>
      <name>Procaterol</name>
      <description>The risk or severity of adverse effects can be increased when Isoprenaline is combined with Procaterol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01407</drugbank-id>
      <name>Clenbuterol</name>
      <description>The risk or severity of adverse effects can be increased when Isoprenaline is combined with Clenbuterol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01408</drugbank-id>
      <name>Bambuterol</name>
      <description>The risk or severity of adverse effects can be increased when Isoprenaline is combined with Bambuterol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB05039</drugbank-id>
      <name>Indacaterol</name>
      <description>The risk or severity of adverse effects can be increased when Isoprenaline is combined with Indacaterol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08957</drugbank-id>
      <name>Hexoprenaline</name>
      <description>The risk or severity of adverse effects can be increased when Isoprenaline is combined with Hexoprenaline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09080</drugbank-id>
      <name>Olodaterol</name>
      <description>The risk or severity of adverse effects can be increased when Isoprenaline is combined with Olodaterol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09082</drugbank-id>
      <name>Vilanterol</name>
      <description>The risk or severity of adverse effects can be increased when Isoprenaline is combined with Vilanterol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11587</drugbank-id>
      <name>Etafedrine</name>
      <description>The risk or severity of adverse effects can be increased when Isoprenaline is combined with Etafedrine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11871</drugbank-id>
      <name>PF-00610355</name>
      <description>The risk or severity of adverse effects can be increased when Isoprenaline is combined with PF-00610355.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12100</drugbank-id>
      <name>Abediterol</name>
      <description>The risk or severity of adverse effects can be increased when Isoprenaline is combined with Abediterol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12526</drugbank-id>
      <name>Batefenterol</name>
      <description>The risk or severity of adverse effects can be increased when Isoprenaline is combined with Batefenterol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13139</drugbank-id>
      <name>Levosalbutamol</name>
      <description>The risk or severity of adverse effects can be increased when Isoprenaline is combined with Levosalbutamol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00187</drugbank-id>
      <name>Esmolol</name>
      <description>The therapeutic efficacy of Isoprenaline can be decreased when used in combination with Esmolol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00195</drugbank-id>
      <name>Betaxolol</name>
      <description>The therapeutic efficacy of Isoprenaline can be decreased when used in combination with Betaxolol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00264</drugbank-id>
      <name>Metoprolol</name>
      <description>The therapeutic efficacy of Isoprenaline can be decreased when used in combination with Metoprolol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00335</drugbank-id>
      <name>Atenolol</name>
      <description>The therapeutic efficacy of Isoprenaline can be decreased when used in combination with Atenolol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00598</drugbank-id>
      <name>Labetalol</name>
      <description>The therapeutic efficacy of Isoprenaline can be decreased when used in combination with Labetalol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00612</drugbank-id>
      <name>Bisoprolol</name>
      <description>The therapeutic efficacy of Isoprenaline can be decreased when used in combination with Bisoprolol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01136</drugbank-id>
      <name>Carvedilol</name>
      <description>The therapeutic efficacy of Isoprenaline can be decreased when used in combination with Carvedilol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01182</drugbank-id>
      <name>Propafenone</name>
      <description>The therapeutic efficacy of Isoprenaline can be decreased when used in combination with Propafenone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01193</drugbank-id>
      <name>Acebutolol</name>
      <description>The therapeutic efficacy of Isoprenaline can be decreased when used in combination with Acebutolol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01295</drugbank-id>
      <name>Bevantolol</name>
      <description>The therapeutic efficacy of Isoprenaline can be decreased when used in combination with Bevantolol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01297</drugbank-id>
      <name>Practolol</name>
      <description>The therapeutic efficacy of Isoprenaline can be decreased when used in combination with Practolol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB03322</drugbank-id>
      <name>Dexpropranolol</name>
      <description>The therapeutic efficacy of Isoprenaline can be decreased when used in combination with Dexpropranolol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04846</drugbank-id>
      <name>Celiprolol</name>
      <description>The therapeutic efficacy of Isoprenaline can be decreased when used in combination with Celiprolol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04861</drugbank-id>
      <name>Nebivolol</name>
      <description>The therapeutic efficacy of Isoprenaline can be decreased when used in combination with Nebivolol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06726</drugbank-id>
      <name>Bufuralol</name>
      <description>The therapeutic efficacy of Isoprenaline can be decreased when used in combination with Bufuralol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08952</drugbank-id>
      <name>Indenolol</name>
      <description>The therapeutic efficacy of Isoprenaline can be decreased when used in combination with Indenolol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09013</drugbank-id>
      <name>Befunolol</name>
      <description>The therapeutic efficacy of Isoprenaline can be decreased when used in combination with Befunolol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09204</drugbank-id>
      <name>Arotinolol</name>
      <description>The therapeutic efficacy of Isoprenaline can be decreased when used in combination with Arotinolol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09351</drugbank-id>
      <name>Levobetaxolol</name>
      <description>The therapeutic efficacy of Isoprenaline can be decreased when used in combination with Levobetaxolol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11770</drugbank-id>
      <name>Talinolol</name>
      <description>The therapeutic efficacy of Isoprenaline can be decreased when used in combination with Talinolol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11785</drugbank-id>
      <name>Anisodamine</name>
      <description>The therapeutic efficacy of Isoprenaline can be decreased when used in combination with Anisodamine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12212</drugbank-id>
      <name>Landiolol</name>
      <description>The therapeutic efficacy of Isoprenaline can be decreased when used in combination with Landiolol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12752</drugbank-id>
      <name>Bucindolol</name>
      <description>The therapeutic efficacy of Isoprenaline can be decreased when used in combination with Bucindolol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13443</drugbank-id>
      <name>Esatenolol</name>
      <description>The therapeutic efficacy of Isoprenaline can be decreased when used in combination with Esatenolol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13757</drugbank-id>
      <name>Epanolol</name>
      <description>The therapeutic efficacy of Isoprenaline can be decreased when used in combination with Epanolol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00368</drugbank-id>
      <name>Norepinephrine</name>
      <description>The therapeutic efficacy of Isoprenaline can be increased when used in combination with Norepinephrine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00668</drugbank-id>
      <name>Epinephrine</name>
      <description>The therapeutic efficacy of Isoprenaline can be increased when used in combination with Epinephrine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06262</drugbank-id>
      <name>Droxidopa</name>
      <description>The therapeutic efficacy of Isoprenaline can be increased when used in combination with Droxidopa.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06707</drugbank-id>
      <name>Levonordefrin</name>
      <description>The therapeutic efficacy of Isoprenaline can be increased when used in combination with Levonordefrin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06814</drugbank-id>
      <name>Protokylol</name>
      <description>The therapeutic efficacy of Isoprenaline can be increased when used in combination with Protokylol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11124</drugbank-id>
      <name>Racepinephrine</name>
      <description>The therapeutic efficacy of Isoprenaline can be increased when used in combination with Racepinephrine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13316</drugbank-id>
      <name>Ibopamine</name>
      <description>The therapeutic efficacy of Isoprenaline can be increased when used in combination with Ibopamine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13917</drugbank-id>
      <name>Deoxyepinephrine</name>
      <description>The therapeutic efficacy of Isoprenaline can be increased when used in combination with Deoxyepinephrine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00226</drugbank-id>
      <name>Guanadrel</name>
      <description>The therapeutic efficacy of Isoprenaline can be decreased when used in combination with Guanadrel.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00392</drugbank-id>
      <name>Profenamine</name>
      <description>The therapeutic efficacy of Isoprenaline can be decreased when used in combination with Profenamine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01158</drugbank-id>
      <name>Bretylium</name>
      <description>The therapeutic efficacy of Isoprenaline can be decreased when used in combination with Bretylium.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01170</drugbank-id>
      <name>Guanethidine</name>
      <description>The therapeutic efficacy of Isoprenaline can be decreased when used in combination with Guanethidine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12057</drugbank-id>
      <name>ORM-12741</name>
      <description>The therapeutic efficacy of Isoprenaline can be decreased when used in combination with ORM-12741.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00184</drugbank-id>
      <name>Nicotine</name>
      <description>The risk or severity of Tachycardia can be increased when Nicotine is combined with Isoprenaline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00193</drugbank-id>
      <name>Tramadol</name>
      <description>The risk or severity of Tachycardia can be increased when Tramadol is combined with Isoprenaline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00209</drugbank-id>
      <name>Trospium</name>
      <description>The risk or severity of Tachycardia can be increased when Trospium is combined with Isoprenaline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00219</drugbank-id>
      <name>Oxyphenonium</name>
      <description>The risk or severity of Tachycardia can be increased when Oxyphenonium is combined with Isoprenaline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00245</drugbank-id>
      <name>Benzatropine</name>
      <description>The risk or severity of Tachycardia can be increased when Benzatropine is combined with Isoprenaline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00261</drugbank-id>
      <name>Anagrelide</name>
      <description>The risk or severity of Tachycardia can be increased when Anagrelide is combined with Isoprenaline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00280</drugbank-id>
      <name>Disopyramide</name>
      <description>The risk or severity of Tachycardia can be increased when Disopyramide is combined with Isoprenaline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00332</drugbank-id>
      <name>Ipratropium</name>
      <description>The risk or severity of Tachycardia can be increased when Ipratropium is combined with Isoprenaline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00340</drugbank-id>
      <name>Metixene</name>
      <description>The risk or severity of Tachycardia can be increased when Metixene is combined with Isoprenaline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00354</drugbank-id>
      <name>Buclizine</name>
      <description>The risk or severity of Tachycardia can be increased when Buclizine is combined with Isoprenaline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00366</drugbank-id>
      <name>Doxylamine</name>
      <description>The risk or severity of Tachycardia can be increased when Doxylamine is combined with Isoprenaline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00376</drugbank-id>
      <name>Trihexyphenidyl</name>
      <description>The risk or severity of Tachycardia can be increased when Trihexyphenidyl is combined with Isoprenaline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00383</drugbank-id>
      <name>Oxyphencyclimine</name>
      <description>The risk or severity of Tachycardia can be increased when Oxyphencyclimine is combined with Isoprenaline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00387</drugbank-id>
      <name>Procyclidine</name>
      <description>The risk or severity of Tachycardia can be increased when Procyclidine is combined with Isoprenaline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00424</drugbank-id>
      <name>Hyoscyamine</name>
      <description>The risk or severity of Tachycardia can be increased when Hyoscyamine is combined with Isoprenaline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00434</drugbank-id>
      <name>Cyproheptadine</name>
      <description>The risk or severity of Tachycardia can be increased when Cyproheptadine is combined with Isoprenaline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00462</drugbank-id>
      <name>Methscopolamine bromide</name>
      <description>The risk or severity of Tachycardia can be increased when Methscopolamine bromide is combined with Isoprenaline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00483</drugbank-id>
      <name>Gallamine triethiodide</name>
      <description>The risk or severity of Tachycardia can be increased when Gallamine triethiodide is combined with Isoprenaline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00496</drugbank-id>
      <name>Darifenacin</name>
      <description>The risk or severity of Tachycardia can be increased when Darifenacin is combined with Isoprenaline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00505</drugbank-id>
      <name>Tridihexethyl</name>
      <description>The risk or severity of Tachycardia can be increased when Tridihexethyl is combined with Isoprenaline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00508</drugbank-id>
      <name>Triflupromazine</name>
      <description>The risk or severity of Tachycardia can be increased when Triflupromazine is combined with Isoprenaline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00517</drugbank-id>
      <name>Anisotropine methylbromide</name>
      <description>The risk or severity of Tachycardia can be increased when Anisotropine methylbromide is combined with Isoprenaline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00555</drugbank-id>
      <name>Lamotrigine</name>
      <description>The risk or severity of Tachycardia can be increased when Lamotrigine is combined with Isoprenaline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00640</drugbank-id>
      <name>Adenosine</name>
      <description>The risk or severity of Tachycardia can be increased when Adenosine is combined with Isoprenaline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00670</drugbank-id>
      <name>Pirenzepine</name>
      <description>The risk or severity of Tachycardia can be increased when Pirenzepine is combined with Isoprenaline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00697</drugbank-id>
      <name>Tizanidine</name>
      <description>The risk or severity of Tachycardia can be increased when Tizanidine is combined with Isoprenaline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00715</drugbank-id>
      <name>Paroxetine</name>
      <description>The risk or severity of Tachycardia can be increased when Paroxetine is combined with Isoprenaline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00725</drugbank-id>
      <name>Homatropine methylbromide</name>
      <description>The risk or severity of Tachycardia can be increased when Homatropine methylbromide is combined with Isoprenaline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00728</drugbank-id>
      <name>Rocuronium</name>
      <description>The risk or severity of Tachycardia can be increased when Rocuronium is combined with Isoprenaline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00747</drugbank-id>
      <name>Scopolamine</name>
      <description>The risk or severity of Tachycardia can be increased when Scopolamine is combined with Isoprenaline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00767</drugbank-id>
      <name>Benzquinamide</name>
      <description>The risk or severity of Tachycardia can be increased when Benzquinamide is combined with Isoprenaline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00771</drugbank-id>
      <name>Clidinium</name>
      <description>The risk or severity of Tachycardia can be increased when Clidinium is combined with Isoprenaline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00782</drugbank-id>
      <name>Propantheline</name>
      <description>The risk or severity of Tachycardia can be increased when Propantheline is combined with Isoprenaline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00804</drugbank-id>
      <name>Dicyclomine</name>
      <description>The risk or severity of Tachycardia can be increased when Dicyclomine is combined with Isoprenaline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00810</drugbank-id>
      <name>Biperiden</name>
      <description>The risk or severity of Tachycardia can be increased when Biperiden is combined with Isoprenaline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00835</drugbank-id>
      <name>Brompheniramine</name>
      <description>The risk or severity of Tachycardia can be increased when Brompheniramine is combined with Isoprenaline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00907</drugbank-id>
      <name>Cocaine</name>
      <description>The risk or severity of Tachycardia can be increased when Cocaine is combined with Isoprenaline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00934</drugbank-id>
      <name>Maprotiline</name>
      <description>The risk or severity of Tachycardia can be increased when Maprotiline is combined with Isoprenaline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00940</drugbank-id>
      <name>Methantheline</name>
      <description>The risk or severity of Tachycardia can be increased when Methantheline is combined with Isoprenaline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00942</drugbank-id>
      <name>Cycrimine</name>
      <description>The risk or severity of Tachycardia can be increased when Cycrimine is combined with Isoprenaline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00986</drugbank-id>
      <name>Glycopyrronium</name>
      <description>The risk or severity of Tachycardia can be increased when Glycopyrronium is combined with Isoprenaline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01036</drugbank-id>
      <name>Tolterodine</name>
      <description>The risk or severity of Tachycardia can be increased when Tolterodine is combined with Isoprenaline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01062</drugbank-id>
      <name>Oxybutynin</name>
      <description>The risk or severity of Tachycardia can be increased when Oxybutynin is combined with Isoprenaline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01069</drugbank-id>
      <name>Promethazine</name>
      <description>The risk or severity of Tachycardia can be increased when Isoprenaline is combined with Promethazine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01075</drugbank-id>
      <name>Diphenhydramine</name>
      <description>The risk or severity of Tachycardia can be increased when Isoprenaline is combined with Diphenhydramine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01148</drugbank-id>
      <name>Flavoxate</name>
      <description>The risk or severity of Tachycardia can be increased when Isoprenaline is combined with Flavoxate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01166</drugbank-id>
      <name>Cilostazol</name>
      <description>The risk or severity of Tachycardia can be increased when Isoprenaline is combined with Cilostazol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01173</drugbank-id>
      <name>Orphenadrine</name>
      <description>The risk or severity of Tachycardia can be increased when Isoprenaline is combined with Orphenadrine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01221</drugbank-id>
      <name>Ketamine</name>
      <description>The risk or severity of Tachycardia can be increased when Isoprenaline is combined with Ketamine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01226</drugbank-id>
      <name>Mivacurium</name>
      <description>The risk or severity of Tachycardia can be increased when Isoprenaline is combined with Mivacurium.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01231</drugbank-id>
      <name>Diphenidol</name>
      <description>The risk or severity of Tachycardia can be increased when Isoprenaline is combined with Diphenidol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01239</drugbank-id>
      <name>Chlorprothixene</name>
      <description>The risk or severity of Tachycardia can be increased when Isoprenaline is combined with Chlorprothixene.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01336</drugbank-id>
      <name>Metocurine</name>
      <description>The risk or severity of Tachycardia can be increased when Isoprenaline is combined with Metocurine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01337</drugbank-id>
      <name>Pancuronium</name>
      <description>The risk or severity of Tachycardia can be increased when Isoprenaline is combined with Pancuronium.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01338</drugbank-id>
      <name>Pipecuronium</name>
      <description>The risk or severity of Tachycardia can be increased when Isoprenaline is combined with Pipecuronium.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01409</drugbank-id>
      <name>Tiotropium</name>
      <description>The risk or severity of Tachycardia can be increased when Isoprenaline is combined with Tiotropium.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01625</drugbank-id>
      <name>Isopropamide</name>
      <description>The risk or severity of Tachycardia can be increased when Isoprenaline is combined with Isopropamide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04834</drugbank-id>
      <name>Rapacuronium</name>
      <description>The risk or severity of Tachycardia can be increased when Isoprenaline is combined with Rapacuronium.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04843</drugbank-id>
      <name>Mepenzolate</name>
      <description>The risk or severity of Tachycardia can be increased when Isoprenaline is combined with Mepenzolate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06702</drugbank-id>
      <name>Fesoterodine</name>
      <description>The risk or severity of Tachycardia can be increased when Isoprenaline is combined with Fesoterodine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06787</drugbank-id>
      <name>Hexocyclium</name>
      <description>The risk or severity of Tachycardia can be increased when Isoprenaline is combined with Hexocyclium.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08801</drugbank-id>
      <name>Dimetindene</name>
      <description>The risk or severity of Tachycardia can be increased when Isoprenaline is combined with Dimetindene.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08897</drugbank-id>
      <name>Aclidinium</name>
      <description>The risk or severity of Tachycardia can be increased when Isoprenaline is combined with Aclidinium.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08997</drugbank-id>
      <name>Dexetimide</name>
      <description>The risk or severity of Tachycardia can be increased when Isoprenaline is combined with Dexetimide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09007</drugbank-id>
      <name>Chlorphenoxamine</name>
      <description>The risk or severity of Tachycardia can be increased when Isoprenaline is combined with Chlorphenoxamine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09023</drugbank-id>
      <name>Benactyzine</name>
      <description>The risk or severity of Tachycardia can be increased when Isoprenaline is combined with Benactyzine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09076</drugbank-id>
      <name>Umeclidinium</name>
      <description>The risk or severity of Tachycardia can be increased when Isoprenaline is combined with Umeclidinium.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09089</drugbank-id>
      <name>Trimebutine</name>
      <description>The risk or severity of Tachycardia can be increased when Isoprenaline is combined with Trimebutine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09262</drugbank-id>
      <name>Imidafenacin</name>
      <description>The risk or severity of Tachycardia can be increased when Isoprenaline is combined with Imidafenacin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09300</drugbank-id>
      <name>Butylscopolamine</name>
      <description>The risk or severity of Tachycardia can be increased when Isoprenaline is combined with Butylscopolamine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11235</drugbank-id>
      <name>Thonzylamine</name>
      <description>The risk or severity of Tachycardia can be increased when Isoprenaline is combined with Thonzylamine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11315</drugbank-id>
      <name>Methscopolamine</name>
      <description>The risk or severity of Tachycardia can be increased when Isoprenaline is combined with Methscopolamine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12086</drugbank-id>
      <name>Oxitropium</name>
      <description>The risk or severity of Tachycardia can be increased when Isoprenaline is combined with Oxitropium.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12554</drugbank-id>
      <name>Mebeverine</name>
      <description>The risk or severity of Tachycardia can be increased when Isoprenaline is combined with Mebeverine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13252</drugbank-id>
      <name>Tropatepine</name>
      <description>The risk or severity of Tachycardia can be increased when Isoprenaline is combined with Tropatepine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13254</drugbank-id>
      <name>Prifinium</name>
      <description>The risk or severity of Tachycardia can be increased when Isoprenaline is combined with Prifinium.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13351</drugbank-id>
      <name>Piperidolate</name>
      <description>The risk or severity of Tachycardia can be increased when Isoprenaline is combined with Piperidolate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13369</drugbank-id>
      <name>Benzilone</name>
      <description>The risk or severity of Tachycardia can be increased when Isoprenaline is combined with Benzilone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13380</drugbank-id>
      <name>Difemerine</name>
      <description>The risk or severity of Tachycardia can be increased when Isoprenaline is combined with Difemerine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13413</drugbank-id>
      <name>Phenglutarimide</name>
      <description>The risk or severity of Tachycardia can be increased when Isoprenaline is combined with Phenglutarimide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13448</drugbank-id>
      <name>Mazaticol</name>
      <description>The risk or severity of Tachycardia can be increased when Isoprenaline is combined with Mazaticol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13468</drugbank-id>
      <name>Etybenzatropine</name>
      <description>The risk or severity of Tachycardia can be increased when Isoprenaline is combined with Etybenzatropine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13500</drugbank-id>
      <name>Otilonium</name>
      <description>The risk or severity of Tachycardia can be increased when Isoprenaline is combined with Otilonium.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13505</drugbank-id>
      <name>Emepronium</name>
      <description>The risk or severity of Tachycardia can be increased when Isoprenaline is combined with Emepronium.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13507</drugbank-id>
      <name>Poldine</name>
      <description>The risk or severity of Tachycardia can be increased when Isoprenaline is combined with Poldine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13542</drugbank-id>
      <name>Bevonium</name>
      <description>The risk or severity of Tachycardia can be increased when Isoprenaline is combined with Bevonium.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13581</drugbank-id>
      <name>Rociverine</name>
      <description>The risk or severity of Tachycardia can be increased when Isoprenaline is combined with Rociverine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13619</drugbank-id>
      <name>Bornaprine</name>
      <description>The risk or severity of Tachycardia can be increased when Isoprenaline is combined with Bornaprine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13636</drugbank-id>
      <name>Etanautine</name>
      <description>The risk or severity of Tachycardia can be increased when Isoprenaline is combined with Etanautine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13666</drugbank-id>
      <name>Tiemonium iodide</name>
      <description>The risk or severity of Tachycardia can be increased when Isoprenaline is combined with Tiemonium iodide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13678</drugbank-id>
      <name>Dihexyverine</name>
      <description>The risk or severity of Tachycardia can be increased when Isoprenaline is combined with Dihexyverine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13695</drugbank-id>
      <name>Penthienate</name>
      <description>The risk or severity of Tachycardia can be increased when Isoprenaline is combined with Penthienate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13720</drugbank-id>
      <name>Diphemanil</name>
      <description>The risk or severity of Tachycardia can be increased when Isoprenaline is combined with Diphemanil.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13738</drugbank-id>
      <name>Camylofin</name>
      <description>The risk or severity of Tachycardia can be increased when Isoprenaline is combined with Camylofin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13759</drugbank-id>
      <name>Fenpiverinium</name>
      <description>The risk or severity of Tachycardia can be increased when Isoprenaline is combined with Fenpiverinium.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13769</drugbank-id>
      <name>Emetonium iodide</name>
      <description>The risk or severity of Tachycardia can be increased when Isoprenaline is combined with Emetonium iodide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13844</drugbank-id>
      <name>Pipenzolate</name>
      <description>The risk or severity of Tachycardia can be increased when Isoprenaline is combined with Pipenzolate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13850</drugbank-id>
      <name>Timepidium</name>
      <description>The risk or severity of Tachycardia can be increased when Isoprenaline is combined with Timepidium.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14009</drugbank-id>
      <name>Medical Cannabis</name>
      <description>The risk or severity of Tachycardia can be increased when Isoprenaline is combined with Medical Cannabis.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00579</drugbank-id>
      <name>Mazindol</name>
      <description>The risk or severity of adverse effects can be increased when Mazindol is combined with Isoprenaline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00017</drugbank-id>
      <name>Salmon Calcitonin</name>
      <description>The risk or severity of adverse effects can be increased when Isoprenaline is combined with Salmon Calcitonin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00024</drugbank-id>
      <name>Thyrotropin alfa</name>
      <description>The risk or severity of adverse effects can be increased when Isoprenaline is combined with Thyrotropin alfa.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00066</drugbank-id>
      <name>Follitropin</name>
      <description>The risk or severity of adverse effects can be increased when Isoprenaline is combined with Follitropin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00279</drugbank-id>
      <name>Liothyronine</name>
      <description>The risk or severity of adverse effects can be increased when Isoprenaline is combined with Liothyronine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00389</drugbank-id>
      <name>Carbimazole</name>
      <description>The risk or severity of adverse effects can be increased when Isoprenaline is combined with Carbimazole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00451</drugbank-id>
      <name>Levothyroxine</name>
      <description>The risk or severity of adverse effects can be increased when Isoprenaline is combined with Levothyroxine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00550</drugbank-id>
      <name>Propylthiouracil</name>
      <description>The risk or severity of adverse effects can be increased when Isoprenaline is combined with Propylthiouracil.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00763</drugbank-id>
      <name>Methimazole</name>
      <description>The risk or severity of adverse effects can be increased when Isoprenaline is combined with Methimazole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01583</drugbank-id>
      <name>Liotrix</name>
      <description>The risk or severity of adverse effects can be increased when Isoprenaline is combined with Liotrix.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB03374</drugbank-id>
      <name>3,5-Diiodotyrosine</name>
      <description>The risk or severity of adverse effects can be increased when Isoprenaline is combined with 3,5-Diiodotyrosine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB03604</drugbank-id>
      <name>Tiratricol</name>
      <description>The risk or severity of adverse effects can be increased when Isoprenaline is combined with Tiratricol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB05084</drugbank-id>
      <name>Abaloparatide</name>
      <description>The risk or severity of adverse effects can be increased when Isoprenaline is combined with Abaloparatide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB05829</drugbank-id>
      <name>Parathyroid hormone</name>
      <description>The risk or severity of adverse effects can be increased when Isoprenaline is combined with Parathyroid hormone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06285</drugbank-id>
      <name>Teriparatide</name>
      <description>The risk or severity of adverse effects can be increased when Isoprenaline is combined with Teriparatide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06715</drugbank-id>
      <name>Potassium Iodide</name>
      <description>The risk or severity of adverse effects can be increased when Isoprenaline is combined with Potassium Iodide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB07637</drugbank-id>
      <name>Dibromotyrosine</name>
      <description>The risk or severity of adverse effects can be increased when Isoprenaline is combined with Dibromotyrosine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09100</drugbank-id>
      <name>Thyroid, porcine</name>
      <description>The risk or severity of adverse effects can be increased when Isoprenaline is combined with Thyroid, porcine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09418</drugbank-id>
      <name>Potassium perchlorate</name>
      <description>The risk or severity of adverse effects can be increased when Isoprenaline is combined with Potassium perchlorate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09421</drugbank-id>
      <name>Protirelin</name>
      <description>The risk or severity of adverse effects can be increased when Isoprenaline is combined with Protirelin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12629</drugbank-id>
      <name>3,5-diiodothyropropionic acid</name>
      <description>The risk or severity of adverse effects can be increased when Isoprenaline is combined with 3,5-diiodothyropropionic acid.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13644</drugbank-id>
      <name>Methylthiouracil</name>
      <description>The risk or severity of adverse effects can be increased when Isoprenaline is combined with Methylthiouracil.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13742</drugbank-id>
      <name>Elcatonin</name>
      <description>The risk or severity of adverse effects can be increased when Isoprenaline is combined with Elcatonin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13804</drugbank-id>
      <name>Benzylthiouracil</name>
      <description>The risk or severity of adverse effects can be increased when Isoprenaline is combined with Benzylthiouracil.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB15263</drugbank-id>
      <name>Thyrotropin</name>
      <description>The risk or severity of adverse effects can be increased when Isoprenaline is combined with Thyrotropin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11823</drugbank-id>
      <name>Esketamine</name>
      <description>The risk or severity of hypertension can be increased when Esketamine is combined with Isoprenaline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14754</drugbank-id>
      <name>Solriamfetol</name>
      <description>The risk or severity of hypertension can be increased when Solriamfetol is combined with Isoprenaline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13946</drugbank-id>
      <name>Testosterone undecanoate</name>
      <description>Testosterone undecanoate may increase the hypertensive activities of Isoprenaline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01016</drugbank-id>
      <name>Glyburide</name>
      <description>The therapeutic efficacy of Glyburide can be decreased when used in combination with Isoprenaline.</description>
    </drug-interaction>
  </drug-interactions>
  <calculated-properties>
    <property>
      <kind>logP</kind>
      <value>-0.27</value>
      <source>ALOGPS</source>
    </property>
    <property>
      <kind>logS</kind>
      <value>-1.6</value>
      <source>ALOGPS</source>
    </property>
    <property>
      <kind>Water Solubility</kind>
      <value>5.86e+00 g/l</value>
      <source>ALOGPS</source>
    </property>
    <property>
      <kind>logP</kind>
      <value>0.24</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>IUPAC Name</kind>
      <value>4-{1-hydroxy-2-[(propan-2-yl)amino]ethyl}benzene-1,2-diol</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Traditional IUPAC Name</kind>
      <value>isoproterenol</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Molecular Weight</kind>
      <value>211.2576</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Monoisotopic Weight</kind>
      <value>211.120843415</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>SMILES</kind>
      <value>CC(C)NCC(O)C1=CC(O)=C(O)C=C1</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Molecular Formula</kind>
      <value>C11H17NO3</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>InChI</kind>
      <value>InChI=1S/C11H17NO3/c1-7(2)12-6-11(15)8-3-4-9(13)10(14)5-8/h3-5,7,11-15H,6H2,1-2H3</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>InChIKey</kind>
      <value>JWZZKOKVBUJMES-UHFFFAOYSA-N</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Polar Surface Area (PSA)</kind>
      <value>72.72</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Refractivity</kind>
      <value>58.4</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Polarizability</kind>
      <value>23.04</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Rotatable Bond Count</kind>
      <value>4</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>H Bond Acceptor Count</kind>
      <value>4</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>H Bond Donor Count</kind>
      <value>4</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>pKa (strongest acidic)</kind>
      <value>9.81</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>pKa (strongest basic)</kind>
      <value>8.96</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Physiological Charge</kind>
      <value>1</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Number of Rings</kind>
      <value>1</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Bioavailability</kind>
      <value>1</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Rule of Five</kind>
      <value>1</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Ghose Filter</kind>
      <value>1</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>MDDR-Like Rule</kind>
      <value>0</value>
      <source>ChemAxon</source>
    </property>
  </calculated-properties>
  <experimental-properties>
    <property>
      <kind>Melting Point</kind>
      <value>180</value>
      <source>U.S. Patent 2,308,232.&#13;
U.S. Patent 2,715,141.</source>
    </property>
    <property>
      <kind>logP</kind>
      <value>1.4</value>
      <source/>
    </property>
  </experimental-properties>
  <external-identifiers>
    <external-identifier>
      <resource>Drugs Product Database (DPD)</resource>
      <identifier>10114</identifier>
    </external-identifier>
    <external-identifier>
      <resource>ChEBI</resource>
      <identifier>64317</identifier>
    </external-identifier>
    <external-identifier>
      <resource>PubChem Compound</resource>
      <identifier>3779</identifier>
    </external-identifier>
    <external-identifier>
      <resource>PubChem Substance</resource>
      <identifier>46507323</identifier>
    </external-identifier>
    <external-identifier>
      <resource>KEGG Compound</resource>
      <identifier>C07056</identifier>
    </external-identifier>
    <external-identifier>
      <resource>ChemSpider</resource>
      <identifier>3647</identifier>
    </external-identifier>
    <external-identifier>
      <resource>BindingDB</resource>
      <identifier>25392</identifier>
    </external-identifier>
    <external-identifier>
      <resource>PharmGKB</resource>
      <identifier>PA450121</identifier>
    </external-identifier>
    <external-identifier>
      <resource>Therapeutic Targets Database</resource>
      <identifier>DNC000819</identifier>
    </external-identifier>
    <external-identifier>
      <resource>IUPHAR</resource>
      <identifier>536</identifier>
    </external-identifier>
    <external-identifier>
      <resource>Guide to Pharmacology</resource>
      <identifier>536</identifier>
    </external-identifier>
    <external-identifier>
      <resource>Wikipedia</resource>
      <identifier>Isoproterenol</identifier>
    </external-identifier>
    <external-identifier>
      <resource>ChEMBL</resource>
      <identifier>CHEMBL434</identifier>
    </external-identifier>
  </external-identifiers>
  <external-links>
    <external-link>
      <resource>RxList</resource>
      <url>http://www.rxlist.com/cgi/generic3/isoproterenol.htm</url>
    </external-link>
    <external-link>
      <resource>Drugs.com</resource>
      <url>http://www.drugs.com/cdi/isoproterenol.html</url>
    </external-link>
  </external-links>
  <pathways>
    <pathway>
      <smpdb-id>SMP0000663</smpdb-id>
      <name>Isoprenaline Action Pathway</name>
      <category>drug_action</category>
      <drugs>
        <drug>
          <drugbank-id>DB00171</drugbank-id>
          <name>ATP</name>
        </drug>
        <drug>
          <drugbank-id>DB01064</drugbank-id>
          <name>Isoprenaline</name>
        </drug>
        <drug>
          <drugbank-id>DB01345</drugbank-id>
          <name>Potassium cation</name>
        </drug>
        <drug>
          <drugbank-id>DB01373</drugbank-id>
          <name>Calcium</name>
        </drug>
        <drug>
          <drugbank-id>DB01378</drugbank-id>
          <name>Magnesium cation</name>
        </drug>
      </drugs>
      <enzymes>
        <uniprot-id>P08588</uniprot-id>
        <uniprot-id>P05023</uniprot-id>
        <uniprot-id>P50993</uniprot-id>
        <uniprot-id>P13637</uniprot-id>
        <uniprot-id>Q13733</uniprot-id>
        <uniprot-id>P05026</uniprot-id>
        <uniprot-id>P14415</uniprot-id>
        <uniprot-id>P54709</uniprot-id>
        <uniprot-id>B7ZKV8</uniprot-id>
        <uniprot-id>P54710</uniprot-id>
        <uniprot-id>P63252</uniprot-id>
        <uniprot-id>P48050</uniprot-id>
        <uniprot-id>P48549</uniprot-id>
        <uniprot-id>P48544</uniprot-id>
        <uniprot-id>Q9UK17</uniprot-id>
        <uniprot-id>Q9NS61</uniprot-id>
        <uniprot-id>P22460</uniprot-id>
        <uniprot-id>Q12959</uniprot-id>
        <uniprot-id>P51787</uniprot-id>
        <uniprot-id>P15382</uniprot-id>
        <uniprot-id>Q9Y6J6</uniprot-id>
        <uniprot-id>Q12809</uniprot-id>
        <uniprot-id>Q5I7T1</uniprot-id>
        <uniprot-id>Q09428</uniprot-id>
        <uniprot-id>Q15842</uniprot-id>
        <uniprot-id>Q14654</uniprot-id>
        <uniprot-id>O60706</uniprot-id>
        <uniprot-id>O00180</uniprot-id>
        <uniprot-id>P32418</uniprot-id>
        <uniprot-id>Q9Y3Q4</uniprot-id>
        <uniprot-id>Q14524</uniprot-id>
        <uniprot-id>Q13425</uniprot-id>
        <uniprot-id>Q13884</uniprot-id>
        <uniprot-id>Q13424</uniprot-id>
        <uniprot-id>Q13936</uniprot-id>
        <uniprot-id>Q9NY47</uniprot-id>
        <uniprot-id>Q02641</uniprot-id>
        <uniprot-id>P08172</uniprot-id>
        <uniprot-id>Q92736</uniprot-id>
        <uniprot-id>P16615</uniprot-id>
        <uniprot-id>P26678</uniprot-id>
        <uniprot-id>P17612</uniprot-id>
        <uniprot-id>P10644</uniprot-id>
        <uniprot-id>P62158</uniprot-id>
        <uniprot-id>Q15746</uniprot-id>
        <uniprot-id>P30556</uniprot-id>
        <uniprot-id>Q9NQ66</uniprot-id>
        <uniprot-id>P02585</uniprot-id>
        <uniprot-id>P19237</uniprot-id>
        <uniprot-id>P13805</uniprot-id>
        <uniprot-id>P63316</uniprot-id>
        <uniprot-id>P19429</uniprot-id>
        <uniprot-id>P45379</uniprot-id>
        <uniprot-id>P48788</uniprot-id>
        <uniprot-id>P45378</uniprot-id>
        <uniprot-id>P09493</uniprot-id>
        <uniprot-id>P07951</uniprot-id>
        <uniprot-id>O95180</uniprot-id>
        <uniprot-id>O43497</uniprot-id>
        <uniprot-id>Q14643</uniprot-id>
      </enzymes>
    </pathway>
  </pathways>
  <reactions/>
  <snp-effects/>
  <snp-adverse-drug-reactions/>
  <targets>
    <target position="1">
      <id>BE0000172</id>
      <name>Beta-1 adrenergic receptor</name>
      <organism>Humans</organism>
      <actions>
        <action>agonist</action>
      </actions>
      <references>
        <articles>
          <article>
            <ref-id>A6209</ref-id>
            <pubmed-id>14734046</pubmed-id>
            <citation>Sato M, Gong H, Terracciano CM, Ranu H, Harding SE: Loss of beta-adrenoceptor response in myocytes overexpressing the Na+/Ca(2+)-exchanger. J Mol Cell Cardiol. 2004 Jan;36(1):43-8.</citation>
          </article>
          <article>
            <ref-id>A6210</ref-id>
            <pubmed-id>15908512</pubmed-id>
            <citation>Jurgens CW, Rau KE, Knudson CA, King JD, Carr PA, Porter JE, Doze VA: Beta1 adrenergic receptor-mediated enhancement of hippocampal CA3 network activity. J Pharmacol Exp Ther. 2005 Aug;314(2):552-60. Epub 2005 May 20.</citation>
          </article>
          <article>
            <ref-id>A6211</ref-id>
            <pubmed-id>16038799</pubmed-id>
            <citation>Kobayashi H, Narita Y, Nishida M, Kurose H: Beta-arrestin2 enhances beta2-adrenergic receptor-mediated nuclear translocation of ERK. Cell Signal. 2005 Oct;17(10):1248-53. Epub 2005 Feb 12.</citation>
          </article>
          <article>
            <ref-id>A9</ref-id>
            <pubmed-id>11752352</pubmed-id>
            <citation>Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5.</citation>
          </article>
          <article>
            <ref-id>A6212</ref-id>
            <pubmed-id>10722</pubmed-id>
            <citation>Ahlquist RP: Present state of alpha- and beta-adrenergic drugs I. The adrenergic receptor. Am Heart J. 1976 Nov;92(5):661-4.</citation>
          </article>
        </articles>
        <textbooks/>
        <links/>
        <attachments/>
      </references>
      <known-action>yes</known-action>
      <polypeptide id="P08588" source="Swiss-Prot">
        <name>Beta-1 adrenergic receptor</name>
        <general-function>Receptor signaling protein activity</general-function>
        <specific-function>Beta-adrenergic receptors mediate the catecholamine-induced activation of adenylate cyclase through the action of G proteins. This receptor binds epinephrine and norepinephrine with approximately equal affinity. Mediates Ras activation through G(s)-alpha- and cAMP-mediated signaling.</specific-function>
        <gene-name>ADRB1</gene-name>
        <locus>10q24-q26</locus>
        <cellular-location>Cell membrane</cellular-location>
        <transmembrane-regions>56-84
94-120
133-154
173-196
223-248
320-349
355-377</transmembrane-regions>
        <signal-regions/>
        <theoretical-pi>9.03</theoretical-pi>
        <molecular-weight>51322.1</molecular-weight>
        <chromosome-location>10</chromosome-location>
        <organism ncbi-taxonomy-id="9606">Humans</organism>
        <external-identifiers>
          <external-identifier>
            <resource>HUGO Gene Nomenclature Committee (HGNC)</resource>
            <identifier>HGNC:285</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenAtlas</resource>
            <identifier>ADRB1</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenBank Gene Database</resource>
            <identifier>J03019</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenBank Protein Database</resource>
            <identifier>178200</identifier>
          </external-identifier>
          <external-identifier>
            <resource>IUPHAR</resource>
            <identifier>28</identifier>
          </external-identifier>
          <external-identifier>
            <resource>Guide to Pharmacology</resource>
            <identifier>28</identifier>
          </external-identifier>
          <external-identifier>
            <resource>UniProtKB</resource>
            <identifier>P08588</identifier>
          </external-identifier>
          <external-identifier>
            <resource>UniProt Accession</resource>
            <identifier>ADRB1_HUMAN</identifier>
          </external-identifier>
        </external-identifiers>
        <synonyms>
          <synonym>ADRB1R</synonym>
          <synonym>B1AR</synonym>
          <synonym>Beta-1 adrenoceptor</synonym>
          <synonym>Beta-1 adrenoreceptor</synonym>
        </synonyms>
        <amino-acid-sequence format="FASTA">&gt;lcl|BSEQ0010188|Beta-1 adrenergic receptor
MGAGVLVLGASEPGNLSSAAPLPDGAATAARLLVPASPPASLLPPASESPEPLSQQWTAG
MGLLMALIVLLIVAGNVLVIVAIAKTPRLQTLTNLFIMSLASADLVMGLLVVPFGATIVV
WGRWEYGSFFCELWTSVDVLCVTASIETLCVIALDRYLAITSPFRYQSLLTRARARGLVC
TVWAISALVSFLPILMHWWRAESDEARRCYNDPKCCDFVTNRAYAIASSVVSFYVPLCIM
AFVYLRVFREAQKQVKKIDSCERRFLGGPARPPSPSPSPVPAPAPPPGPPRPAAAAATAP
LANGRAGKRRPSRLVALREQKALKTLGIIMGVFTLCWLPFFLANVVKAFHRELVPDRLFV
FFNWLGYANSAFNPIIYCRSPDFRKAFQRLLCCARRAARRRHATHGDRPRASGCLARPGP
PPSPGAASDDDDDDVVGATPPARLLEPWAGCNGGAAADSDSSLDEPCRPGFASESKV</amino-acid-sequence>
        <gene-sequence format="FASTA">&gt;lcl|BSEQ0010189|Beta-1 adrenergic receptor (ADRB1)
ATGGGCGCGGGGGTGCTCGTCCTGGGCGCCTCCGAGCCCGGTAACCTGTCGTCGGCCGCA
CCGCTCCCCGACGGCGCGGCCACCGCGGCGCGGCTGCTGGTGCCCGCGTCGCCGCCCGCC
TCGTTGCTGCCTCCCGCCAGCGAAAGCCCCGAGCCGCTGTCTCAGCAGTGGACAGCGGGC
ATGGGTCTGCTGATGGCGCTCATCGTGCTGCTCATCGTGGCGGGCAATGTGCTGGTGATC
GTGGCCATCGCCAAGACGCCGCGGCTGCAGACGCTCACCAACCTCTTCATCATGTCCCTG
GCCAGCGCCGACCTGGTCATGGGGCTGCTGGTGGTGCCGTTCGGGGCCACCATCGTGGTG
TGGGGCCGCTGGGAGTACGGCTCCTTCTTCTGCGAGCTGTGGACCTCAGTGGACGTGCTG
TGCGTGACGGCCAGCATCGAGACCCTGTGTGTCATTGCCCTGGACCGCTACCTCGCCATC
ACCTCGCCCTTCCGCTACCAGAGCCTGCTGACGCGCGCGCGGGCGCGGGGCCTCGTGTGC
ACCGTGTGGGCCATCTCGGCCCTGGTGTCCTTCCTGCCCATCCTCATGCACTGGTGGCGG
GCGGAGAGCGACGAGGCGCGCCGCTGCTACAACGACCCCAAGTGCTGCGACTTCGTCACC
AACCGGGCCTACGCCATCGCCTCGTCCGTAGTCTCCTTCTACGTGCCCCTGTGCATCATG
GCCTTCGTGTACCTGCGGGTGTTCCGCGAGGCCCAGAAGCAGGTGAAGAAGATCGACAGC
TGCGAGCGCCGTTTCCTCGGCGGCCCAGCGCGGCCGCCCTCGCCCTCGCCCTCGCCCGTC
CCCGCGCCCGCGCCGCCGCCCGGACCCCCGCGCCCCGCCGCCGCCGCCGCCACCGCCCCG
CTGGCCAACGGGCGTGCGGGTAAGCGGCGGCCCTCGCGCCTCGTGGCCCTGCGCGAGCAG
AAGGCGCTCAAGACGCTGGGCATCATCATGGGCGTCTTCACGCTCTGCTGGCTGCCCTTC
TTCCTGGCCAACGTGGTGAAGGCCTTCCACCGCGAGCTGGTGCCCGACCGCCTCTTCGTC
TTCTTCAACTGGCTGGGCTACGCCAACTCGGCCTTCAACCCCATCATCTACTGCCGCAGC
CCCGACTTCCGCAAGGCCTTCCAGGGACTGCTCTGCTGCGCGCGCAGGGCTGCCCGCCGG
CGCCACGCGACCCACGGAGACCGGCCGCGCGCCTCGGGCTGTCTGGCCCGGCCCGGACCC
CCGCCATCGCCCGGGGCCGCCTCGGACGACGACGACGACGATGTCGTCGGGGCCACGCCG
CCCGCGCGCCTGCTGGAGCCCTGGGCCGGCTGCAACGGCGGGGCGGCGGCGGACAGCGAC
TCGAGCCTGGACGAGCCGTGCCGCCCCGGCTTCGCCTCGGAATCCAAGGTGTAG</gene-sequence>
        <pfams>
          <pfam>
            <identifier>PF00001</identifier>
            <name>7tm_1</name>
          </pfam>
        </pfams>
        <go-classifiers>
          <go-classifier>
            <category>component</category>
            <description>early endosome</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>integral component of plasma membrane</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>plasma membrane</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>alpha-2A adrenergic receptor binding</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>beta-adrenergic receptor activity</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>beta1-adrenergic receptor activity</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>epinephrine binding</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>norepinephrine binding</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>PDZ domain binding</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>protein heterodimerization activity</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>Ras guanyl-nucleotide exchange factor activity</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>receptor signaling protein activity</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>activation of adenylate cyclase activity</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>adenylate cyclase-activating adrenergic receptor signaling pathway</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>brown fat cell differentiation</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>cell-cell signaling</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>diet induced thermogenesis</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>fear response</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>heat generation</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>intracellular signal transduction</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>negative regulation of multicellular organism growth</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>positive regulation of cAMP biosynthetic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>positive regulation of cAMP-mediated signaling</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>positive regulation of GTPase activity</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>positive regulation of heart rate by epinephrine-norepinephrine</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>positive regulation of the force of heart contraction by epinephrine-norepinephrine</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>response to cold</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>temperature homeostasis</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>vasodilation by norepinephrine-epinephrine involved in regulation of systemic arterial blood pressure</description>
          </go-classifier>
        </go-classifiers>
      </polypeptide>
    </target>
    <target position="2">
      <id>BE0000694</id>
      <name>Beta-2 adrenergic receptor</name>
      <organism>Humans</organism>
      <actions>
        <action>agonist</action>
      </actions>
      <references>
        <articles>
          <article>
            <ref-id>A11028</ref-id>
            <pubmed-id>12963495</pubmed-id>
            <citation>Abraham G, Kottke C, Dhein S, Ungemach FR: Pharmacological and biochemical characterization of the beta-adrenergic signal transduction pathway in different segments of the respiratory tract. Biochem Pharmacol. 2003 Sep 15;66(6):1067-81.</citation>
          </article>
          <article>
            <ref-id>A11029</ref-id>
            <pubmed-id>14656380</pubmed-id>
            <citation>Jones SM, Hiller FC, Jacobi SE, Foreman SK, Pittman LM, Cornett LE: Enhanced beta2-adrenergic receptor (beta2AR) signaling by adeno-associated viral (AAV)-mediated gene transfer. BMC Pharmacol. 2003 Dec 4;3:15.</citation>
          </article>
          <article>
            <ref-id>A11030</ref-id>
            <pubmed-id>14752060</pubmed-id>
            <citation>Teixeira CE, Baracat JS, Zanesco A, Antunes E, De Nucci G: Atypical beta-adrenoceptor subtypes mediate relaxations of rabbit corpus cavernosum. J Pharmacol Exp Ther. 2004 May;309(2):587-93. Epub 2004 Jan 29.</citation>
          </article>
          <article>
            <ref-id>A11031</ref-id>
            <pubmed-id>15105445</pubmed-id>
            <citation>Odley A, Hahn HS, Lynch RA, Marreez Y, Osinska H, Robbins J, Dorn GW 2nd: Regulation of cardiac contractility by Rab4-modulated beta2-adrenergic receptor recycling. Proc Natl Acad Sci U S A. 2004 May 4;101(18):7082-7. Epub 2004 Apr 22.</citation>
          </article>
          <article>
            <ref-id>A11032</ref-id>
            <pubmed-id>15151902</pubmed-id>
            <citation>Uezono Y, Kaibara M, Murasaki O, Taniyama K: Involvement of G protein betagamma-subunits in diverse signaling induced by G(i/o)-coupled receptors: study using the Xenopus oocyte expression system. Am J Physiol Cell Physiol. 2004 Oct;287(4):C885-94. Epub 2004 May 19.</citation>
          </article>
          <article>
            <ref-id>A9</ref-id>
            <pubmed-id>11752352</pubmed-id>
            <citation>Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5.</citation>
          </article>
          <article>
            <ref-id>A6212</ref-id>
            <pubmed-id>10722</pubmed-id>
            <citation>Ahlquist RP: Present state of alpha- and beta-adrenergic drugs I. The adrenergic receptor. Am Heart J. 1976 Nov;92(5):661-4.</citation>
          </article>
        </articles>
        <textbooks/>
        <links/>
        <attachments/>
      </references>
      <known-action>yes</known-action>
      <polypeptide id="P07550" source="Swiss-Prot">
        <name>Beta-2 adrenergic receptor</name>
        <general-function>Protein homodimerization activity</general-function>
        <specific-function>Beta-adrenergic receptors mediate the catecholamine-induced activation of adenylate cyclase through the action of G proteins. The beta-2-adrenergic receptor binds epinephrine with an approximately 30-fold greater affinity than it does norepinephrine.</specific-function>
        <gene-name>ADRB2</gene-name>
        <locus>5q31-q32</locus>
        <cellular-location>Cell membrane</cellular-location>
        <transmembrane-regions>35-58
72-95
107-129
151-174
197-220
275-298
306-329</transmembrane-regions>
        <signal-regions/>
        <theoretical-pi>7.44</theoretical-pi>
        <molecular-weight>46458.32</molecular-weight>
        <chromosome-location>5</chromosome-location>
        <organism ncbi-taxonomy-id="9606">Humans</organism>
        <external-identifiers>
          <external-identifier>
            <resource>HUGO Gene Nomenclature Committee (HGNC)</resource>
            <identifier>HGNC:286</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenAtlas</resource>
            <identifier>ADRB2</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenBank Gene Database</resource>
            <identifier>Y00106</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenBank Protein Database</resource>
            <identifier>29371</identifier>
          </external-identifier>
          <external-identifier>
            <resource>IUPHAR</resource>
            <identifier>29</identifier>
          </external-identifier>
          <external-identifier>
            <resource>Guide to Pharmacology</resource>
            <identifier>29</identifier>
          </external-identifier>
          <external-identifier>
            <resource>UniProtKB</resource>
            <identifier>P07550</identifier>
          </external-identifier>
          <external-identifier>
            <resource>UniProt Accession</resource>
            <identifier>ADRB2_HUMAN</identifier>
          </external-identifier>
        </external-identifiers>
        <synonyms>
          <synonym>ADRB2R</synonym>
          <synonym>B2AR</synonym>
          <synonym>Beta-2 adrenoceptor</synonym>
          <synonym>Beta-2 adrenoreceptor</synonym>
        </synonyms>
        <amino-acid-sequence format="FASTA">&gt;lcl|BSEQ0037061|Beta-2 adrenergic receptor
MGQPGNGSAFLLAPNGSHAPDHDVTQERDEVWVVGMGIVMSLIVLAIVFGNVLVITAIAK
FERLQTVTNYFITSLACADLVMGLAVVPFGAAHILMKMWTFGNFWCEFWTSIDVLCVTAS
IETLCVIAVDRYFAITSPFKYQSLLTKNKARVIILMVWIVSGLTSFLPIQMHWYRATHQE
AINCYANETCCDFFTNQAYAIASSIVSFYVPLVIMVFVYSRVFQEAKRQLQKIDKSEGRF
HVQNLSQVEQDGRTGHGLRRSSKFCLKEHKALKTLGIIMGTFTLCWLPFFIVNIVHVIQD
NLIRKEVYILLNWIGYVNSGFNPLIYCRSPDFRIAFQELLCLRRSSLKAYGNGYSSNGNT
GEQSGYHVEQEKENKLLCEDLPGTEDFVGHQGTVPSDNIDSQGRNCSTNDSLL</amino-acid-sequence>
        <gene-sequence format="FASTA">&gt;lcl|BSEQ0020478|Beta-2 adrenergic receptor (ADRB2)
ATGGGGCAACCCGGGAACGGCAGCGCCTTCTTGCTGGCACCCAATAGAAGCCATGCGCCG
GACCACGACGTCACGCAGCAAAGGGACGAGGTGTGGGTGGTGGGCATGGGCATCGTCATG
TCTCTCATCGTCCTGGCCATCGTGTTTGGCAATGTGCTGGTCATCACAGCCATTGCCAAG
TTCGAGCGTCTGCAGACGGTCACCAACTACTTCATCACTTCACTGGCCTGTGCTGATCTG
GTCATGGGCCTGGCAGTGGTGCCCTTTGGGGCCGCCCATATTCTTATGAAAATGTGGACT
TTTGGCAACTTCTGGTGCGAGTTTTGGACTTCCATTGATGTGCTGTGCGTCACGGCCAGC
ATTGAGACCCTGTGCGTGATCGCAGTGGATCGCTACTTTGCCATTACTTCACCTTTCAAG
TACCAGAGCCTGCTGACCAAGAATAAGGCCCGGGTGATCATTCTGATGGTGTGGATTGTG
TCAGGCCTTACCTCCTTCTTGCCCATTCAGATGCACTGGTACCGGGCCACCCACCAGGAA
GCCATCAACTGCTATGCCAATGAGACCTGCTGTGACTTCTTCACGAACCAAGCCTATGCC
ATTGCCTCTTCCATCGTGTCCTTCTACGTTCCCCTGGTGATCATGGTCTTCGTCTACTCC
AGGGTCTTTCAGGAGGCCAAAAGGCAGCTCCAGAAGATTGACAAATCTGAGGGCCGCTTC
CATGTCCAGAACCTTAGCCAGGTGGAGCAGGATGGGCGGACGGGGCATGGACTCCGCAGA
TCTTCCAAGTTCTGCTTGAAGGAGCACAAAGCCCTCAAGACGTTAGGCATCATCATGGGC
ACTTTCACCCTCTGCTGGCTGCCCTTCTTCATCGTTAACATTGTGCATGTGATCCAGGAT
AACCTCATCCGTAAGGAAGTTTACATCCTCCTAAATTGGATAGGCTATGTCAATTCTGGT
TTCAATCCCCTTATCTACTGCCGGAGCCCAGATTTCAGGATTGCCTTCCAGGAGCTTCTG
TGCCTGCGCAGGTCTTCTTTGAAGGCCTATGGGAATGGCTACTCCAGCAACGGCAACACA
GGGGAGCAGAGTGGATATCACGTGGAACAGGAGAAAGAAAATAAACTGCTGTGTGAAGAC
CTCCCAGGCACGGAAGACTTTGTGGGCCATCAAGGTACTGTGCCTAGCGATAACATTGAT
TCACAAGGGAGGAATTGTAGTACAAATGACTCACTGCTGTAA</gene-sequence>
        <pfams>
          <pfam>
            <identifier>PF00001</identifier>
            <name>7tm_1</name>
          </pfam>
        </pfams>
        <go-classifiers>
          <go-classifier>
            <category>component</category>
            <description>apical plasma membrane</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>axon</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>dendritic spine</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>early endosome</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>endosome</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>integral component of plasma membrane</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>lysosome</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>neuronal cell body membrane</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>nucleus</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>plasma membrane</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>receptor complex</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>sarcolemma</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>beta2-adrenergic receptor activity</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>dopamine binding</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>drug binding</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>epinephrine binding</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>norepinephrine binding</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>potassium channel regulator activity</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>protein homodimerization activity</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>activation of adenylate cyclase activity</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>activation of transmembrane receptor protein tyrosine kinase activity</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>adenylate cyclase-activating adrenergic receptor signaling pathway</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>adenylate cyclase-modulating G-protein coupled receptor signaling pathway</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>aging</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>associative learning</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>bone resorption</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>brown fat cell differentiation</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>cell surface receptor signaling pathway</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>cell-cell signaling</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>cellular response to hypoxia</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>desensitization of G-protein coupled receptor protein signaling pathway by arrestin</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>diaphragm contraction</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>diet induced thermogenesis</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>endosome to lysosome transport</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>estrous cycle</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>excitatory postsynaptic potential</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>female pregnancy</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>heat generation</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>liver regeneration</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>mitophagy in response to mitochondrial depolarization</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>negative regulation of angiogenesis</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>negative regulation of inflammatory response</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>negative regulation of multicellular organism growth</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>negative regulation of ossification</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>negative regulation of platelet aggregation</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>negative regulation of smooth muscle contraction</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>negative regulation of urine volume</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>positive regulation of apoptotic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>positive regulation of ATPase activity</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>positive regulation of autophagosome maturation</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>positive regulation of bone mineralization</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>positive regulation of cell proliferation</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>positive regulation of lipophagy</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>positive regulation of MAPK cascade</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>positive regulation of potassium ion transport</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>positive regulation of protein ubiquitination</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>positive regulation of skeletal muscle tissue growth</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>positive regulation of sodium ion transport</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>positive regulation of the force of heart contraction by epinephrine</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>positive regulation of transcription from RNA polymerase II promoter</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>positive regulation of vasodilation</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>receptor-mediated endocytosis</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>regulation of calcium ion transport</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>regulation of sensory perception of pain</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>response to cold</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>response to dexamethasone</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>response to estrogen</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>response to monoamine</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>response to progesterone</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>response to testosterone</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>synaptic transmission, glutamatergic</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>vasodilation by norepinephrine-epinephrine involved in regulation of systemic arterial blood pressure</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>wound healing</description>
          </go-classifier>
        </go-classifiers>
      </polypeptide>
    </target>
    <target position="3">
      <id>BE0001012</id>
      <name>Beta-3 adrenergic receptor</name>
      <organism>Humans</organism>
      <actions>
        <action>agonist</action>
      </actions>
      <references>
        <articles>
          <article>
            <ref-id>A6212</ref-id>
            <pubmed-id>10722</pubmed-id>
            <citation>Ahlquist RP: Present state of alpha- and beta-adrenergic drugs I. The adrenergic receptor. Am Heart J. 1976 Nov;92(5):661-4.</citation>
          </article>
          <article>
            <ref-id>A16622</ref-id>
            <pubmed-id>10824635</pubmed-id>
            <citation>Schiffelers SL, Blaak EE, Saris WH, van Baak MA: In vivo beta3-adrenergic stimulation of human thermogenesis and lipid use. Clin Pharmacol Ther. 2000 May;67(5):558-66.</citation>
          </article>
        </articles>
        <textbooks/>
        <links/>
        <attachments/>
      </references>
      <known-action>yes</known-action>
      <polypeptide id="P13945" source="Swiss-Prot">
        <name>Beta-3 adrenergic receptor</name>
        <general-function>Protein homodimerization activity</general-function>
        <specific-function>Beta-adrenergic receptors mediate the catecholamine-induced activation of adenylate cyclase through the action of G proteins. Beta-3 is involved in the regulation of lipolysis and thermogenesis.</specific-function>
        <gene-name>ADRB3</gene-name>
        <locus>8p12-p11.2</locus>
        <cellular-location>Cell membrane</cellular-location>
        <transmembrane-regions>37-63
73-91
112-133
156-178
204-225
293-314
327-347</transmembrane-regions>
        <signal-regions/>
        <theoretical-pi>9.07</theoretical-pi>
        <molecular-weight>43518.615</molecular-weight>
        <chromosome-location>8</chromosome-location>
        <organism ncbi-taxonomy-id="9606">Humans</organism>
        <external-identifiers>
          <external-identifier>
            <resource>HUGO Gene Nomenclature Committee (HGNC)</resource>
            <identifier>HGNC:288</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenAtlas</resource>
            <identifier>ADRB3</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenBank Gene Database</resource>
            <identifier>M29932</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenBank Protein Database</resource>
            <identifier>178896</identifier>
          </external-identifier>
          <external-identifier>
            <resource>IUPHAR</resource>
            <identifier>30</identifier>
          </external-identifier>
          <external-identifier>
            <resource>Guide to Pharmacology</resource>
            <identifier>30</identifier>
          </external-identifier>
          <external-identifier>
            <resource>UniProtKB</resource>
            <identifier>P13945</identifier>
          </external-identifier>
          <external-identifier>
            <resource>UniProt Accession</resource>
            <identifier>ADRB3_HUMAN</identifier>
          </external-identifier>
        </external-identifiers>
        <synonyms>
          <synonym>ADRB3R</synonym>
          <synonym>B3AR</synonym>
          <synonym>Beta-3 adrenoceptor</synonym>
          <synonym>Beta-3 adrenoreceptor</synonym>
        </synonyms>
        <amino-acid-sequence format="FASTA">&gt;lcl|BSEQ0010709|Beta-3 adrenergic receptor
MAPWPHENSSLAPWPDLPTLAPNTANTSGLPGVPWEAALAGALLALAVLATVGGNLLVIV
AIAWTPRLQTMTNVFVTSLAAADLVMGLLVVPPAATLALTGHWPLGATGCELWTSVDVLC
VTASIETLCALAVDRYLAVTNPLRYGALVTKRCARTAVVLVWVVSAAVSFAPIMSQWWRV
GADAEAQRCHSNPRCCAFASNMPYVLLSSSVSFYLPLLVMLFVYARVFVVATRQLRLLRG
ELGRFPPEESPPAPSRSLAPAPVGTCAPPEGVPACGRRPARLLPLREHRALCTLGLIMGT
FTLCWLPFFLANVLRALGGPSLVPGPAFLALNWLGYANSAFNPLIYCRSPDFRSAFRRLL
CRCGRRLPPEPCAAARPALFPSGVPAARSSPAQPRLCQRLDGASWGVS</amino-acid-sequence>
        <gene-sequence format="FASTA">&gt;lcl|BSEQ0010710|Beta-3 adrenergic receptor (ADRB3)
ATGGCTCCGTGGCCTCACGAGAACAGCTCTCTTGCCCCATGGCCGGACCTCCCCACCCTG
GCGCCCAATACCGCCAACACCAGTGGGCTGCCAGGGGTTCCGTGGGAGGCGGCCCTAGCC
GGGGCCCTGCTGGCGCTGGCGGTGCTGGCCACCGTGGGAGGCAACCTGCTGGTCATCGTG
GCCATCGCCTGGACTCCGAGACTCCAGACCATGACCAACGTGTTCGTGACTTCGCTGGCC
GCAGCCGACCTGGTGATGGGACTCCTGGTGGTGCCGCCGGCGGCCACCTTGGCGCTGACT
GGCCACTGGCCGTTGGGCGCCACTGGCTGCGAGCTGTGGACCTCGGTGGACGTGCTGTGT
GTGACCGCCAGCATCGAAACCCTGTGCGCCCTGGCCGTGGACCGCTACCTGGCTGTGACC
AACCCGCTGCGTTACGGCGCACTGGTCACCAAGCGCTGCGCCCGGACAGCTGTGGTCCTG
GTGTGGGTCGTGTCGGCCGCGGTGTCGTTTGCGCCCATCATGAGCCAGTGGTGGCGCGTA
GGGGCCGACGCCGAGGCGCAGCGCTGCCACTCCAACCCGCGCTGCTGTGCCTTCGCCTCC
AACATGCCCTACGTGCTGCTGTCCTCCTCCGTCTCCTTCTACCTTCCTCTTCTCGTGATG
CTCTTCGTCTACGCGCGGGTTTTCGTGGTGGCTACGCGCCAGCTGCGCTTGCTGCGCGGG
GAGCTGGGCCGCTTTCCGCCCGAGGAGTCTCCGCCGGCGCCGTCGCGCTCTCTGGCCCCG
GCCCCGGTGGGGACGTGCGCTCCGCCCGAAGGGGTGCCCGCCTGCGGCCGGCGGCCCGCG
CGCCTCCTGCCTCTCCGGGAACACCGGGCCCTGTGCACCTTGGGTCTCATCATGGGCACC
TTCACTCTCTGCTGGTTGCCCTTCTTTCTGGCCAACGTGCTGCGCGCCCTGGGGGGCCCC
TCTCTAGTCCCGGGCCCGGCTTTCCTTGCCCTGAACTGGCTAGGTTATGCCAATTCTGCC
TTCAACCCGCTCATCTACTGCCGCAGCCCGGACTTTCGCAGCGCCTTCCGCCGTCTTCTG
TGCCGCTGCGGCCGTCGCCTGCCTCCGGAGCCCTGCGCCGCCGCCCGCCCGGCCCTCTTC
CCCTCGGGCGTTCCTGCGGCCCGGAGCAGCCCAGCGCAGCCCAGGCTTTGCCAACGGCTC
GACGGGGCTTCTTGGGGAGTTTCTTAG</gene-sequence>
        <pfams>
          <pfam>
            <identifier>PF00001</identifier>
            <name>7tm_1</name>
          </pfam>
        </pfams>
        <go-classifiers>
          <go-classifier>
            <category>component</category>
            <description>integral component of plasma membrane</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>nucleus</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>plasma membrane</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>receptor complex</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>beta-adrenergic receptor activity</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>beta3-adrenergic receptor activity</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>epinephrine binding</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>norepinephrine binding</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>protein homodimerization activity</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>activation of adenylate cyclase activity</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>adenylate cyclase-activating adrenergic receptor signaling pathway</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>adenylate cyclase-modulating G-protein coupled receptor signaling pathway</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>aging</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>brown fat cell differentiation</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>carbohydrate metabolic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>cell-cell signaling</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>diet induced thermogenesis</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>eating behavior</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>energy reserve metabolic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>G-protein coupled receptor signaling pathway, coupled to cyclic nucleotide second messenger</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>generation of precursor metabolites and energy</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>heat generation</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>negative regulation of multicellular organism growth</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>positive regulation of MAPK cascade</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>response to antibiotic</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>response to cold</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>temperature homeostasis</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>vasodilation by norepinephrine-epinephrine involved in regulation of systemic arterial blood pressure</description>
          </go-classifier>
        </go-classifiers>
      </polypeptide>
    </target>
    <target position="4">
      <id>BE0000923</id>
      <name>Mitogen-activated protein kinase 1</name>
      <organism>Humans</organism>
      <actions>
        <action>inducer</action>
      </actions>
      <references>
        <articles>
          <article>
            <ref-id>A16623</ref-id>
            <pubmed-id>20732414</pubmed-id>
            <citation>Vaniotis G, Del Duca D, Trieu P, Rohlicek CV, Hebert TE, Allen BG: Nuclear beta-adrenergic receptors modulate gene expression in adult rat heart. Cell Signal. 2011 Jan;23(1):89-98. doi: 10.1016/j.cellsig.2010.08.007. Epub 2010  Aug 21.</citation>
          </article>
          <article>
            <ref-id>A16624</ref-id>
            <pubmed-id>12963636</pubmed-id>
            <citation>Oudit GY, Crackower MA, Eriksson U, Sarao R, Kozieradzki I, Sasaki T, Irie-Sasaki J, Gidrewicz D, Rybin VO, Wada T, Steinberg SF, Backx PH, Penninger JM: Phosphoinositide 3-kinase gamma-deficient mice are protected from isoproterenol-induced heart failure. Circulation. 2003 Oct 28;108(17):2147-52. Epub 2003 Sep 8.</citation>
          </article>
          <article>
            <ref-id>A16625</ref-id>
            <pubmed-id>13679574</pubmed-id>
            <citation>Azzi M, Charest PG, Angers S, Rousseau G, Kohout T, Bouvier M, Pineyro G: Beta-arrestin-mediated activation of MAPK by inverse agonists reveals distinct active conformations for G protein-coupled receptors. Proc Natl Acad Sci U S A. 2003 Sep 30;100(20):11406-11. Epub 2003 Sep 17.</citation>
          </article>
          <article>
            <ref-id>A16626</ref-id>
            <pubmed-id>15138589</pubmed-id>
            <citation>Adissu HA, Schuller HM: Antagonistic growth regulation of cell lines derived from human lung adenocarcinomas of Clara cell and aveolar type II cell lineage: Implications for chemoprevention. Int J Oncol. 2004 Jun;24(6):1467-72.</citation>
          </article>
          <article>
            <ref-id>A16627</ref-id>
            <pubmed-id>15292328</pubmed-id>
            <citation>Dubey RK, Jackson EK, Gillespie DG, Zacharia LC, Imthurn B: Catecholamines block the antimitogenic effect of estradiol on human coronary artery smooth muscle cells. J Clin Endocrinol Metab. 2004 Aug;89(8):3922-31.</citation>
          </article>
          <article>
            <ref-id>A16628</ref-id>
            <pubmed-id>15689414</pubmed-id>
            <citation>Yeh CK, Ghosh PM, Dang H, Liu Q, Lin AL, Zhang BX, Katz MS: beta-Adrenergic-responsive activation of extracellular signal-regulated protein kinases in salivary cells: role of epidermal growth factor receptor and cAMP. Am J Physiol Cell Physiol. 2005 Jun;288(6):C1357-66. Epub 2005 Feb 2.</citation>
          </article>
        </articles>
        <textbooks/>
        <links/>
        <attachments/>
      </references>
      <known-action>unknown</known-action>
      <polypeptide id="P28482" source="Swiss-Prot">
        <name>Mitogen-activated protein kinase 1</name>
        <general-function>Rna polymerase ii carboxy-terminal domain kinase activity</general-function>
        <specific-function>Serine/threonine kinase which acts as an essential component of the MAP kinase signal transduction pathway. MAPK1/ERK2 and MAPK3/ERK1 are the 2 MAPKs which play an important role in the MAPK/ERK cascade. They participate also in a signaling cascade initiated by activated KIT and KITLG/SCF. Depending on the cellular context, the MAPK/ERK cascade mediates diverse biological functions such as cell growth, adhesion, survival and differentiation through the regulation of transcription, translation, cytoskeletal rearrangements. The MAPK/ERK cascade plays also a role in initiation and regulation of meiosis, mitosis, and postmitotic functions in differentiated cells by phosphorylating a number of transcription factors. About 160 substrates have already been discovered for ERKs. Many of these substrates are localized in the nucleus, and seem to participate in the regulation of transcription upon stimulation. However, other substrates are found in the cytosol as well as in other cellular organelles, and those are responsible for processes such as translation, mitosis and apoptosis. Moreover, the MAPK/ERK cascade is also involved in the regulation of the endosomal dynamics, including lysosome processing and endosome cycling through the perinuclear recycling compartment (PNRC); as well as in the fragmentation of the Golgi apparatus during mitosis. The substrates include transcription factors (such as ATF2, BCL6, ELK1, ERF, FOS, HSF4 or SPZ1), cytoskeletal elements (such as CANX, CTTN, GJA1, MAP2, MAPT, PXN, SORBS3 or STMN1), regulators of apoptosis (such as BAD, BTG2, CASP9, DAPK1, IER3, MCL1 or PPARG), regulators of translation (such as EIF4EBP1) and a variety of other signaling-related molecules (like ARHGEF2, DCC, FRS2 or GRB10). Protein kinases (such as RAF1, RPS6KA1/RSK1, RPS6KA3/RSK2, RPS6KA2/RSK3, RPS6KA6/RSK4, SYK, MKNK1/MNK1, MKNK2/MNK2, RPS6KA5/MSK1, RPS6KA4/MSK2, MAPKAPK3 or MAPKAPK5) and phosphatases (such as DUSP1, DUSP4, DUSP6 or DUSP16) are other substrates which enable the propagation the MAPK/ERK signal to additional cytosolic and nuclear targets, thereby extending the specificity of the cascade. Mediates phosphorylation of TPR in respons to EGF stimulation. May play a role in the spindle assembly checkpoint. Phosphorylates PML and promotes its interaction with PIN1, leading to PML degradation.Acts as a transcriptional repressor. Binds to a [GC]AAA[GC] consensus sequence. Repress the expression of interferon gamma-induced genes. Seems to bind to the promoter of CCL5, DMP1, IFIH1, IFITM1, IRF7, IRF9, LAMP3, OAS1, OAS2, OAS3 and STAT1. Transcriptional activity is independent of kinase activity.</specific-function>
        <gene-name>MAPK1</gene-name>
        <locus>22q11.2|22q11.21</locus>
        <cellular-location>Cytoplasm</cellular-location>
        <transmembrane-regions/>
        <signal-regions/>
        <theoretical-pi>6.99</theoretical-pi>
        <molecular-weight>41389.265</molecular-weight>
        <chromosome-location>22</chromosome-location>
        <organism ncbi-taxonomy-id="9606">Humans</organism>
        <external-identifiers>
          <external-identifier>
            <resource>HUGO Gene Nomenclature Committee (HGNC)</resource>
            <identifier>HGNC:6871</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenAtlas</resource>
            <identifier>MAPK1</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenBank Gene Database</resource>
            <identifier>M84489</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenBank Protein Database</resource>
            <identifier>182191</identifier>
          </external-identifier>
          <external-identifier>
            <resource>Guide to Pharmacology</resource>
            <identifier>1495</identifier>
          </external-identifier>
          <external-identifier>
            <resource>UniProtKB</resource>
            <identifier>P28482</identifier>
          </external-identifier>
          <external-identifier>
            <resource>UniProt Accession</resource>
            <identifier>MK01_HUMAN</identifier>
          </external-identifier>
        </external-identifiers>
        <synonyms>
          <synonym>2.7.11.24</synonym>
          <synonym>ERK-2</synonym>
          <synonym>ERK2</synonym>
          <synonym>ERT1</synonym>
          <synonym>Extracellular signal-regulated kinase 2</synonym>
          <synonym>MAP kinase 1</synonym>
          <synonym>MAP kinase 2</synonym>
          <synonym>MAP kinase isoform p42</synonym>
          <synonym>MAPK 2</synonym>
          <synonym>Mitogen-activated protein kinase 2</synonym>
          <synonym>p42-MAPK</synonym>
          <synonym>PRKM1</synonym>
          <synonym>PRKM2</synonym>
        </synonyms>
        <amino-acid-sequence format="FASTA">&gt;lcl|BSEQ0001838|Mitogen-activated protein kinase 1
MAAAAAAGAGPEMVRGQVFDVGPRYTNLSYIGEGAYGMVCSAYDNVNKVRVAIKKISPFE
HQTYCQRTLREIKILLRFRHENIIGINDIIRAPTIEQMKDVYIVQDLMETDLYKLLKTQH
LSNDHICYFLYQILRGLKYIHSANVLHRDLKPSNLLLNTTCDLKICDFGLARVADPDHDH
TGFLTEYVATRWYRAPEIMLNSKGYTKSIDIWSVGCILAEMLSNRPIFPGKHYLDQLNHI
LGILGSPSQEDLNCIINLKARNYLLSLPHKNKVPWNRLFPNADSKALDLLDKMLTFNPHK
RIEVEQALAHPYLEQYYDPSDEPIAEAPFKFDMELDDLPKEKLKELIFEETARFQPGYRS
</amino-acid-sequence>
        <gene-sequence format="FASTA">&gt;lcl|BSEQ0010648|Mitogen-activated protein kinase 1 (MAPK1)
ATGGCGGCGGCGGCGGCGGCGGGCGCGGGCCCGGAGATGGTCCGCGGGCAGGTGTTCGAC
GTGGGGCCGCGCTACACCAACCTCTCGTACATCGGCGAGGGCGCCTACGGCATGGTGTGC
TCTGCTTATGATAATGTCAACAAAGTTCGAGTAGCTATCAAGAAAATCAGCCCCTTTGAG
CACCAGACCTACTGCCAGAGAACCCTGAGGGAGATAAAAATCTTACTGCGCTTCAGACAT
GAGAACATCATTGGAATCAATGACATTATTCGAGCACCAACCATCGAGCAAATGAAAGAT
GTATATATAGTACAGGACCTCATGGAAACAGATCTTTACAAGCTCTTGAAGACACAACAC
CTCAGCAATGACCATATCTGCTATTTTCTCTACCAGATCCTCAGAGGGTTAAAATATATC
CATTCAGCTAACGTTCTGCACCGTGACCTCAAGCCTTCCAACCTGCTGCTCAACACCACC
TGTGATCTCAAGATCTGTGACTTTGGCCTGGCCCGTGTTGCAGATCCAGACCATGATCAC
ACAGGGTTCCTGACAGAATATGTGGCCACACGTTGGTACAGGGCTCCAGAAATTATGTTG
AATTCCAAGGGCTACACCAAGTCCATTGATATTTGGTCTGTAGGCTGCATTCTGGCAGAA
ATGCTTTCTAACAGGCCCATCTTTCCAGGGAAGCATTATCTTGACCAGCTGAACCACATT
TTGGGTATTCTTGGATCCCCATCACAAGAAGACCTGAATTGTATAATAAATTTAAAAGCT
AGGAACTATTTGCTTTCTCTTCCACACAAAAATAAGGTGCCATGGAACAGGCTGTTCCCA
AATGCTGACTCCAAAGCTCTGGACTTATTGGACAAAATGTTGACATTCAACCCACACAAG
AGGATTGAAGTAGAACAGGCTCTGGCCCACCCATATCTGGAGCAGTATTACGACCCGAGT
GACGAGCCCATCGCCGAAGCACCATTCAAGTTCGACATGGAATTGGATGACTTGCCTAAG
GAAAAGCTCAAAGAACTAATTTTTGAAGAGACTGCTAGATTCCAGCCAGGATACAGATCT
TAA</gene-sequence>
        <pfams>
          <pfam>
            <identifier>PF00069</identifier>
            <name>Pkinase</name>
          </pfam>
        </pfams>
        <go-classifiers>
          <go-classifier>
            <category>component</category>
            <description>axon</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>caveola</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>cytoplasm</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>cytoskeleton</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>cytosol</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>dendrite cytoplasm</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>early endosome</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>extracellular exosome</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>focal adhesion</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>Golgi apparatus</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>late endosome</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>microtubule cytoskeleton</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>microtubule organizing center</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>mitochondrion</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>mitotic spindle</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>nucleoplasm</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>nucleus</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>perikaryon</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>protein complex</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>pseudopodium</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>ATP binding</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>DNA binding</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>MAP kinase activity</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>phosphatase binding</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>protein serine/threonine kinase activity</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>RNA polymerase II carboxy-terminal domain kinase activity</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>activation of MAPK activity</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>activation of MAPKK activity</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>apoptotic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>axon guidance</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>B cell receptor signaling pathway</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>blood coagulation</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>caveolin-mediated endocytosis</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>cell cycle</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>cellular response to DNA damage stimulus</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>cellular response to granulocyte macrophage colony-stimulating factor stimulus</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>cellular response to heat</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>chemotaxis</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>cytosine metabolic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>epidermal growth factor receptor signaling pathway</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>ERBB signaling pathway</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>ERK1 and ERK2 cascade</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>Fc-epsilon receptor signaling pathway</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>Fc-gamma receptor signaling pathway involved in phagocytosis</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>fibroblast growth factor receptor signaling pathway</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>innate immune response</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>insulin receptor signaling pathway</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>JAK-STAT cascade involved in growth hormone signaling pathway</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>labyrinthine layer blood vessel development</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>lipopolysaccharide-mediated signaling pathway</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>long-term synaptic potentiation</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>lung morphogenesis</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>mammary gland epithelial cell proliferation</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>MAPK cascade</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>MAPK import into nucleus</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>MyD88-dependent toll-like receptor signaling pathway</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>MyD88-independent toll-like receptor signaling pathway</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>negative regulation of cell differentiation</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>neurotrophin TRK receptor signaling pathway</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>peptidyl-serine phosphorylation</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>peptidyl-threonine phosphorylation</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>platelet activation</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>positive regulation of cell migration</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>positive regulation of cell proliferation</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>positive regulation of peptidyl-threonine phosphorylation</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>positive regulation of telomerase activity</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>positive regulation of telomere capping</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>positive regulation of telomere maintenance via telomerase</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>positive regulation of transcription, DNA-templated</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>positive regulation of translation</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>protein phosphorylation</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>Ras protein signal transduction</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>regulation of cellular response to heat</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>regulation of cytoskeleton organization</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>regulation of early endosome to late endosome transport</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>regulation of Golgi inheritance</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>regulation of protein stability</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>regulation of sequence-specific DNA binding transcription factor activity</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>regulation of stress-activated MAPK cascade</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>response to epidermal growth factor</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>response to estrogen</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>response to exogenous dsRNA</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>response to stress</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>response to toxic substance</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>sensory perception of pain</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>signal transduction</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>small GTPase mediated signal transduction</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>stress-activated MAPK cascade</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>synaptic transmission</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>T cell receptor signaling pathway</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>toll-like receptor 10 signaling pathway</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>toll-like receptor 2 signaling pathway</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>toll-like receptor 3 signaling pathway</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>toll-like receptor 4 signaling pathway</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>toll-like receptor 5 signaling pathway</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>toll-like receptor 9 signaling pathway</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>toll-like receptor signaling pathway</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>toll-like receptor TLR1</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>toll-like receptor TLR6</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>trachea formation</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>transcription, DNA-templated</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>TRIF-dependent toll-like receptor signaling pathway</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>vascular endothelial growth factor receptor signaling pathway</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>viral process</description>
          </go-classifier>
        </go-classifiers>
      </polypeptide>
    </target>
    <target position="5">
      <id>BE0000955</id>
      <name>Phosphatidylinositol 3-kinase regulatory subunit alpha</name>
      <organism>Humans</organism>
      <actions>
        <action>agonist</action>
      </actions>
      <references>
        <articles>
          <article>
            <ref-id>A12365</ref-id>
            <pubmed-id>15110780</pubmed-id>
            <citation>Slomiany BL, Slomiany A: Salivary phospholipid secretion in response to beta-adrenergic stimulation is mediated by Src kinase-dependent epidermal growth factor receptor transactivation. Biochem Biophys Res Commun. 2004 May 21;318(1):247-52.</citation>
          </article>
          <article>
            <ref-id>A12366</ref-id>
            <pubmed-id>15381832</pubmed-id>
            <citation>Slomiany BL, Slomiany A: Secretion of gastric mucus phospholipids in response to beta-adrenergic G protein-coupled receptor activation is mediated by SRC kinase-dependent epidermal growth factor receptor transactivation. J Physiol Pharmacol. 2004 Sep;55(3):627-38.</citation>
          </article>
          <article>
            <ref-id>A12367</ref-id>
            <pubmed-id>15527548</pubmed-id>
            <citation>Slomiany BL, Slomiany A: Src-kinase-dependent epidermal growth factor receptor transactivation in salivary mucin secretion in response to beta-adrenergic G-protein-coupled receptor activation. Inflammopharmacology. 2004;12(3):233-45.</citation>
          </article>
          <article>
            <ref-id>A12368</ref-id>
            <pubmed-id>15618457</pubmed-id>
            <citation>Machida K, Inoue H, Matsumoto K, Tsuda M, Fukuyama S, Koto H, Aizawa H, Kureishi Y, Hara N, Nakanishi Y: Activation of PI3K-Akt pathway mediates antiapoptotic effects of beta-adrenergic agonist in airway eosinophils. Am J Physiol Lung Cell Mol Physiol. 2005 May;288(5):L860-7. Epub 2004 Dec 23.</citation>
          </article>
          <article>
            <ref-id>A12369</ref-id>
            <pubmed-id>15985706</pubmed-id>
            <citation>Slomiany BL, Slomiany A: Gastric mucin secretion in response to beta-adrenergic G protein-coupled receptor activation is mediated by SRC kinase-dependent epidermal growth factor receptor transactivation. J Physiol Pharmacol. 2005 Jun;56(2):247-58.</citation>
          </article>
        </articles>
        <textbooks/>
        <links/>
        <attachments/>
      </references>
      <known-action>unknown</known-action>
      <polypeptide id="P27986" source="Swiss-Prot">
        <name>Phosphatidylinositol 3-kinase regulatory subunit alpha</name>
        <general-function>Transmembrane receptor protein tyrosine kinase adaptor activity</general-function>
        <specific-function>Binds to activated (phosphorylated) protein-Tyr kinases, through its SH2 domain, and acts as an adapter, mediating the association of the p110 catalytic unit to the plasma membrane. Necessary for the insulin-stimulated increase in glucose uptake and glycogen synthesis in insulin-sensitive tissues. Plays an important role in signaling in response to FGFR1, FGFR2, FGFR3, FGFR4, KITLG/SCF, KIT, PDGFRA and PDGFRB. Likewise, plays a role in ITGB2 signaling (PubMed:17626883, PubMed:19805105, PubMed:7518429). Modulates the cellular response to ER stress by promoting nuclear translocation of XBP1 isoform 2 in a ER stress-and/or insulin-dependent manner during metabolic overloading in the liver and hence plays a role in glucose tolerance improvement (PubMed:20348923).</specific-function>
        <gene-name>PIK3R1</gene-name>
        <locus>5q13.1</locus>
        <cellular-location>Cytoplasmic</cellular-location>
        <transmembrane-regions/>
        <signal-regions/>
        <theoretical-pi>6.06</theoretical-pi>
        <molecular-weight>83597.675</molecular-weight>
        <chromosome-location>5</chromosome-location>
        <organism ncbi-taxonomy-id="9606">Humans</organism>
        <external-identifiers>
          <external-identifier>
            <resource>HUGO Gene Nomenclature Committee (HGNC)</resource>
            <identifier>HGNC:8979</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenAtlas</resource>
            <identifier>PIK3R1</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenBank Gene Database</resource>
            <identifier>M61906</identifier>
          </external-identifier>
          <external-identifier>
            <resource>UniProtKB</resource>
            <identifier>P27986</identifier>
          </external-identifier>
          <external-identifier>
            <resource>UniProt Accession</resource>
            <identifier>P85A_HUMAN</identifier>
          </external-identifier>
        </external-identifiers>
        <synonyms>
          <synonym>GRB1</synonym>
          <synonym>Phosphatidylinositol 3-kinase 85 kDa regulatory subunit alpha</synonym>
          <synonym>PI3-kinase regulatory subunit alpha</synonym>
          <synonym>PI3-kinase subunit p85-alpha</synonym>
          <synonym>PtdIns-3-kinase regulatory subunit p85-alpha</synonym>
        </synonyms>
        <amino-acid-sequence format="FASTA">&gt;lcl|BSEQ0001901|Phosphatidylinositol 3-kinase regulatory subunit alpha
MSAEGYQYRALYDYKKEREEDIDLHLGDILTVNKGSLVALGFSDGQEARPEEIGWLNGYN
ETTGERGDFPGTYVEYIGRKKISPPTPKPRPPRPLPVAPGSSKTEADVEQQALTLPDLAE
QFAPPDIAPPLLIKLVEAIEKKGLECSTLYRTQSSSNLAELRQLLDCDTPSVDLEMIDVH
VLADAFKRYLLDLPNPVIPAAVYSEMISLAPEVQSSEEYIQLLKKLIRSPSIPHQYWLTL
QYLLKHFFKLSQTSSKNLLNARVLSEIFSPMLFRFSAASSDNTENLIKVIEILISTEWNE
RQPAPALPPKPPKPTTVANNGMNNNMSLQDAEWYWGDISREEVNEKLRDTADGTFLVRDA
STKMHGDYTLTLRKGGNNKLIKIFHRDGKYGFSDPLTFSSVVELINHYRNESLAQYNPKL
DVKLLYPVSKYQQDQVVKEDNIEAVGKKLHEYNTQFQEKSREYDRLYEEYTRTSQEIQMK
RTAIEAFNETIKIFEEQCQTQERYSKEYIEKFKREGNEKEIQRIMHNYDKLKSRISEIID
SRRRLEEDLKKQAAEYREIDKRMNSIKPDLIQLRKTRDQYLMWLTQKGVRQKKLNEWLGN
ENTEDQYSLVEDDEDLPHHDEKTWNVGSSNRNKAENLLRGKRDGTFLVRESSKQGCYACS
VVVDGEVKHCVINKTATGYGFAEPYNLYSSLKELVLHYQHTSLVQHNDSLNVTLAYPVYA
QQRR</amino-acid-sequence>
        <gene-sequence format="FASTA">&gt;lcl|BSEQ0021657|Phosphatidylinositol 3-kinase regulatory subunit alpha (PIK3R1)
ATGCATGGTGATTATACTCTTACACTAAGGAAAGGGGGAAATAACAAATTAATCAAAATA
TTTCATCGAGATGGGAAATATGGCTTCTCTGACCCATTAACCTTCAGTTCTGTGGTTGAA
TTAATAAACCACTACCGGAATGAATCTCTAGCTCAGTATAATCCCAAATTGGATGTGAAA
TTACTTTATCCAGTATCCAAATACCAACAGGATCAAGTTGTCAAAGAAGATAATATTGAA
GCTGTAGGGAAAAAATTACATGAATATAACACTCAGTTTCAAGAAAAAAGTCGAGAATAT
GATAGATTATATGAAGAATATACCCGCACATCCCAGGAAATCCAAATGAAAAGGACAGCT
ATTGAAGCATTTAATGAAACCATAAAAATATTTGAAGAACAGTGCCAGACCCAAGAGCGG
TACAGCAAAGAATACATAGAAAAGTTTAAACGTGAAGGCAATGAGAAAGAAATACAAAGG
ATTATGCATAATTATGATAAGTTGAAGTCTCGAATCAGTGAAATTATTGACAGTAGAAGA
AGATTGGAAGAAGACTTGAAGAAGCAGGCAGCTGAGTATCGAGAAATTGACAAACGTATG
AACAGCATTAAACCAGACCTTATCCAGCTGAGAAAGACGAGAGACCAATACTTGATGTGG
TTGACTCAAAAAGGTGTTCGGCAAAAGAAGTTGAACGAGTGGTTGGGCAATGAAAACACT
GAAGACCAATATTCACTGGTGGAAGATGATGAAGATTTGCCCCATCATGATGAGAAGACA
TGGAATGTTGGAAGCAGCAACCGAAACAAAGCTGAAAACCTGTTGCGAGGGAAGCGAGAT
GGCACTTTTCTTGTCCGGGAGAGCAGTAAACAGGGCTGCTATGCCTGCTCTGTAGTGGTG
GACGGCGAAGTAAAGCATTGTGTCATAAACAAAACAGCAACTGGCTATGGCTTTGCCGAG
CCCTATAACTTGTACAGCTCTCTGAAAGAACTGGTGCTACATTACCAACACACCTCCCTT
GTGCAGCACAACGACTCCCTCAATGTCACACTAGCCTACCCAGTATATGCACAGCAGAGG
CGATGA</gene-sequence>
        <pfams>
          <pfam>
            <identifier>PF00017</identifier>
            <name>SH2</name>
          </pfam>
          <pfam>
            <identifier>PF00620</identifier>
            <name>RhoGAP</name>
          </pfam>
          <pfam>
            <identifier>PF16454</identifier>
            <name>PI3K_P85_iSH2</name>
          </pfam>
        </pfams>
        <go-classifiers>
          <go-classifier>
            <category>component</category>
            <description>cell-cell junction</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>cis-Golgi network</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>cytoplasm</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>cytosol</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>membrane</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>nucleus</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>perinuclear endoplasmic reticulum membrane</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>phosphatidylinositol 3-kinase complex</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>phosphatidylinositol 3-kinase complex, class IA</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>plasma membrane</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>1-phosphatidylinositol-3-kinase regulator activity</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>ErbB-3 class receptor binding</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>insulin binding</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>insulin receptor binding</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>insulin receptor substrate binding</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>insulin-like growth factor receptor binding</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>neurotrophin TRKA receptor binding</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>phosphatidylinositol 3-kinase binding</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>phosphatidylinositol 3-kinase regulator activity</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>protein phosphatase binding</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>transcription factor binding</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>transmembrane receptor protein tyrosine kinase adaptor activity</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>B cell differentiation</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>blood coagulation</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>cellular glucose homeostasis</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>cellular response to insulin stimulus</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>cellular response to UV</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>epidermal growth factor receptor signaling pathway</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>extrinsic apoptotic signaling pathway via death domain receptors</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>Fc-epsilon receptor signaling pathway</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>Fc-gamma receptor signaling pathway involved in phagocytosis</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>fibroblast growth factor receptor signaling pathway</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>growth hormone receptor signaling pathway</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>innate immune response</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>insulin receptor signaling pathway</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>insulin-like growth factor receptor signaling pathway</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>intrinsic apoptotic signaling pathway in response to DNA damage</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>leukocyte migration</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>negative regulation of apoptotic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>negative regulation of cell-matrix adhesion</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>negative regulation of osteoclast differentiation</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>neurotrophin TRK receptor signaling pathway</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>NFAT protein import into nucleus</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>phosphatidylinositol 3-kinase signaling</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>phosphatidylinositol biosynthetic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>phosphatidylinositol phosphorylation</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>phosphatidylinositol-mediated signaling</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>phospholipid metabolic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>platelet activation</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>positive regulation of cell migration</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>positive regulation of endoplasmic reticulum unfolded protein response</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>positive regulation of establishment of protein localization to plasma membrane</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>positive regulation of glucose import</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>positive regulation of glucose import in response to insulin stimulus</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>positive regulation of RNA splicing</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>positive regulation of transcription factor import into nucleus</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>positive regulation of transcription from RNA polymerase II promoter</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>positive regulation of tumor necrosis factor production</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>protein phosphorylation</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>protein stabilization</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>regulation of phosphatidylinositol 3-kinase activity</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>regulation of stress fiber assembly</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>response to endoplasmic reticulum stress</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>small molecule metabolic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>T cell costimulation</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>T cell receptor signaling pathway</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>vascular endothelial growth factor receptor signaling pathway</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>viral process</description>
          </go-classifier>
        </go-classifiers>
      </polypeptide>
    </target>
    <target position="6">
      <id>BE0002383</id>
      <name>Phosphatidylinositol 3-kinase regulatory subunit beta</name>
      <organism>Humans</organism>
      <actions>
        <action>agonist</action>
      </actions>
      <references>
        <articles>
          <article>
            <ref-id>A12365</ref-id>
            <pubmed-id>15110780</pubmed-id>
            <citation>Slomiany BL, Slomiany A: Salivary phospholipid secretion in response to beta-adrenergic stimulation is mediated by Src kinase-dependent epidermal growth factor receptor transactivation. Biochem Biophys Res Commun. 2004 May 21;318(1):247-52.</citation>
          </article>
          <article>
            <ref-id>A12366</ref-id>
            <pubmed-id>15381832</pubmed-id>
            <citation>Slomiany BL, Slomiany A: Secretion of gastric mucus phospholipids in response to beta-adrenergic G protein-coupled receptor activation is mediated by SRC kinase-dependent epidermal growth factor receptor transactivation. J Physiol Pharmacol. 2004 Sep;55(3):627-38.</citation>
          </article>
          <article>
            <ref-id>A12367</ref-id>
            <pubmed-id>15527548</pubmed-id>
            <citation>Slomiany BL, Slomiany A: Src-kinase-dependent epidermal growth factor receptor transactivation in salivary mucin secretion in response to beta-adrenergic G-protein-coupled receptor activation. Inflammopharmacology. 2004;12(3):233-45.</citation>
          </article>
          <article>
            <ref-id>A12368</ref-id>
            <pubmed-id>15618457</pubmed-id>
            <citation>Machida K, Inoue H, Matsumoto K, Tsuda M, Fukuyama S, Koto H, Aizawa H, Kureishi Y, Hara N, Nakanishi Y: Activation of PI3K-Akt pathway mediates antiapoptotic effects of beta-adrenergic agonist in airway eosinophils. Am J Physiol Lung Cell Mol Physiol. 2005 May;288(5):L860-7. Epub 2004 Dec 23.</citation>
          </article>
          <article>
            <ref-id>A12369</ref-id>
            <pubmed-id>15985706</pubmed-id>
            <citation>Slomiany BL, Slomiany A: Gastric mucin secretion in response to beta-adrenergic G protein-coupled receptor activation is mediated by SRC kinase-dependent epidermal growth factor receptor transactivation. J Physiol Pharmacol. 2005 Jun;56(2):247-58.</citation>
          </article>
        </articles>
        <textbooks/>
        <links/>
        <attachments/>
      </references>
      <known-action>unknown</known-action>
      <polypeptide id="O00459" source="Swiss-Prot">
        <name>Phosphatidylinositol 3-kinase regulatory subunit beta</name>
        <general-function>Receptor tyrosine kinase binding</general-function>
        <specific-function>Regulatory subunit of phosphoinositide-3-kinase (PI3K), a kinase that phosphorylates PtdIns(4,5)P2 (Phosphatidylinositol 4,5-bisphosphate) to generate phosphatidylinositol 3,4,5-trisphosphate (PIP3). PIP3 plays a key role by recruiting PH domain-containing proteins to the membrane, including AKT1 and PDPK1, activating signaling cascades involved in cell growth, survival, proliferation, motility and morphology. Binds to activated (phosphorylated) protein-tyrosine kinases, through its SH2 domain, and acts as an adapter, mediating the association of the p110 catalytic unit to the plasma membrane. Indirectly regulates autophagy (PubMed:23604317). Promotes nuclear translocation of XBP1 isoform 2 in a ER stress- and/or insulin-dependent manner during metabolic overloading in the liver and hence plays a role in glucose tolerance improvement (By similarity).</specific-function>
        <gene-name>PIK3R2</gene-name>
        <locus>19q13.2-q13.4</locus>
        <cellular-location/>
        <transmembrane-regions/>
        <signal-regions/>
        <theoretical-pi>6.48</theoretical-pi>
        <molecular-weight>81544.505</molecular-weight>
        <chromosome-location>19</chromosome-location>
        <organism ncbi-taxonomy-id="9606">Humans</organism>
        <external-identifiers>
          <external-identifier>
            <resource>HUGO Gene Nomenclature Committee (HGNC)</resource>
            <identifier>HGNC:8980</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenAtlas</resource>
            <identifier>PIK3R2</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenBank Gene Database</resource>
            <identifier>X80907</identifier>
          </external-identifier>
          <external-identifier>
            <resource>UniProtKB</resource>
            <identifier>O00459</identifier>
          </external-identifier>
          <external-identifier>
            <resource>UniProt Accession</resource>
            <identifier>P85B_HUMAN</identifier>
          </external-identifier>
        </external-identifiers>
        <synonyms>
          <synonym>Phosphatidylinositol 3-kinase 85 kDa regulatory subunit beta</synonym>
          <synonym>PI3-kinase regulatory subunit beta</synonym>
          <synonym>PI3-kinase subunit p85-beta</synonym>
          <synonym>PtdIns-3-kinase regulatory subunit p85-beta</synonym>
        </synonyms>
        <amino-acid-sequence format="FASTA">&gt;lcl|BSEQ0019276|Phosphatidylinositol 3-kinase regulatory subunit beta
MAGPEGFQYRALYPFRRERPEDLELLPGDVLVVSRAALQALGVAEGGERCPQSVGWMPGL
NERTRQRGDFPGTYVEFLGPVALARPGPRPRGPRPLPARPRDGAPEPGLTLPDLPEQFSP
PDVAPPLLVKLVEAIERTGLDSESHYRPELPAPRTDWSLSDVDQWDTAALADGIKSFLLA
LPAPLVTPEASAEARRALREAAGPVGPALEPPTLPLHRALTLRFLLQHLGRVASRAPALG
PAVRALGATFGPLLLRAPPPPSSPPPGGAPDGSEPSPDFPALLVEKLLQEHLEEQEVAPP
ALPPKPPKAKPASTVLANGGSPPSLQDAEWYWGDISREEVNEKLRDTPDGTFLVRDASSK
IQGEYTLTLRKGGNNKLIKVFHRDGHYGFSEPLTFCSVVDLINHYRHESLAQYNAKLDTR
LLYPVSKYQQDQIVKEDSVEAVGAQLKVYHQQYQDKSREYDQLYEEYTRTSQELQMKRTA
IEAFNETIKIFEEQGQTQEKCSKEYLERFRREGNEKEMQRILLNSERLKSRIAEIHESRT
KLEQQLRAQASDNREIDKRMNSLKPDLMQLRKIRDQYLVWLTQKGARQKKINEWLGIKNE
TEDQYALMEDEDDLPHHEERTWYVGKINRTQAEEMLSGKRDGTFLIRESSQRGCYACSVV
VDGDTKHCVIYRTATGFGFAEPYNLYGSLKELVLHYQHASLVQHNDALTVTLAHPVRAPG
PGPPPAAR</amino-acid-sequence>
        <gene-sequence format="FASTA">&gt;lcl|BSEQ0019277|Phosphatidylinositol 3-kinase regulatory subunit beta (PIK3R2)
ATGGCGGGCCCTGAGGGCTTCCAGTACCGCGCTCTGTACCCGTTCCGCCGGGAGCGGCCG
GAGGACCTGGAGCTGCTGCCCGGCGACGTGCTGGTAGTGAGCCGGGCGGCCTTGCAGGCG
CTGGGCGTGGCCGAGGGTGGCGAGCGCTGCCCACAGAGCGTGGGCTGGATGCCCGGCCTC
AACGAGCGCACACGGCAGCGAGGTGACTTCCCTGGCACCTATGTGGAGTTCCTGGGGCCC
GTGGCCCTGGCCCGGCCCGGCCCTCGCCCACGGGGCCCCCGCCCACTGCCCGCCAGGCCC
CGTGATGGGGCCCCTGAGCCAGGCCTCACACTCCCCGACTTGCCCGAGCAGTTCTCCCCA
CCTGATGTGGCTCCCCCTCTTCTGGTGAAGCTTGTGGAGGCCATTGAAAGGACAGGGCTG
GACAGCGAATCTCACTACCGCCCGGAGCTGCCCGCACCGCGTACAGACTGGTCCCTGAGC
GACGTGGATCAGTGGGACACGGCAGCCCTGGCTGACGGCATTAAGAGCTTCCTGCTGGCA
CTGCCCGCGCCGCTCGTGACCCCCGAGGCCTCGGCCGAGGCGCGCCGGGCCCTGCGGGAG
GCCGCGGGGCCCGTGGGGCCGGCGCTGGAGCCACCGACGCTGCCGCTGCACCGCGCGCTC
ACGCTGCGCTTCCTGCTCCAGCACCTGGGCCGCGTGGCCCGCCGCGCCCCGGCCCTGGGT
CCCGCGGTCCGGGCCCTGGGCGCCACCTTTGGGCCGCTGCTGCTGCGCGCGCCGCCGCCG
CCGTCCTCGCCGCCGCCAGGGGGCGCTCCCGACGGGAGTGAGCCCAGCCCTGACTTCCCG
GCGCTGCTGGTGGAGAAGCTGCTTCAGGAACACTTGGAAGAGCAGGAGGTTGCGCCCCCA
GCGCTGCCGCCTAAACCCCCCAAGGCAAAGCCGGCCCCCACAGTCCTGGCCAATGGAGGG
AGCCCACCCTCCCTGCAGGATGCTGAGTGGTACTGGGGGGACATTTCAAGGGAGGAGGTG
AACGAGAAACTCCGGGACACTCCCGATGGCACCTTCCTAGTCCGAGATGCTTCTAGCAAG
ATCCAGGGCGAGTACACGCTGACCCTCAGGAAAGGCGGGAACAATAAGCTGATCAAGGTC
TTCCACCGAGATGGGCACTATGGCTTCTCAGAGCCACTCACCTTCTGCTCCGTTGTGGAC
CTCATCAATCACTACCGCCACGAGTCTCTGGCCCAGTACAATGCCAAGCTGGACACACGG
CTCCTCTACCCTGTGTCCAAATACCAGCAGGACCAGATTGTCAAGGAGGACAGCGTGGAG
GCAGTGGGCGCCCAGCTTAAGGTCTATCACCAGCAGTACCAGGACAAGAGCCGCGAGTAT
GACCAGCTTTATGAAGAGTACACACGGACCTCCCAGGAGCTGCAGATGAAGCGTACTGCA
ATTGAGGCCTTCAATGAGACTATCAAGATCTTTGAAGAGCAGGGCCAGACTCAAGAGAAA
TGCAGCAAGGAATACCTGGAGCGCTTCCGGCGTGAGGGCAACGAGAAAGAGATGCAAAGG
ATCCTGCTGAACTCCGAGCGGCTCAAGTCCCGCATTGCCGAGATCCATGAGAGCCGCACG
AAGCTGGAGCAGCAGCTGCGGGCCCAGGCCTCGGACAACAGAGAGATCGACAAGCGCATG
AACAGCCTCAAGCCGGACCTCATGCAGCTGCGCAAGATCCGAGACCAGTACCTCGTGTGG
CTCACCCAGAAAGGCGCCCGGCAGAAGAAAATCAACGAGTGGCTGGGGATTAAAAATGAG
ACTGAGGACCAGTACGCACTCATGGAGGACGAGGACGATCTCCCGCACCACGAGGAACGC
ACTTGGTACGTGGGCAAGATCAACCGCACGCAGGCAGAGGAGATGCTGAGTGGCAAGCGG
GATGGCACCTTCCTCATCCGCGAGAGCAGCCAGCGGGGCTGCTACGCCTGCTCCGTGGTA
GTGGACGGCGACACCAAGCACTGCGTCATCTACCGCACGGCCACCGGCTTCGGCTTCGCG
GAGCCCTACAACCTGTACGGGTCGCTGAAGGAGCTGGTGCTGCACTACCAGCACGCCTCG
CTGGTGCAGCACAACGACGCGCTCACCGTCACCCTGGCGCACCCAGTGCGCGCCCCGGGC
CCCGGCCCGCCGCCTGCCGCCCGCTGA</gene-sequence>
        <pfams>
          <pfam>
            <identifier>PF00017</identifier>
            <name>SH2</name>
          </pfam>
          <pfam>
            <identifier>PF00620</identifier>
            <name>RhoGAP</name>
          </pfam>
          <pfam>
            <identifier>PF16454</identifier>
            <name>PI3K_P85_iSH2</name>
          </pfam>
        </pfams>
        <go-classifiers>
          <go-classifier>
            <category>component</category>
            <description>cytosol</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>nucleus</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>phosphatidylinositol 3-kinase complex</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>1-phosphatidylinositol-3-kinase regulator activity</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>protein heterodimerization activity</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>protein phosphatase binding</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>receptor tyrosine kinase binding</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>blood coagulation</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>cellular glucose homeostasis</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>cellular response to insulin stimulus</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>epidermal growth factor receptor signaling pathway</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>Fc-epsilon receptor signaling pathway</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>Fc-gamma receptor signaling pathway involved in phagocytosis</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>fibroblast growth factor receptor signaling pathway</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>innate immune response</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>insulin receptor signaling pathway</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>leukocyte migration</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>neurotrophin TRK receptor signaling pathway</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>phosphatidylinositol 3-kinase signaling</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>phosphatidylinositol biosynthetic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>phosphatidylinositol phosphorylation</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>phosphatidylinositol-3-phosphate biosynthetic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>phosphatidylinositol-mediated signaling</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>phospholipid metabolic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>positive regulation of glucose import in response to insulin stimulus</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>positive regulation of transcription factor import into nucleus</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>positive regulation of transcription from RNA polymerase II promoter</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>protein transport</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>regulation of autophagy</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>regulation of phosphatidylinositol 3-kinase activity</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>regulation of small GTPase mediated signal transduction</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>response to endoplasmic reticulum stress</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>small GTPase mediated signal transduction</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>small molecule metabolic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>T cell receptor signaling pathway</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>vascular endothelial growth factor receptor signaling pathway</description>
          </go-classifier>
        </go-classifiers>
      </polypeptide>
    </target>
    <target position="7">
      <id>BE0002384</id>
      <name>Phosphatidylinositol 3-kinase regulatory subunit gamma</name>
      <organism>Humans</organism>
      <actions>
        <action>agonist</action>
      </actions>
      <references>
        <articles>
          <article>
            <ref-id>A12365</ref-id>
            <pubmed-id>15110780</pubmed-id>
            <citation>Slomiany BL, Slomiany A: Salivary phospholipid secretion in response to beta-adrenergic stimulation is mediated by Src kinase-dependent epidermal growth factor receptor transactivation. Biochem Biophys Res Commun. 2004 May 21;318(1):247-52.</citation>
          </article>
          <article>
            <ref-id>A12366</ref-id>
            <pubmed-id>15381832</pubmed-id>
            <citation>Slomiany BL, Slomiany A: Secretion of gastric mucus phospholipids in response to beta-adrenergic G protein-coupled receptor activation is mediated by SRC kinase-dependent epidermal growth factor receptor transactivation. J Physiol Pharmacol. 2004 Sep;55(3):627-38.</citation>
          </article>
          <article>
            <ref-id>A12367</ref-id>
            <pubmed-id>15527548</pubmed-id>
            <citation>Slomiany BL, Slomiany A: Src-kinase-dependent epidermal growth factor receptor transactivation in salivary mucin secretion in response to beta-adrenergic G-protein-coupled receptor activation. Inflammopharmacology. 2004;12(3):233-45.</citation>
          </article>
          <article>
            <ref-id>A12368</ref-id>
            <pubmed-id>15618457</pubmed-id>
            <citation>Machida K, Inoue H, Matsumoto K, Tsuda M, Fukuyama S, Koto H, Aizawa H, Kureishi Y, Hara N, Nakanishi Y: Activation of PI3K-Akt pathway mediates antiapoptotic effects of beta-adrenergic agonist in airway eosinophils. Am J Physiol Lung Cell Mol Physiol. 2005 May;288(5):L860-7. Epub 2004 Dec 23.</citation>
          </article>
          <article>
            <ref-id>A12369</ref-id>
            <pubmed-id>15985706</pubmed-id>
            <citation>Slomiany BL, Slomiany A: Gastric mucin secretion in response to beta-adrenergic G protein-coupled receptor activation is mediated by SRC kinase-dependent epidermal growth factor receptor transactivation. J Physiol Pharmacol. 2005 Jun;56(2):247-58.</citation>
          </article>
        </articles>
        <textbooks/>
        <links/>
        <attachments/>
      </references>
      <known-action>unknown</known-action>
      <polypeptide id="Q92569" source="Swiss-Prot">
        <name>Phosphatidylinositol 3-kinase regulatory subunit gamma</name>
        <general-function>1-phosphatidylinositol-3-kinase regulator activity</general-function>
        <specific-function>Binds to activated (phosphorylated) protein-tyrosine kinases through its SH2 domain and regulates their kinase activity. During insulin stimulation, it also binds to IRS-1.</specific-function>
        <gene-name>PIK3R3</gene-name>
        <locus>1p34.1</locus>
        <cellular-location/>
        <transmembrane-regions/>
        <signal-regions/>
        <theoretical-pi>6.02</theoretical-pi>
        <molecular-weight>54448.0</molecular-weight>
        <chromosome-location>1</chromosome-location>
        <organism ncbi-taxonomy-id="9606">Humans</organism>
        <external-identifiers>
          <external-identifier>
            <resource>HUGO Gene Nomenclature Committee (HGNC)</resource>
            <identifier>HGNC:8981</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenAtlas</resource>
            <identifier>PIK3R3</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenBank Gene Database</resource>
            <identifier>D88532</identifier>
          </external-identifier>
          <external-identifier>
            <resource>UniProtKB</resource>
            <identifier>Q92569</identifier>
          </external-identifier>
          <external-identifier>
            <resource>UniProt Accession</resource>
            <identifier>P55G_HUMAN</identifier>
          </external-identifier>
        </external-identifiers>
        <synonyms>
          <synonym>p55PIK</synonym>
          <synonym>Phosphatidylinositol 3-kinase 55 kDa regulatory subunit gamma</synonym>
          <synonym>PI3-kinase regulatory subunit gamma</synonym>
          <synonym>PI3-kinase subunit p55-gamma</synonym>
          <synonym>PtdIns-3-kinase regulatory subunit p55-gamma</synonym>
        </synonyms>
        <amino-acid-sequence format="FASTA">&gt;lcl|BSEQ0037200|Phosphatidylinositol 3-kinase regulatory subunit gamma
MYNTVWSMDRDDADWREVMMPYSTELIFYIEMDPPALPPKPPKPMTSAVPNGMKDSSVSL
QDAEWYWGDISREEVNDKLRDMPDGTFLVRDASTKMQGDYTLTLRKGGNNKLIKIYHRDG
KYGFSDPLTFNSVVELINHYHHESLAQYNPKLDVKLMYPVSRYQQDQLVKEDNIDAVGKK
LQEYHSQYQEKSKEYDRLYEEYTRTSQEIQMKRTAIEAFNETIKIFEEQCHTQEQHSKEY
IERFRREGNEKEIERIMMNYDKLKSRLGEIHDSKMRLEQDLKNQALDNREIDKKMNSIKP
DLIQLRKIRDQHLVWLNHKGVRQKRLNVWLGIKNEDADENYFINEEDENLPHYDEKTWFV
EDINRVQAEDLLYGKPDGAFLIRESSKKGCYACSVVADGEVKHCVIYSTARGYGFAEPYN
LYSSLKELVLHYQQTSLVQHNDSLNVRLAYPVHAQMPSLCR</amino-acid-sequence>
        <gene-sequence format="FASTA">&gt;lcl|BSEQ0011710|Phosphatidylinositol 3-kinase regulatory subunit gamma (PIK3R3)
ATGTACAATACGGTGTGGAGTATGGACCGCGATGACGCAGACTGGAGGGAGGTGATGATG
CCCTATTCGACAGAACTGATATTTTATATTGAAATGGATCCTCCAGCTCTTCCACCAAAG
CCACCTAAGCCAATGACTTCAGCAGTTCCAAATGGAATGAAGGACAGTTCTGTTTCTCTT
CAGGATGCAGAATGGTACTGGGGGGATATTTCAAGGGAGGAGGTAAATGACAAATTGCGG
GATATGCCAGATGGGACCTTCTTGGTCCGAGATGCCTCAACAAAAATGCAGGGAGATTAT
ACTTTGACTTTGCGGAAGGGAGGCAATAATAAGTTAATAAAGATCTATCACCGGGATGGT
AAATATGGCTTTTCTGATCCTCTGACATTTAATTCCGTGGTGGAGCTCATTAACCACTAT
CACCATGAATCTCTTGCTCAGTACAATCCCAAACTTGATGTGAAGCTGATGTACCCAGTG
TCCAGATACCAACAGGATCAGTTGGTAAAAGAAGATAATATTGATGCAGTAGGTAAAAAA
CTGCAAGAATACCACTCTCAGTATCAGGAGAAGAGTAAAGAGTATGATAGGCTGTATGAA
GAATATACTAGAACATCCCAGGAAATACAGATGAAGAGGACTGCAATAGAAGCTTTTAAT
GAAACAATTAAAATATTTGAAGAGCAGTGTCACACACAAGAACAACATAGCAAAGAATAT
ATTGAGCGATTTCGCAGAGAGGGGAATGAAAAGGAGATTGAACGAATTATGATGAATTAT
GATAAATTGAAATCACGTCTGGGTGAGATTCATGATAGCAAAATGCGTCTAGAGCAGGAT
TTGAAGAATCAAGCTTTGGACAACCGAGAAATAGATAAAAAAATGAATAGCATCAAACCT
GACCTGATCCAGCTGCGAAAGATCCGAGATCAACACCTTGTATGGCTCAATCACAAAGGA
GTGAGACAGAAACGCCTGAATGTCTGGCTGGGAATTAAGAATGAGGATGCTGATGAGAAC
TATTTTATCAATGAGGAAGATGAAAACCTGCCCCATTATGATGAGAAAACCTGGTTTGTT
GAGGATATCAATCGAGTACAAGCAGAGGACTTGCTTTATGGGAAACCTGATGGTGCATTC
TTAATTCGTGAGAGTAGCAAGAAAGGATGCTATGCTTGCTCTGTGGTGGCCGATGGGGAA
GTGAAGCACTGTGTGATCTACAGCACTGCTCGGGGCTATGGCTTTGCAGAGCCCTACAAC
CTGTACAGCTCTCTGAAGGAGCTAGTGCTCCATTACCAGCAGACATCCTTGGTTCAGCAC
AACGACTCCCTCAACGTCAGGCTTGCCTACCCTGTTCATGCACAGATGCCCTCGCTTTGC
AGATAA</gene-sequence>
        <pfams>
          <pfam>
            <identifier>PF00017</identifier>
            <name>SH2</name>
          </pfam>
          <pfam>
            <identifier>PF16454</identifier>
            <name>PI3K_P85_iSH2</name>
          </pfam>
        </pfams>
        <go-classifiers>
          <go-classifier>
            <category>component</category>
            <description>cytosol</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>phosphatidylinositol 3-kinase complex</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>1-phosphatidylinositol-3-kinase activity</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>1-phosphatidylinositol-3-kinase regulator activity</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>insulin receptor signaling pathway</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>phosphatidylinositol biosynthetic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>phosphatidylinositol phosphorylation</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>phosphatidylinositol-3-phosphate biosynthetic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>phospholipid metabolic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>positive regulation of glucose import in response to insulin stimulus</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>regulation of phosphatidylinositol 3-kinase activity</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>small molecule metabolic process</description>
          </go-classifier>
        </go-classifiers>
      </polypeptide>
    </target>
    <target position="9">
      <id>BE0003429</id>
      <name>CAMP phosphodiesterase</name>
      <organism>Trypanosoma cruzi</organism>
      <actions>
        <action>activator</action>
      </actions>
      <references>
        <articles>
          <article>
            <ref-id>A18193</ref-id>
            <pubmed-id>2153956</pubmed-id>
            <citation>Degerman E, Smith CJ, Tornqvist H, Vasta V, Belfrage P, Manganiello VC: Evidence that insulin and isoprenaline activate the cGMP-inhibited low-Km cAMP phosphodiesterase in rat fat cells by phosphorylation. Proc Natl Acad Sci U S A. 1990 Jan;87(2):533-7.</citation>
          </article>
        </articles>
        <textbooks/>
        <links/>
        <attachments/>
      </references>
      <known-action>unknown</known-action>
      <polypeptide id="Q4ZHU6" source="TrEMBL">
        <name>CAMP phosphodiesterase</name>
        <general-function>Metal ion binding</general-function>
        <specific-function/>
        <gene-name>PDE4</gene-name>
        <locus/>
        <cellular-location>Cytoplasmic</cellular-location>
        <transmembrane-regions/>
        <signal-regions/>
        <theoretical-pi>6.23</theoretical-pi>
        <molecular-weight>103168.655</molecular-weight>
        <chromosome-location/>
        <organism ncbi-taxonomy-id="5693">Trypanosoma cruzi</organism>
        <external-identifiers>
          <external-identifier>
            <resource>GenBank Gene Database</resource>
            <identifier>DQ008164</identifier>
          </external-identifier>
          <external-identifier>
            <resource>UniProtKB</resource>
            <identifier>Q4ZHU6</identifier>
          </external-identifier>
          <external-identifier>
            <resource>UniProt Accession</resource>
            <identifier>Q4ZHU6_TRYCR</identifier>
          </external-identifier>
        </external-identifiers>
        <synonyms/>
        <amino-acid-sequence format="FASTA">&gt;lcl|BSEQ0012400|CAMP phosphodiesterase
MSEDAGLPVPRSQWVERSVSCATCGKRFSLFTAKSNCPCCGKLCCSDCVQAECAIVGGSA
PSKVCIDCFSMLQSRRRVEPDEGSSFREFNAASAFPLQTRLLADGRVESGETSRVSPPND
GRVQHFSRANGYSNSLPVLDEYVDDLLRKSELLRMENDVLLNRLREQEAEIQALRLERDR
AVARIVPDGGSMAGRSGTPQVSDEIVKELREELAVAHLRIESVEGELKNALDRAKSSETV
VKNLKQHLCNYKEEVVRLLQSREEVEMLPGVSGHRDMISTRRLPPSIVQDTILAVVPPKS
CAAIGTDVDLRDWGFDTFEVASRVPSVLQSVAMHVALAWDFFASQEEAQKWAFLVAAVEN
NYRPNPYHNAIHAADVLQGTFSLVSAAKPLMEHLTPLECKAAAFAALTHDVCHPGRTNAF
LAAVQDPVSFKFSGKGTLEQLHTVTAFELLNVTEFDFTSSMDNASFLEFKNIVSHLIGHT
DMSLHSETIAKHGAKLSAGGFDCTCKEDRLEALSLLLHAADIGASSRGVAIARKWLVILQ
EFADQAEDERRRGLPVTPGFDTPSSVEKSQIPFLDFFVIPTFDLLHQLFPSIEEPLHNLR
KLRELYAAKAGVTTPFPPPVDYRSREERIRSLEAELAYFRRREEEFHRQLQELRTASENE
NKSSAAPMTREGALNKQSQLVCRGEGNMNADWADAGGGFRNGKDVRDLQDVSMDHLVSSK
TVESDTGDSRPRSRRGSKAETTKAYERNLGEREAALMATARLMENREKRLAVLSEKLAEI
AEGLHEERKRLKPMEEFKTPCFSRETELISEESASMDVTHRFSTQWEAEGRLARKYRELD
ELLLIVRAMRMGYAARRNTHLGWKALSATLAEREAAITEAVELSRQRRRHLEEGRGLHPT
ATQLDRLENAIFQLMSATTLLTQC</amino-acid-sequence>
        <gene-sequence format="FASTA">&gt;lcl|BSEQ0006689|2775 bp
ATGTCGGAGGACGCTGGGCTTCCCGTGCCACGGAGTCAGTGGGTTGAGAGGAGCGTCAGC
TGTGCGACGTGCGGGAAGAGATTCTCCCTCTTCACCGCCAAGTCGAACTGCCCATGCTGC
GGGAAGCTTTGTTGCTCCGACTGCGTTCAGGCCGAGTGTGCCATTGTGGGCGGCAGTGCT
CCGTCAAAAGTATGTATTGATTGCTTCTCAATGCTTCAGAGCCGGCGACGCGTGGAGCCG
GATGAGGGATCATCTTTTCGGGAATTTAATGCGGCATCTGCATTTCCGCTTCAGACGCGA
CTCCTCGCTGACGGGCGGGTGGAAAGTGGAGAAACTTCTCGGGTAAGCCCGCCAAACGAT
GGAAGGGTGCAGCATTTTTCGAGAGCCAACGGGTACAGCAATTCTTTGCCCGTGCTCGAC
GAGTATGTTGATGATCTGCTGAGGAAGTCAGAATTGCTTCGAATGGAGAATGATGTCCTG
CTCAACCGCCTCCGGGAACAGGAGGCTGAGATCCAAGCGCTTCGTTTGGAACGGGATCGG
GCCGTTGCACGCATCGTGCCTGATGGAGGAAGTATGGCAGGCAGAAGTGGTACCCCACAA
GTGTCTGATGAAATCGTCAAGGAATTGCGTGAAGAACTGGCCGTAGCTCATCTTCGCATT
GAGTCAGTGGAAGGGGAACTGAAGAATGCACTGGATCGGGCAAAATCGAGCGAAACGGTG
GTGAAAAATCTGAAACAACACCTATGTAATTATAAGGAAGAAGTTGTCCGACTTCTACAG
TCCCGAGAAGAAGTGGAAATGCTTCCAGGGGTTAGTGGTCATAGGGACATGATATCAACA
CGTCGCCTTCCTCCATCTATTGTACAGGATACAATACTCGCAGTTGTTCCACCGAAGTCC
TGTGCCGCAATTGGCACGGACGTCGATCTGCGAGACTGGGGGTTTGATACCTTCGAGGTG
GCCTCTCGTGTCCCATCGGTGCTGCAAAGCGTCGCGATGCACGTTGCATTGGCGTGGGAT
TTTTTTGCTTCTCAGGAAGAGGCACAAAAATGGGCTTTTTTGGTTGCCGCGGTGGAAAAC
AACTACAGACCAAATCCTTATCATAATGCGATACATGCGGCGGATGTTCTTCAAGGCACG
TTTTCTCTTGTGTCGGCTGCAAAGCCATTGATGGAGCATTTGACACCACTGGAATGTAAG
GCTGCCGCATTTGCTGCATTGACACACGACGTTTGTCATCCGGGACGCACAAATGCCTTT
TTGGCTGCTGTGCAAGATCCTGTGAGTTTCAAGTTCAGTGGTAAAGGGACTTTGGAACAG
CTTCACACGGTGACAGCGTTTGAATTATTGAATGTAACCGAATTTGACTTTACCAGTTCA
ATGGACAACGCATCGTTTCTGGAATTCAAGAATATCGTGTCGCATCTCATTGGGCACACC
GATATGTCTTTGCATTCTGAGACTATTGCGAAGCATGGGGCAAAGTTGAGTGCTGGTGGT
TTTGATTGCACATGTAAAGAGGATCGTTTGGAGGCCCTTTCACTTCTTCTACATGCCGCT
GACATTGGTGCAAGTTCTCGTGGCGTGGCTATTGCGAGAAAGTGGTTGGTGATTCTGCAG
GAGTTTGCTGATCAGGCTGAAGATGAACGCCGTCGCGGCCTGCCGGTAACTCCCGGTTTT
GATACACCGTCTTCTGTGGAAAAGTCGCAGATTCCTTTTCTTGACTTTTTCGTTATACCC
ACCTTCGATCTGCTGCATCAACTGTTTCCGAGTATCGAGGAACCCCTGCACAACCTCCGC
AAATTGCGGGAATTATATGCCGCAAAGGCAGGCGTGACGACACCGTTTCCCCCGCCAGTT
GATTACCGGAGCCGTGAGGAAAGGATAAGGAGTCTTGAGGCAGAACTTGCGTACTTTCGC
AGGCGGGAAGAGGAGTTTCATCGCCAGTTGCAGGAGCTGAGAACAGCCAGTGAAAATGAG
AATAAAAGTTCTGCCGCGCCAATGACGAGAGAGGGGGCGTTAAATAAGCAATCCCAGTTG
GTGTGTAGAGGGGAGGGAAATATGAATGCCGACTGGGCGGATGCCGGAGGTGGGTTTCGG
AATGGGAAGGATGTGAGGGACTTGCAAGATGTGTCCATGGACCACCTGGTGAGCAGCAAG
ACCGTTGAGTCGGACACGGGCGATAGCAGACCGCGAAGCCGACGGGGAAGCAAGGCTGAA
ACGACGAAAGCTTATGAGCGAAACTTGGGCGAACGAGAAGCGGCGCTCATGGCGACTGCG
AGATTAATGGAGAATCGTGAGAAAAGGTTGGCCGTCCTTTCCGAAAAACTCGCAGAAATT
GCAGAGGGGCTGCACGAGGAGAGGAAGCGCTTAAAACCCATGGAAGAATTTAAGACTCCC
TGCTTTTCCCGAGAAACAGAACTTATTTCTGAGGAAAGCGCGTCCATGGATGTTACGCAT
CGTTTTTCAACTCAATGGGAGGCGGAAGGACGTCTTGCAAGGAAATACAGAGAATTGGAT
GAACTACTTTTGATTGTGCGTGCTATGCGCATGGGGTATGCGGCAAGACGCAACACGCAT
CTTGGGTGGAAAGCTTTGTCTGCGACCCTAGCGGAACGTGAGGCGGCTATTACTGAGGCT
GTGGAGTTGTCACGTCAACGACGTAGGCATTTGGAGGAGGGAAGAGGACTGCATCCCACG
GCAACACAACTGGACCGATTGGAGAACGCCATCTTTCAGTTGATGTCAGCCACCACTCTG
TTGACGCAGTGCTGA</gene-sequence>
        <pfams>
          <pfam>
            <identifier>PF00233</identifier>
            <name>PDEase_I</name>
          </pfam>
          <pfam>
            <identifier>PF01363</identifier>
            <name>FYVE</name>
          </pfam>
        </pfams>
        <go-classifiers>
          <go-classifier>
            <category>function</category>
            <description>3',5'-cyclic-nucleotide phosphodiesterase activity</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>metal ion binding</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>signal transduction</description>
          </go-classifier>
        </go-classifiers>
      </polypeptide>
    </target>
    <target position="10">
      <id>BE0002390</id>
      <name>Superoxide dismutase [Cu-Zn]</name>
      <organism>Humans</organism>
      <actions/>
      <references>
        <articles>
          <article>
            <ref-id>A20196</ref-id>
            <pubmed-id>23612299</pubmed-id>
            <citation>Wright GS, Antonyuk SV, Kershaw NM, Strange RW, Samar Hasnain S: Ligand binding and aggregation of pathogenic SOD1. Nat Commun. 2013;4:1758. doi: 10.1038/ncomms2750.</citation>
          </article>
        </articles>
        <textbooks/>
        <links/>
        <attachments/>
      </references>
      <known-action>unknown</known-action>
      <polypeptide id="P00441" source="Swiss-Prot">
        <name>Superoxide dismutase [Cu-Zn]</name>
        <general-function>Zinc ion binding</general-function>
        <specific-function>Destroys radicals which are normally produced within the cells and which are toxic to biological systems.</specific-function>
        <gene-name>SOD1</gene-name>
        <locus/>
        <cellular-location>Cytoplasm</cellular-location>
        <transmembrane-regions/>
        <signal-regions/>
        <theoretical-pi>6.07</theoretical-pi>
        <molecular-weight>15935.685</molecular-weight>
        <chromosome-location>21</chromosome-location>
        <organism ncbi-taxonomy-id="9606">Humans</organism>
        <external-identifiers>
          <external-identifier>
            <resource>HUGO Gene Nomenclature Committee (HGNC)</resource>
            <identifier>HGNC:11179</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenAtlas</resource>
            <identifier>SOD1</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenBank Gene Database</resource>
            <identifier>L44139</identifier>
          </external-identifier>
          <external-identifier>
            <resource>UniProtKB</resource>
            <identifier>P00441</identifier>
          </external-identifier>
          <external-identifier>
            <resource>UniProt Accession</resource>
            <identifier>SODC_HUMAN</identifier>
          </external-identifier>
        </external-identifiers>
        <synonyms>
          <synonym>1.15.1.1</synonym>
          <synonym>hSod1</synonym>
          <synonym>Superoxide dismutase 1</synonym>
        </synonyms>
        <amino-acid-sequence format="FASTA">&gt;lcl|BSEQ0021851|Superoxide dismutase [Cu-Zn]
MATKAVCVLKGDGPVQGIINFEQKESNGPVKVWGSIKGLTEGLHGFHVHEFGDNTAGCTS
AGPHFNPLSRKHGGPKDEERHVGDLGNVTADKDGVADVSIEDSVISLSGDHCIIGRTLVV
HEKADDLGKGGNEESTKTGNAGSRLACGVIGIAQ</amino-acid-sequence>
        <gene-sequence format="FASTA">&gt;lcl|BSEQ0021852|Superoxide dismutase [Cu-Zn] (SOD1)
ATGGCGACGAAGGCCGTGTGCGTGCTGAAGGGCGACGGCCCAGTGCAGGGCATCATCAAT
TTCGAGCAGAAGGAAAGTAATGGACCAGTGAAGGTGTGGGGAAGCATTAAAGGACTGACT
GAAGGCCTGCATGGATTCCATGTTCATGAGTTTGGAGATAATACAGCAGGCTGTACCAGT
GCAGGTCCTCACTTTAATCCTCTATCCAGAAAACACGGTGGGCCAAAGGATGAAGAGAGG
CATGTTGGAGACTTGGGCAATGTGACTGCTGACAAAGATGGTGTGGCCGATGTGTCTATT
GAAGATTCTGTGATCTCACTCTCAGGAGACCATTGCATCATTGGCCGCACACTGGTGGTC
CATGAAAAAGCAGATGACTTGGGCAAAGGTGGAAATGAAGAAAGTACAAAGACAGGAAAC
GCTGGAAGTCGTTTGGCTTGTGGTGTAATTGGGATCGCCCAATAA</gene-sequence>
        <pfams>
          <pfam>
            <identifier>PF00080</identifier>
            <name>Sod_Cu</name>
          </pfam>
        </pfams>
        <go-classifiers>
          <go-classifier>
            <category>component</category>
            <description>cytoplasm</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>cytoplasmic vesicle</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>cytosol</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>dendrite cytoplasm</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>dense core granule</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>extracellular exosome</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>extracellular matrix</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>extracellular region</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>extracellular space</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>lysosome</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>mitochondrial intermembrane space</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>mitochondrial matrix</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>mitochondrion</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>myelin sheath</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>neuronal cell body</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>nucleoplasm</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>nucleus</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>peroxisome</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>protein complex</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>chaperone binding</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>copper ion binding</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>identical protein binding</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>protein homodimerization activity</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>protein phosphatase 2B binding</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>Rac GTPase binding</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>superoxide dismutase activity</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>zinc ion binding</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>activation of MAPK activity</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>anterograde axon cargo transport</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>auditory receptor cell stereocilium organization</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>blood coagulation</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>cell aging</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>cellular iron ion homeostasis</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>cellular response to ATP</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>cellular response to cadmium ion</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>cellular response to potassium ion</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>embryo implantation</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>glutathione metabolic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>heart contraction</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>hydrogen peroxide biosynthetic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>locomotory behavior</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>muscle cell cellular homeostasis</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>myeloid cell homeostasis</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>negative regulation of cholesterol biosynthetic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>negative regulation of neuron apoptotic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>neurofilament cytoskeleton organization</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>ovarian follicle development</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>peripheral nervous system myelin maintenance</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>placenta development</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>platelet activation</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>platelet degranulation</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>positive regulation of apoptotic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>positive regulation of catalytic activity</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>positive regulation of cytokine production</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>positive regulation of oxidative stress-induced intrinsic apoptotic signaling pathway</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>positive regulation of superoxide anion generation</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>reactive oxygen species metabolic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>regulation of blood pressure</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>regulation of GTPase activity</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>regulation of mitochondrial membrane potential</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>regulation of multicellular organism growth</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>regulation of organ growth</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>regulation of protein kinase activity</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>regulation of T cell differentiation in thymus</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>relaxation of vascular smooth muscle</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>removal of superoxide radicals</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>response to amphetamine</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>response to antibiotic</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>response to antipsychotic drug</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>response to axon injury</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>response to carbon monoxide</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>response to copper ion</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>response to drug</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>response to ethanol</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>response to heat</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>response to hydrogen peroxide</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>response to nutrient levels</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>response to organic substance</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>response to reactive oxygen species</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>response to superoxide</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>retina homeostasis</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>retrograde axon cargo transport</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>sensory perception of sound</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>spermatogenesis</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>superoxide anion generation</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>superoxide metabolic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>thymus development</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>transmission of nerve impulse</description>
          </go-classifier>
        </go-classifiers>
      </polypeptide>
    </target>
  </targets>
  <enzymes>
    <enzyme position="8">
      <id>BE0003543</id>
      <name>Cytochrome P450 1A1</name>
      <organism>Humans</organism>
      <actions>
        <action>inhibitor</action>
      </actions>
      <references>
        <articles>
          <article>
            <ref-id>A17716</ref-id>
            <pubmed-id>15627480</pubmed-id>
            <citation>Konstandi M, Kostakis D, Harkitis P, Marselos M, Johnson EO, Adamidis K, Lang MA: Role of adrenoceptor-linked signaling pathways in the regulation of CYP1A1 gene expression. Biochem Pharmacol. 2005 Jan 15;69(2):277-87.</citation>
          </article>
        </articles>
        <textbooks/>
        <links/>
        <attachments/>
      </references>
      <known-action>unknown</known-action>
      <polypeptide id="P04798" source="Swiss-Prot">
        <name>Cytochrome P450 1A1</name>
        <general-function>Vitamin d 24-hydroxylase activity</general-function>
        <specific-function>Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics.</specific-function>
        <gene-name>CYP1A1</gene-name>
        <locus>15q24.1</locus>
        <cellular-location>Endoplasmic reticulum membrane</cellular-location>
        <transmembrane-regions/>
        <signal-regions/>
        <theoretical-pi>8.47</theoretical-pi>
        <molecular-weight>58164.815</molecular-weight>
        <chromosome-location>15</chromosome-location>
        <organism ncbi-taxonomy-id="9606">Humans</organism>
        <external-identifiers>
          <external-identifier>
            <resource>HUGO Gene Nomenclature Committee (HGNC)</resource>
            <identifier>HGNC:2595</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenBank Gene Database</resource>
            <identifier>K03191</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenBank Protein Database</resource>
            <identifier>181276</identifier>
          </external-identifier>
          <external-identifier>
            <resource>Guide to Pharmacology</resource>
            <identifier>1318</identifier>
          </external-identifier>
          <external-identifier>
            <resource>UniProtKB</resource>
            <identifier>P04798</identifier>
          </external-identifier>
          <external-identifier>
            <resource>UniProt Accession</resource>
            <identifier>CP1A1_HUMAN</identifier>
          </external-identifier>
        </external-identifiers>
        <synonyms>
          <synonym>1.14.14.1</synonym>
          <synonym>CYPIA1</synonym>
          <synonym>Cytochrome P450 form 6</synonym>
          <synonym>Cytochrome P450-C</synonym>
          <synonym>Cytochrome P450-P1</synonym>
        </synonyms>
        <amino-acid-sequence format="FASTA">&gt;lcl|BSEQ0006827|Cytochrome P450 1A1
MLFPISMSATEFLLASVIFCLVFWVIRASRPQVPKGLKNPPGPWGWPLIGHMLTLGKNPH
LALSRMSQQYGDVLQIRIGSTPVVVLSGLDTIRQALVRQGDDFKGRPDLYTFTLISNGQS
MSFSPDSGPVWAARRRLAQNGLKSFSIASDPASSTSCYLEEHVSKEAEVLISTLQELMAG
PGHFNPYRYVVVSVTNVICAICFGRRYDHNHQELLSLVNLNNNFGEVVGSGNPADFIPIL
RYLPNPSLNAFKDLNEKFYSFMQKMVKEHYKTFEKGHIRDITDSLIEHCQEKQLDENANV
QLSDEKIINIVLDLFGAGFDTVTTAISWSLMYLVMNPRVQRKIQEELDTVIGRSRRPRLS
DRSHLPYMEAFILETFRHSSFVPFTIPHSTTRDTSLKGFYIPKGRCVFVNQWQINHDQKL
WVNPSEFLPERFLTPDGAIDKVLSEKVIIFGMGKRKCIGETIARWEVFLFLAILLQRVEF
SVPLGVKVDMTPIYGLTMKHACCEHFQMQLRS</amino-acid-sequence>
        <gene-sequence format="FASTA">&gt;lcl|BSEQ0012466|Cytochrome P450 1A1 (CYP1A1)
ATGCTTTTCCCAATCTCCATGTCGGCCACGGAGTTTCTTCTGGCCTCTGTCATCTTCTGT
CTGGTATTCTGGGTAATCAGGGCCTCAAGACCTCAGGTCCCCAAAGGCCTGAAGAATCCA
CCAGGGCCATGGGGCTGGCCTCTGATTGGGCACATGCTGACCCTGGGAAAGAACCCGCAC
CTGGCACTGTCAAGGATGAGCCAGCAGTATGGGGACGTGCTGCAGATCCGAATTGGCTCC
ACACCCGTGGTGGTGCTGAGCGGCCTGGACACCATCCGGCAGGCCCTGGTGCGGCAGGGC
GATGATTTCAAGGGCCGGCCCGACCTCTACACCTTCACCCTCATCAGTAATGGTCAGAGC
ATGTCCTTCAGCCCAGACTCTGGACCAGTGTGGGCTGCCCGCCGGCGCCTGGCCCAGAAT
GGCCTGAAAAGTTTCTCCATTGCCTCTGACCCAGCCTCCTCAACCTCCTGCTACCTGGAA
GAGCATGTGAGCAAGGAGGCTGAGGTCCTGATAAGCACGTTGCAGGAGCTGATGGCAGGG
CCTGGGCACTTTAACCCCTACAGGTATGTGGTGGTATCAGTGACCAATGTCATCTGTGCC
ATTTGCTTTGGCCGGCGCTATGACCACAACCACCAAGAACTGCTTAGCCTAGTCAACCTG
AATAATAATTTCGGGGAGGTGGTTGGCTCTGGAAACCCAGCTGACTTCATCCCTATTCTT
CGCTACCTACCCAACCCTTCCCTGAATGCCTTCAAGGACCTGAATGAGAAGTTCTACAGC
TTCATGCAGAAGATGGTCAAGGAGCACTACAAAACCTTTGAGAAGGGCCACATCCGGGAC
ATCACAGACAGCCTGATTGAGCACTGTCAGGAGAAGCAGCTGGATGAGAACGCCAATGTC
CAGCTGTCAGATGAGAAGATCATTAACATCGTCTTGGACCTCTTTGGAGCTGGGTTTGAC
ACAGTCACAACTGCTATCTCCTGGAGCCTCATGTATTTGGTGATGAACCCCAGGGTACAG
AGAAAGATCCAAGAGGAGCTAGACACAGTGATTGGCAGGTCACGGCGGCCCCGGCTCTCT
GACAGATCCCATCTGCCCTATATGGAGGCCTTCATCCTGGAGACCTTCCGACACTCTTCC
TTCGTCCCCTTCACCATCCCCCACAGCACAACAAGAGACACAAGTTTGAAAGGCTTTTAC
ATCCCCAAGGGGCGTTGTGTCTTTGTAAACCAGTGGCAGATCAACCATGACCAGAAGCTA
TGGGTCAACCCATCTGAGTTCCTACCTGAACGGTTTCTCACCCCTGATGGTGCTATCGAC
AAGGTGTTAAGTGAGAAGGTGATTATCTTTGGCATGGGCAAGCGGAAGTGTATCGGTGAG
ACCATTGCCCGCTGGGAGGTCTTTCTCTTCCTGGCTATCCTGCTGCAACGGGTGGAATTC
AGCGTGCCACTGGGCGTGAAGGTGGACATGACCCCCATCTATGGGCTAACCATGAAGCAT
GCCTGCTGTGAGCACTTCCAAATGCAGCTGCGCTCTTAG</gene-sequence>
        <pfams>
          <pfam>
            <identifier>PF00067</identifier>
            <name>p450</name>
          </pfam>
        </pfams>
        <go-classifiers>
          <go-classifier>
            <category>component</category>
            <description>endoplasmic reticulum membrane</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>mitochondrion</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>aromatase activity</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>demethylase activity</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>flavonoid 3'-monooxygenase activity</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>heme binding</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>iron ion binding</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>monooxygenase activity</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>oxidoreductase activity</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>oxidoreductase activity, acting on diphenols and related substances as donors</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>oxygen binding</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>steroid hydroxylase activity</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>vitamin D 24-hydroxylase activity</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>9-cis-retinoic acid biosynthetic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>aging</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>amine metabolic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>arachidonic acid metabolic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>camera-type eye development</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>cell proliferation</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>cellular lipid metabolic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>cellular response to organic cyclic compound</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>coumarin metabolic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>dibenzo-p-dioxin catabolic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>digestive tract development</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>drug metabolic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>embryo development ending in birth or egg hatching</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>epoxygenase P450 pathway</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>flavonoid metabolic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>hepatocyte differentiation</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>hydrogen peroxide biosynthetic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>insecticide metabolic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>maternal process involved in parturition</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>omega-hydroxylase P450 pathway</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>oxidation-reduction process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>porphyrin-containing compound metabolic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>positive regulation of G1/S transition of mitotic cell cycle</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>response to antibiotic</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>response to arsenic-containing substance</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>response to drug</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>response to food</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>response to herbicide</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>response to hyperoxia</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>response to hypoxia</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>response to immobilization stress</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>response to iron(III) ion</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>response to lipopolysaccharide</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>response to nematode</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>response to virus</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>response to vitamin A</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>response to wounding</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>small molecule metabolic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>vitamin D metabolic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>xenobiotic metabolic process</description>
          </go-classifier>
        </go-classifiers>
      </polypeptide>
      <inhibition-strength>unknown</inhibition-strength>
      <induction-strength/>
    </enzyme>
  </enzymes>
  <carriers/>
  <transporters/>
</drug>